,trial_id,discovery_date,title,summary,link,published_date,source,relevant,Sources__source_id,Sources__name,Sources__link
0,494609,2023-03-31 14:01:24.868533,Ukulele Playing to Improve Cognition in People With Multiple Sclerosis: A Feasibility Study,"<b>Conditions</b>:    Multiple Sclerosis;   Pathologic Processes;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune Diseases of the Nervous System;   Nervous System Diseases;   Demyelinating Diseases;   Autoimmune Diseases;   Immune System Diseases<br /><b>Interventions</b>:    Behavioral: Music Training Intervention;   Behavioral: Music Listening<br /><b>Sponsor</b>:    University of Texas at Austin<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05792176?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-31 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
1,492838,2023-03-29 13:11:45.784861,Evaluation of a Self-management Program to Prevent Falls in People With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Fall prevention program;   Other: Brochure<br /><b>Sponsor</b>:    Karolinska Institutet<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05789225?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-29 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
2,491899,2023-03-28 13:41:41.571487,Walking and Thinking - Brain Activity During Complex Walking in People With Multiple Sclerosis,"<b>Conditions</b>:    Multiple Sclerosis;   Gait Disorders, Neurologic;   Neuro-Degenerative Disease;   Aging<br /><b>Intervention</b>:    Other: No intervention<br /><b>Sponsors</b>:    Karolinska Institutet;   Karolinska University Hospital<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05787704?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-28 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
3,491897,2023-03-28 13:41:41.566227,Identifying and Characterizing Preclinical MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: biological samples<br /><b>Sponsors</b>:    Yale University;   Roche-Genentech<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05787795?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-28 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
4,491860,2023-03-28 12:20:47.153646,"A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 with a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients with Relapsing Multiple Sclerosis to Evaluate Effic...","<p>EudraCT Number: 2016-001448-21<br />Sponsor Protocol Number: MS200527-0086<br />Sponsor Name: Merck KGaA<br />Start Date: 2017-02-16<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001448-21/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001448-21/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001448-21/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001448-21/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001448-21/BG"">BG</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2016-001448-21,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
5,489907,2023-03-24 13:01:11.193711,Role of Muscle Vibration in Improving Fatigue in Patients With MS,"<b>Condition</b>:    Purpose of This Study is to Verify the Use of Vibrations on Fatigue in Patients With MS<br /><b>Intervention</b>:    Device: vibra<br /><b>Sponsor</b>:    IRCCS Centro Neurolesi ""Bonino-Pulejo""<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05783999?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-24 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
6,489900,2023-03-24 13:01:11.157720,Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Amyloid PET-CT,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Diagnostic Test: 18F-florbetaben PET/CT<br /><b>Sponsor</b>:    Istituti Clinici Scientifici Maugeri SpA<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05783934?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-24 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
7,489370,2023-03-23 13:20:53.918133,A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsors</b>:    Celestra Health Systems;   University of Ottawa;   The Ottawa Hospital<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05781113?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-23 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
8,488775,2023-03-22 13:20:41.409635,Targeting the Gut Dysbiosis to Treat Inflammation-driven Synaptopathy in MS,<b>Condition</b>:    Patient Participation<br /><b>Interventions</b>:    Dietary Supplement: Prebiotics and Probiotics supplementation;   Dietary Supplement: Placebo supplementation;   Procedure: peripheral blood withdrawal;   Procedure: Transcranial Magnetic Stimulation (TMS)<br /><b>Sponsors</b>:    Neuromed IRCCS;   I.R.C.C.S. Fondazione Santa Lucia<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05779449?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-22 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
9,488070,2023-03-21 13:00:54.730090,Mechanical Determinants of Upper Limbs Oscillation During Gait,<b>Conditions</b>:    Multiple Sclerosis;   Poststroke/CVA Hemiparesis;   Parkinson Disease;   Cerebral Palsy;   Amputation<br /><b>Interventions</b>:    Other: Healthy subjects;   Other: Pathologic group<br /><b>Sponsor</b>:    Istituto Auxologico Italiano<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05778474?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-21 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
10,488062,2023-03-21 13:00:54.699587,Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Ozanimod Oral Capsule<br /><b>Sponsor</b>:    I.R.C.C.S. Fondazione Santa Lucia<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05777902?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-21 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
11,488061,2023-03-21 13:00:54.692173,"Determination of Compliance to Mediterranean Diet, Impacts on Walking and Quality of Life in Multiple Sclerosis","<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    University of Gaziantep<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05777629?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-21 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
12,487578,2023-03-20 17:40:48.917752,Diagnostic Value of eVOG,<b>Conditions</b>:    Multiple Sclerosis;   Radiologically Isolated Syndrome;   White Matter Lesions<br /><b>Intervention</b>:    Procedure: eVOG<br /><b>Sponsor</b>:    Centre Hospitalier Universitaire de Nice<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05776511?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-20 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
13,487576,2023-03-20 17:40:48.910361,Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years,<b>Condition</b>:    Relapsing Multiple Sclerosis<br /><b>Intervention</b>:    Other: Ofatumumab<br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05776888?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-20 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
14,487403,2023-03-20 09:00:55.265771,"Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumab versus standard ocrelizumab in relapsing remitting multiple sclerosis: a randomized controlled trial","<p>EudraCT Number: 2021-004791-34<br />Sponsor Protocol Number: BLOOMS<br />Sponsor Name: VU medical center<br />Start Date: 2022-03-16<br />Medical condition: Multiple sclerosis<br />Disease: <br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-004791-34/NL"">NL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2021-004791-34,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
15,485713,2023-03-17 13:10:43.899977,Danish non-inferiority study of ocrelizumab and rituximab in MS (DanNORMS): A randomized study comparing the efficacy of ocrelizumab and rituximab in active multiple sclerosis.,"<p>EudraCT Number: 2020-002981-15<br />Sponsor Protocol Number: DanNORMS<br />Sponsor Name: Danish Multiple Sclerosis Center, Rigshospitalet<br />Start Date: 2020-12-15<br />Medical condition: Multiple sclerosis.<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002981-15/DK"">DK</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-002981-15,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
16,485075,2023-03-16 13:10:54.523340,Clinical and Urodynamic Assessment of Bladder Sensation in Multiple Sclerosis,<b>Condition</b>:    Overactive Bladder<br /><b>Intervention</b>:    Procedure: Repeated cystometries with bladder sensations assessment<br /><b>Sponsor</b>:    Assistance Publique - Hôpitaux de Paris<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05772637?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-16 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
17,483864,2023-03-14 13:20:41.996891,A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS),<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Diroximel Fumarate;   Drug: Dimethyl Fumarate;   Drug: Disease-Modifying Therapies (DMTs)<br /><b>Sponsor</b>:    Biogen<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05767736?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-14 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
18,480677,2023-03-09 13:50:42.458081,Czech Pharmaco-epidemiological Study on Disease Modifying Drugs,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab<br /><b>Sponsor</b>:    IMPULS Endowment Fund<br /><b>Completed</b>",https://clinicaltrials.gov/ct2/show/NCT05762003?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-09 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
19,480049,2023-03-08 15:40:45.761255,Awareness of Osteoporosis in Multiple Sclerosis Patients,<b>Conditions</b>:    Multiple Sclerosis;   Osteoporosis;   Osteoporosis Risk<br /><b>Intervention</b>:    Other: Patient Participation Form<br /><b>Sponsor</b>:    Uskudar State Hospital<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05760651?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-08 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
20,480043,2023-03-08 15:40:45.736206,"Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group","<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Biological: Anti-Mullerian hormone (AMH) level;   Other: Antral follicle count (AFC);   Other: Clinical assessment<br /><b>Sponsor</b>:    University Hospital, Bordeaux<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05754593?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-06 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
21,479313,2023-03-07 14:30:48.449222,PURO - PUlmonary Rehabilitation With O-RAGT Platform,<b>Conditions</b>:    Multiple Sclerosis;   Spinal Cord Injury;   Stroke;   Traumatic Brain Damage<br /><b>Intervention</b>:    Device: UANGO suite exoskeleton<br /><b>Sponsors</b>:    Fondazione Don Carlo Gnocchi Onlus;   Roessingh Research and Development;   Hospital Nacional de Parapléjicos de Toledo;   Lithuanian University of Health Sciences<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05757830?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-07 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
22,479303,2023-03-07 14:30:48.420176,RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.,<b>Conditions</b>:    Multiple Sclerosis;   Relapsing-remitting Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Perfusion of treatment Rituximab;   Drug: Perfusion of treatment Ocrelizumab<br /><b>Sponsor</b>:    Rennes University Hospital<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05758831?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-07 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
23,478564,2023-03-06 14:00:44.891062,WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Relapsing-remitting Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: GEMS Plus;   Behavioral: GEMS<br /><b>Sponsor</b>:    Kessler Foundation<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05755061?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-06 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
24,478559,2023-03-06 14:00:44.854553,"Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group.","<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Biological: Anti-Mullerian hormone (AMH) level;   Other: Antral follicle count (AFC);   Other: Clinical assessment<br /><b>Sponsor</b>:    University Hospital, Bordeaux<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05754593?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-06 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
25,475659,2023-03-02 14:20:38.322417,"Physical Activity, Sedentary Behaviour and Cardiometabolic Health in Multiple Sclerosis","<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Hasselt University<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05752630?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-03-02 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
26,475630,2023-03-02 13:00:59.400210,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO
INVESTIGATE THE EFFICACY OF FENEBRUTINIB IN RELAPSING MULTIPLE SCLEROSIS","<p>EudraCT Number: 2021-003772-14<br />Sponsor Protocol Number: GN43271<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2021-11-18<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003772-14/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003772-14/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003772-14/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2021-003772-14,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
27,473826,2023-02-28 11:30:48.818923,Pain in Neurorehabilitation Through Wearable Devices: an Exploratory Study,<b>Conditions</b>:    Pain;   Multiple Sclerosis<br /><b>Intervention</b>:    Diagnostic Test: monitoring<br /><b>Sponsor</b>:    Azienda Usl di Bologna<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05747040?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-02-28 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
28,473824,2023-02-28 11:30:48.813750,Implication of 5-HT7 Receptor in Inflammatory Mechanisms in Multiple Sclerosis,<b>Conditions</b>:    Healthy;   Multiple Sclerosis<br /><b>Intervention</b>:    Biological: Blood sample<br /><b>Sponsor</b>:    Centre Hospitalier Régional d'Orléans<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05746845?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-02-28 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
29,473822,2023-02-28 11:30:48.808518,Definition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Diagnostic Test: quantification of sensory and autonomic small nerve fibers by punch skin biopsy;   Diagnostic Test: Cardiovascular Reflexes testing;   Other: Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms<br /><b>Sponsor</b>:    Istituti Clinici Scientifici Maugeri SpA<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05748015?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-02-28 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
30,473819,2023-02-28 11:30:48.799803,The Impact of Interferon Beta 1a on Egyptian Relapse-Remitting Multiple Sclerosis Patients,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Blood sample collection<br /><b>Sponsor</b>:    German University in Cairo<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05735067?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-02-21 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
31,470466,2023-02-23 13:50:46.069497,Reliability and Validity of Outcome Measures for Pain in Multiple Sclerosis,<b>Condition</b>:    Pain<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Hasselt University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05742152?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-02-23 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
32,470464,2023-02-23 13:50:46.060988,Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Progressive Multiple Sclerosis<br /><b>Interventions</b>:    Dietary Supplement: Nicotinamid riboside;   Dietary Supplement: Placebo<br /><b>Sponsor</b>:    Haukeland University Hospital<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05740722?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-02-23 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
33,469469,2023-02-21 14:11:14.728214,"High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis",<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Procedure: High-Intensity Treadmill Training;   Procedure: Treadmill Training with Perturbations;   Procedure: Standard Treadmill Training<br /><b>Sponsors</b>:    Marquette University;   Indiana University;   Medical College of Wisconsin;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05735691?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-02-20 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
34,469466,2023-02-21 14:11:14.716521,The Impact of Interferon Beta 1a on Egyptian Relapse-Reemitting Multiple Sclerosis Patients,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Blood sample collection<br /><b>Sponsor</b>:    German University in Cairo<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05735067?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-02-20 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
35,468988,2023-02-20 18:00:48.990340,Behandling med botulinumtoxin vid neurogen blåsfunktionsstörning,"<p>EudraCT Number: 2005-003068-47<br />Sponsor Protocol Number: UROBOTOX 1<br />Sponsor Name: Region Skåne, Universitetssjukhuset i Lund, Urologiska kliniken<br />Start Date: 2005-09-22<br />Medical condition: The trial addresses patients with severe symptoms of neurogenic detrusor overactivity (urgency and/or urge incontinence). Eligible are those patients who have failed conservative treatment such as ...<br />Disease: <br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003068-47/SE"">SE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2005-003068-47,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
36,467452,2023-02-17 14:21:17.227069,A Pilot Randomized Controlled Trial of A Comprehensive Cognitive and Affective Intervention for Neurocognitive Disorders,<b>Conditions</b>:    Neurocognitive Disorders;   Cognitive Dysfunction;   Traumatic Brain Injury;   Multiple Sclerosis;   Mild Cognitive Impairment<br /><b>Interventions</b>:    Behavioral: CRT;   Behavioral: CBT;   Behavioral: Modifiable lifestyle factors;   Behavioral: Usual care Psychoeducation<br /><b>Sponsor</b>:    University of Michigan<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05732285?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-02-17 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
37,466827,2023-02-16 13:50:49.867602,Dalfampridine in Egyptian Patients With Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Dalfampridine ER, 10 Mg Oral Tablet, Extended Release;   Drug: Placebo<br /><b>Sponsor</b>:    Ain Shams University<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05730738?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-02-16 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
38,465051,2023-02-13 14:20:51.092046,At-Home Gait Assessment,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsors</b>:    NYU Langone Health;   United States Department of Defense<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05724901?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-02-13 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
39,463534,2023-02-10 19:10:47.052580,"A Phase 1/2 Multiple-Ascending-Dose Study With a Long-Term Open-Label
Extension to Assess the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics, and Effect on Disease Progression of BIIB105
...","<p>EudraCT Number: 2020-000207-36<br />Sponsor Protocol Number: 275AS101<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2020-11-18<br />Medical condition: ALS and ALS associated with ataxin-2 (ATXN2) poly-CAG expansion (polyQ-ALS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10002026<br />Term: Amyotrophic lateral sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10010331 - Congenital, familial and genetic disorders<br />Classification Code: 10052653<br />Term: Amyotrophic lateral sclerosis gene carrier<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000207-36/NL"">NL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2020-000207-36,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
40,462197,2023-02-08 15:40:41.814791,Ultra-high-field Brain MRI in Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Diagnostic Test: Brain MRI (3T, 7T, 9.4T)<br /><b>Sponsors</b>:    Zuyderland Medisch Centrum;   Scannexus<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05718947?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-02-08 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
41,461268,2023-02-07 01:20:40.481718,A 2-year prospective study to evaluate the onset of action of Mavenclad® in subjects with highly active relapsing multiple sclerosis,"<p>EudraCT Number: 2017-002631-42<br />Sponsor Protocol Number: MS700568_0022<br />Sponsor Name: Merck KGaA <br />Start Date: 2018-04-18<br />Medical condition: Relapsing multiple sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002631-42/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2017-002631-42,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
42,461011,2023-02-06 13:47:37.569301,Wearables for the Bladder: an In-home Treatment Feasibility Pilot Study,"<b>Conditions</b>:    Multiple Sclerosis;   Urinary Bladder, Overactive<br /><b>Interventions</b>:    Device: WeB;   Other: Standard pelvic floor physical therapy<br /><b>Sponsors</b>:    University of California, San Francisco;   National Multiple Sclerosis Society<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05715268?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-02-06 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
43,461006,2023-02-06 13:47:37.556197,Home-based Action Observation Treatment With Virtual-reality for Arm Rehabilitation in People With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Home-based Action Observation Treatment with virtual-reality for upper limb rehabilitation;   Other: Home-based landscape observation with virtual-reality for upper limb rehabilitation<br /><b>Sponsors</b>:    IRCCS San Raffaele;   Istituto di Neuroscienze Consiglio Nazionale delle Ricerche<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05713890?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-02-06 12:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
44,459539,2023-02-03 13:40:45.373603,"Examining the Impact of an Online, Non-restrictive Diet Among Persons With Multiple Sclerosis","<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: 800g Challenge<br /><b>Sponsor</b>:    University of North Texas, Denton, TX<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05712408?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-02-03 12:00:00.000000,,,,,
45,458148,2023-01-31 15:01:20.991586,Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Clinically Isolated Syndrome;   Relapsing Remitting Multiple Sclerosis;   Progressive Multiple Sclerosis<br /><b>Interventions</b>:    Diagnostic Test: Eye tracking;   Diagnostic Test: Microperimetry;   Diagnostic Test: Optical coherence tomography (OCT);   Diagnostic Test: Visual processing speed test<br /><b>Sponsors</b>:    Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA;   Fundación Eugenio Rodríguez Pascual;   Hospital del Río Hortega<br /><b>Enrolling by invitation</b>,https://clinicaltrials.gov/ct2/show/NCT05706220?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-01-31 12:00:00.000000,,,,,
46,458146,2023-01-31 15:01:20.985511,Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS),<b>Condition</b>:    Relapse Remitting Multiple Sclerosis<br /><b>Intervention</b>:    Other: Blood Draw<br /><b>Sponsor</b>:    Thomas Jefferson University<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05705986?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-01-31 12:00:00.000000,,,,,
47,457773,2023-01-30 14:42:42.738076,"A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous RO7121932 in Participants With Multiple Sclerosis",<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: RO7121932<br /><b>Sponsor</b>:    Hoffmann-La Roche<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05704361?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-01-30 12:00:00.000000,,,,,
48,456540,2023-01-27 16:47:09.042140,Understanding the &#39;Wearing Off&#39; Effect From Disease-modifying Therapies (DMT) in Patients With Multiple Sclerosis: an Interview Based Study Among Patients and Clinicians,,https://www.novartis.com//clinicaltrials/study/nct05627271,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
49,456472,2023-01-27 14:10:49.062160,A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Natalizumab<br /><b>Sponsor</b>:    Biogen<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05701423?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-01-27 12:00:00.000000,,,,,
50,455969,2023-01-26 14:20:45.348870,Multiple Sclerosis and Respiratory and Functional Capacity,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test<br /><b>Sponsors</b>:    Nigde Omer Halisdemir University;   Pamukkale University<br /><b>Completed</b>",https://clinicaltrials.gov/ct2/show/NCT05697523?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-01-26 12:00:00.000000,,,,,
51,454477,2023-01-23 13:40:48.110763,"A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc...","<p>EudraCT Number: 2010-020315-36<br />Sponsor Protocol Number: WA21093<br />Sponsor Name: F.Hoffmann-La Roche<br />Start Date: 2011-10-18<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/IE"">IE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/CZ"">CZ</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020315-36,,,,,,
52,453260,2023-01-20 09:47:09.794479,"A Single-arm, Prospective, Multi-center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Relapsing Multiple Sclerosis Who Discontinue Intravenously Delivered Anti-CD20 Monoclonal Antibody (aCD20 mAb) Therapy (OLIKOS)",,https://www.novartis.com//clinicaltrials/study/nct04486716,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
53,452970,2023-01-19 13:40:49.701276,Cognitive Reserve-building Activities in Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Cognitive Leisure Activities<br /><b>Sponsors</b>:    Rigshospitalet, Denmark;   University of Copenhagen<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05691192?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-01-19 12:00:00.000000,,,,,
54,452592,2023-01-18 14:20:48.914198,A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Diroximel Fumarate;   Biological: Alemtuzumab;   Drug: Fingolimod;   Drug: Glatiramer acetate;   Biological: Interferon beta;   Biological: Natalizumab;   Biological: Ocrelizumab;   Biological: Peginterferon beta-1a;   Drug: Siponimod<br /><b>Sponsor</b>:    Biogen<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05688436?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-01-18 12:00:00.000000,,,,,
55,452482,2023-01-18 07:47:08.577111,"A 24-month, Open-label, Prospective, Multicenter Interventional, Single-arm Study Assessing the Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Relapsing Multiple Sclerosis (RMS) Patients in China",,https://www.novartis.com//clinicaltrials/study/nct04667949,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
56,452191,2023-01-17 13:40:47.568125,Multiple Sclerosis Prediction and Monitoring of Progression Study,"<b>Condition</b>:    Progressive Multiple Sclerosis<br /><b>Intervention</b>:    Device: Bytelfies kit - sensor dot<br /><b>Sponsors</b>:    University Hospital, Ghent;   University Ghent;   Byteflies<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05685784?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-01-16 12:00:00.000000,,,,,
57,450990,2023-01-13 13:40:49.376847,"Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM","<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Interventions</b>:    Other: NeuroQuant;   Other: Automated Neuropsychological Assessment Matrices;   Other: EDSS;   Other: Physical Examination<br /><b>Sponsor</b>:    George Washington University<br /><b>Completed</b>",https://clinicaltrials.gov/ct2/show/NCT05684016?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-01-13 12:00:00.000000,,,,,
58,450755,2023-01-12 14:21:20.036202,Efficacy of Square- Stepping Exercises in Individuals With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Square Step Exercises Program;   Other: Home Exercise Program<br /><b>Sponsor</b>:    Pamukkale University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05682963?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-01-12 12:00:00.000000,,,,,
59,448739,2023-01-04 13:51:09.887364,"Cardiovascular Fitness of Patients With Multiple Sclerosis, Effect of Exercise on Fatigue and Depression",<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Procedure: Controlled combined exercise group;   Procedure: Conventional rehabilitation<br /><b>Sponsor</b>:    University Hospital Ostrava<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05671588?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-01-04 12:00:00.000000,,,,,
60,448738,2023-01-04 13:51:09.884242,CogMS - A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Custom study version of icompanion app<br /><b>Sponsor</b>:    icometrix<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05671055?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2023-01-04 12:00:00.000000,,,,,
61,448311,2023-01-03 09:40:59.539622,"Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do...","<p>EudraCT Number: 2007-006338-32<br />Sponsor Protocol Number: WA21493<br />Sponsor Name: Hoffman La Roche Ltd<br />Start Date: 2008-05-06<br />Medical condition: Relapsing remitting multiple sclerosis<br />Disease: <br />Version: 9.1<br />SOC Term: <br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/DK"">DK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/BG"">BG</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/IT"">IT</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-006338-32,,,,,,
62,443239,2022-12-24 12:33:08.200346,Swiss Study of the Impact of Mayzent (Siponimod) on Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study,,https://www.novartis.com//clinicaltrials/study/nct04895202,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
63,442545,2022-12-23 13:30:50.591339,An Observational Biomarker Study in Multiple Sclerosis (MS) Patients,"<b>Conditions</b>:    Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary Progressive<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    LAPIX Therapeutics Inc.<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05663853?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-23 12:00:00.000000,,,,,
64,442543,2022-12-23 13:30:50.586314,Validity and Reliability of Lower Extremity Position Test in Patients With Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis, Sensory Impairments, Proprioception, Validity, Reliability<br /><b>Intervention</b>:    Diagnostic Test: Lower extremity position test<br /><b>Sponsor</b>:    Pamukkale University<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05663541?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-23 12:00:00.000000,,,,,
65,441839,2022-12-22 13:40:50.276553,Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Device: Eye-Tracking<br /><b>Sponsor</b>:    Innodem Neurosciences<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05661266?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-22 12:00:00.000000,,,,,
66,441035,2022-12-21 13:41:10.668762,A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS),"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Bristol-Myers Squibb<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05658601?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-21 12:00:00.000000,,,,,
67,441033,2022-12-21 13:41:10.661311,VIRtual Versus UsuAL In-office Care for Multiple Sclerosis (VIRTUAL-MS),"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Multiple Sclerosis Clinical Care Delivery<br /><b>Sponsors</b>:    The Cleveland Clinic;   University of California, San Francisco;   University of Washington<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05660187?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-21 12:00:00.000000,,,,,
68,440325,2022-12-20 13:50:47.658084,Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate),<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Diroximel Fumarate;   Drug: Avonex;   Biological: Tysabri;   Drug: Dimethyl Fumarate<br /><b>Sponsor</b>:    Biogen<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05658497?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-20 12:00:00.000000,,,,,
69,440322,2022-12-20 13:50:47.652801,A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Dimethyl fumarate<br /><b>Sponsor</b>:    Biogen<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05658484?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-20 12:00:00.000000,,,,,
70,440234,2022-12-20 10:30:42.669915,"PHASE 2, 24-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FO...","<p>EudraCT Number: 2019-003607-35<br />Sponsor Protocol Number: C0221002<br />Sponsor Name: Pfizer Inc.<br />Start Date: 2020-10-26<br />Medical condition: Focal Segmental Glomerulosclerosis (FSGS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10038359 - Renal and urinary disorders<br />Classification Code: 10067757<br />Term: Focal segmental glomerulosclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003607-35/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003607-35/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003607-35/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003607-35/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003607-35/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-003607-35,,,,,,
71,437647,2022-12-16 13:52:31.855338,Peripheral Immunological Effects of High-dose Vitamin D Treatment in Healthy Subjects,<b>Condition</b>:    Vitamin d Deficiency<br /><b>Interventions</b>:    Drug: Vitamin D;   Drug: Placebo<br /><b>Sponsor</b>:    Centre Hospitalier Universitaire de Nīmes<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05654818?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-16 12:00:00.000000,,,,,
72,436950,2022-12-15 12:40:57.014223,"A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclero...","<p>EudraCT Number: 2016-003100-30<br />Sponsor Protocol Number: EFC13429<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2017-04-04<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 19.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/ES"">ES</a> (Temporarily Halted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/DE"">DE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/NO"">NO</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/GR"">GR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/PT"">PT</a> (Temporarily Halted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/NL"">NL</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/BE"">BE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/BG"">BG</a> (Temporarily Halted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/3rd"">Outside EU/EEA</a>, <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/PL"">PL</a> (Temporarily Halted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/IT"">IT</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003100-30,,,,,,
73,436537,2022-12-14 14:10:44.983240,Silent Progression Activity Monitoring - SPAM Study,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: NO INTERVENTION<br /><b>Sponsor</b>:    Centre Hospitalier Universitaire de Nice<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05650281?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-14 12:00:00.000000,,,,,
74,436100,2022-12-13 13:50:56.957492,"The Relationships Between Personal Identity, Autobiographical Memory and Future Thinking in People With Multiple Sclerosis","<b>Conditions</b>:    Multiple Sclerosis, Relapsing-Remitting;   Healthy Controls<br /><b>Intervention</b>:    Behavioral: Neuropsychological tests and psychological questionnaires<br /><b>Sponsors</b>:    Centre d'Investigation Clinique et Technologique 805;   University Paris 8 Vincennes Saint Denis;   ARSEP foundation<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05648292?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-13 12:00:00.000000,,,,,
75,434400,2022-12-09 14:21:13.617512,Nomad P-KAFO Study,"<b>Conditions</b>:    Cerebrovascular Accident;   Post-polio Syndrome;   Spinal Cord Injuries;   Multiple Sclerosis;   Muscular Dystrophy;   Paralysis<br /><b>Intervention</b>:    Device: Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH)<br /><b>Sponsor</b>:    Shirley Ryan AbilityLab<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05644522?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-09 12:00:00.000000,,,,,
76,433982,2022-12-08 14:20:46.612312,The Reliability and Validity of the L-test in Patients With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: L test;   Other: Timed Up and Go test;   Other: 10 meter walk test;   Other: Six Minute Walk Test;   Other: The timed 360° turn test<br /><b>Sponsor</b>:    Gazi University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05641714?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-08 12:00:00.000000,,,,,
77,433759,2022-12-07 23:25:07.521692,An Open-label Multicenter Study to Assess Response to Influenza Vaccine in Participants With Multiple Sclerosis Treated With Ofatumumab 20 mg Subcutaneously,,https://www.novartis.com//clinicaltrials/study/nct04667117,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
78,433600,2022-12-07 14:32:28.633066,Physical Activity in Persons Newly Diagnosed With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis (MS)<br /><b>Intervention</b>:    Behavioral: Physical activity behavioral intervention in persons newly diagnosed with MS<br /><b>Sponsor</b>:    University of Alabama at Birmingham<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05641532?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-07 12:00:00.000000,,,,,
79,433247,2022-12-06 15:04:19.709460,The Effect of Augmented Reality Based Telerehabilitation Application on Neuromuscular and Sensorimotor Parameters in Multiple Sclerosis Patients,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Augmented Reality Based Telerehabilitation Application;   Other: Training face-to-face<br /><b>Sponsor</b>:    Ankara Yildirim Beyazıt University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05639517?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-06 12:00:00.000000,,,,,
80,431629,2022-12-02 15:20:34.418148,A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives,<b>Conditions</b>:    Age-Related Macular Degeneration;   Allergies;   Alpha-Gal Syndrome;   Alzheimer Disease;   Amyloidosis;   Ankylosing Spondylitis;   Arthritis;   Alopecia Areata;   Asthma;   Atopic Dermatitis;   Autism;   Autoimmune Hepatitis;   Behcet's Disease;   Beta-Thalassemia;   Cancer;   Celiac Disease;   Kidney Diseases;   COPD;   Crohn Disease;   Cystic Fibrosis;   Diabetes;   Dravet Syndrome;   DMD;   Fibromyalgia;   Graves Disease;   Thyroid Diseases;   Hepatitis;   Hidradenitis Suppurativa;   ITP;   Leukemia;   ALS;   Lupus or SLE;   Lymphoma;   Multiple Sclerosis;   Myasthenia Gravis;   Heart Diseases;   Parkinson Disease;   Pemphigus Vulgaris;   Cirrhosis;   Psoriasis;   Schizophrenia;   Scleroderma;   Sickle Cell Disease;   Stroke;   Ulcerative Colitis;   Vasculitis;   Vitiligo<br /><b>Intervention</b>:    Diagnostic Test: Specimen sample<br /><b>Sponsor</b>:    Sanguine Biosciences<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05635266?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-02 12:00:00.000000,,,,,
81,431628,2022-12-02 15:20:34.416494,Kesimpta (Ofatumumab) Pregnancy Registry,<b>Conditions</b>:    Multiple Sclerosis;   Pregnancy<br /><b>Intervention</b>:    Other: Kesimpta<br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05634967?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-02 12:00:00.000000,,,,,
82,431626,2022-12-02 15:20:34.412534,Effect of Vestibular Rehabilitation on Trunk Kinetic and Kinematic Parameters in Patients With Multiple Sclerosis,<b>Condition</b>:    Vestibular Rehabilitation in MS<br /><b>Interventions</b>:    Other: Cawthorne Cooksey exercise protocol;   Other: conventional vestibular rehabilitation<br /><b>Sponsor</b>:    October 6 University<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05635890?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-02 12:00:00.000000,,,,,
83,431620,2022-12-02 15:20:34.400246,Disability Level and Trunk Control in Individuals With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Assessment<br /><b>Sponsors</b>:    Hacettepe University;   Bandırma Onyedi Eylül University<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05634993?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-02 12:00:00.000000,,,,,
84,431375,2022-12-01 15:16:35.846814,Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis (MS)<br /><b>Intervention</b>:    Other: MRI<br /><b>Sponsor</b>:    Assistance Publique - Hôpitaux de Paris<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05633875?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-12-01 12:00:00.000000,,,,,
85,431188,2022-11-30 16:42:07.943009,Feasibility and Effectiveness of a Mindfulness Program Delivered by Web to Patients During Hospitalization and Caregivers.,<b>Condition</b>:    Chronic Migraine; Multiple Sclerosis; Motoneuron Disease<br /><b>Intervention</b>:    Other: no comparator - TAU (Treatment-as-usual)<br /><b>Sponsor</b>:    Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05623254?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-11-21 12:00:00.000000,,,,,
86,431008,2022-11-29 13:50:55.520797,A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: SAR443820;   Other: Placebo<br /><b>Sponsor</b>:    Sanofi<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05630547?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-11-29 12:00:00.000000,,,,,
87,430181,2022-11-25 14:50:51.915053,Sunlight-mediated Inter-organ Leukocyte Exchange,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Device: 311 nm narrowband UVB irradiation<br /><b>Sponsor</b>:    University Hospital Muenster<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05627609?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-11-25 12:00:00.000000,,,,,
88,430180,2022-11-25 14:50:51.911429,The 'Wearing Off' Effect of DMT,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: ocrelizumab;   Other: natalizumab;   Other: ofatumumab<br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05627271?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-11-24 12:00:00.000000,,,,,
89,428981,2022-11-18 14:10:45.500399,OFSEP Very High Definition Cohort,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: MRI<br /><b>Sponsor</b>:    EDMUS Foundation<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05622643?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-11-18 12:00:00.000000,,,,,
90,427945,2022-11-14 13:29:35.166945,The Effect of Motor Imagery on Balance in Persons With Multiple Sclerosis,<b>Conditions</b>:    Falls;   Motor Imagery;   Multiple Sclerosis;   Balance;   Fatigue<br /><b>Intervention</b>:    Other: Motor Imagery as compared to physical practice for balance tasks<br /><b>Sponsor</b>:    Dominican University of New York<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05615207?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-11-14 12:00:00.000000,,,,,
91,427943,2022-11-14 13:29:35.160973,Effect of Bio-electromagnetic Energy Regulation Therapy on Erectile Dysfunction in Patients With Multiple Sclerosis,"<b>Conditions</b>:    Erectile Dysfunction Due to Diseases Classified Elsewhere;   Multiple Sclerosis, Relapsing-Remitting<br /><b>Interventions</b>:    Device: bio-electromagnetic energy regulation therapy (BEMER) machine model type: B.BOX CLASSIC, model NO: 420100, 12-15 Volt, (BEMER Int.AG, Liechtenstein product).;   Device: placebo BEMER<br /><b>Sponsor</b>:    Imam Abdulrahman Bin Faisal University<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05615454?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-11-14 12:00:00.000000,,,,,
92,426577,2022-11-09 13:22:21.097464,Telerehabilitation of Multidomain Cognitive Impairment in Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Clinical assessment;   Other: Classical cognitive evaluation of several domains:;   Other: Ecological evaluation;   Behavioral: Patent reported outcomes (PRO's);   Other: Telerehabilitation : active procedure;   Other: Telerehabilitation : comparator procedure<br /><b>Sponsors</b>:    University Hospital, Bordeaux;   Celgene<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05611047?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-11-09 12:00:00.000000,,,,,
93,426374,2022-11-09 00:15:47.456296,A Non-interventional Study Evaluating Kesimpta® (Ofatumumab) Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies [KAIROS],,https://www.novartis.com//clinicaltrials/study/nct05566756,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
94,423964,2022-11-04 13:00:15.542187,Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve,"<b>Conditions</b>:    Demyelinating Diseases;   Multiple Sclerosis;   Neuromyelitis Optica Spectrum Disorder Attack;   Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease;   Optic Neuritis<br /><b>Intervention</b>:    Other: non-interventional study<br /><b>Sponsor</b>:    Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05605951?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-11-04 12:00:00.000000,,,,,
95,423961,2022-11-04 13:00:15.536060,"A Post-Authorization, Long-term Study of Ozanimod Real-world Safety","<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Bristol-Myers Squibb<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05605782?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-11-04 12:00:00.000000,,,,,
96,423441,2022-11-03 13:00:16.745266,"Lesion Load and Location in Relation to Cognition, Fatigue and Physical Disability in RRMS","<b>Condition</b>:    Relapsing Remitting Multiple Sclerosis<br /><b>Interventions</b>:    Diagnostic Test: VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures);   Other: Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)<br /><b>Sponsor</b>:    Assiut University<br /><b>Completed</b>",https://clinicaltrials.gov/ct2/show/NCT05604092?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-11-03 12:00:00.000000,,,,,
97,422154,2022-11-01 06:30:17.217248,Multiple Sclerosis and Menopause: the effect of hormone replacement therapy on clinical picture and immunology of multiple sclerosis,"<p>EudraCT Number: 2014-005129-10<br />Sponsor Protocol Number: Elovaara09112014<br />Sponsor Name: Irina Elovaara<br />Start Date: 2015-01-27<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 17.1<br />SOC Term: 100000004852<br />Classification Code: 10064137<br />Term: Progression of multiple sclerosis<br />Level: LLT<br />Version: 17.1<br />SOC Term: 100000004852<br />Classification Code: 10070425<br />Term: Multiple sclerosis exacerbation<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005129-10/FI"">FI</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-005129-10,,,,,,
98,418050,2022-10-28 12:45:13.649755,"Performance and Long-term Safety of FlowOx2.0™, Multiple Sclerosis, Spasticity and Pain","<b>Conditions</b>:    Multiple Sclerosis;   Spasticity, Muscle;   Pain<br /><b>Intervention</b>:    Device: FlowOx 2.0<br /><b>Sponsor</b>:    Otivio AS<br /><b>Enrolling by invitation</b>",https://clinicaltrials.gov/ct2/show/NCT05598736?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-10-28 12:00:00.000000,,,,,
99,416680,2022-10-27 13:47:00.076321,"A 12-month, Prospective, Multi-center Post-authorization Commitment (PAC) Study Monitoring Safety in Adult Patients With Relapsing-remitting Multiple Sclerosis Newly Initiated on Gilenya (Fingolimod) in Taiwan (SPRING)",,https://www.novartis.com//clinicaltrials/study/nct04480853,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
100,416599,2022-10-27 12:30:18.003110,Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients,<b>Conditions</b>:    Shingles;   Zoster<br /><b>Intervention</b>:    Biological: recombinant zoster vaccine<br /><b>Sponsor</b>:    Prof Patrice Lalive<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05596526?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-10-27 12:00:00.000000,,,,,
101,412930,2022-10-25 08:00:17.576790,"An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis","<p>EudraCT Number: 2017-004703-51<br />Sponsor Protocol Number: COMB157G2399<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2019-01-10<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004703-51,,,,,,
102,412442,2022-10-25 00:40:14.485582,"AN OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF OCRELIZUMAB IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTING MULTIPLE SCLE...","<p>EudraCT Number: 2016-002667-34<br />Sponsor Protocol Number: WA39085<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2020-03-06<br />Medical condition: Relapsing-remitting multiple sclerosis (MS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10039720<br />Term: Sclerosis multiple<br />Level: LLT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002667-34/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002667-34/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002667-34,,,,,,
103,412421,2022-10-25 00:15:18.515701,"A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-
Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy
and Safety of BG00012 and BIIB017 ...","<p>EudraCT Number: 2018-000516-22<br />Sponsor Protocol Number: 800MS301<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2019-07-08<br />Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS) <br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029205<br />Term: Nervous system disorders<br />Level: SOC<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000516-22/PT"">PT</a> (Not Authorised), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000516-22/EE"">EE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000516-22/HU"">HU</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000516-22,,,,,,
104,407407,2022-10-21 12:25:18.740122,Turkish Version of F-2-MS,"<b>Conditions</b>:    Cultural Adaptation;   Reliability;   Validity;   Multiple Sclerosis;   Fatigue<br /><b>Intervention</b>:    Other: Cultural adaptation, reliability and validity<br /><b>Sponsor</b>:    Pamukkale University<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05590533?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-10-21 12:00:00.000000,,,,,
105,404355,2022-10-19 12:50:08.887350,Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Neurogenic Bladder<br /><b>Interventions</b>:    Diagnostic Test: Urodynamic Study (Filling cystometry and pressure-flow study);   Diagnostic Test: Questionnaires;   Diagnostic Test: Uroflowmetry<br /><b>Sponsor</b>:    Koç University<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05587101?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-10-19 12:00:00.000000,,,,,
106,404354,2022-10-19 12:50:08.884841,Teleassessment in Ataxic Multiple Sclerosis,<b>Conditions</b>:    Ataxia;   Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Hacettepe University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05585541?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-10-19 12:00:00.000000,,,,,
107,403105,2022-10-17 17:35:19.146681,"A Phase IIa, Open-label, Multicentre Dose-Finding Trial in Patients with Relapsing Forms of Multiple Sclerosis (RMS) to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101","<p>EudraCT Number: 2022-000253-92<br />Sponsor Protocol Number: EHP-101-MS02<br />Sponsor Name: Emerald Health Pharmaceuticals Inc.<br />Start Date: 2022-10-14<br />Medical condition: Relapsing Forms of Multiple Sclerosis (RMS)<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000253-92/ES"">ES</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2022-000253-92,,,,,,
108,401170,2022-10-14 12:55:15.648650,Transient and Immediate Motor Effects of Exercise in Progressive Multiple Sclerosis,"<b>Conditions</b>:    Multiple Sclerosis, Chronic Progressive;   High-Intensity Interval Training;   Motor Symptoms<br /><b>Interventions</b>:    Behavioral: HIIT;   Behavioral: MCT<br /><b>Sponsor</b>:    Klinik Valens<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05562414?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-30 12:00:00.000000,,,,,
109,400545,2022-10-13 15:57:03.370462,Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Ofatunumab<br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05576779?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-10-13 12:00:00.000000,,,,,
110,400302,2022-10-13 06:40:18.064662,"Multi-center, Randomized, Double-blind, Parallel-group, Double-dummy, Active-controlled, Comparative Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Vers...","<p>EudraCT Number: 2020-004431-24<br />Sponsor Protocol Number: 67896153MSC3001<br />Sponsor Name: Janssen-Cilag International NV<br />Start Date: 2022-09-30<br />Medical condition: Relapsing-remitting Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004431-24/SE"">SE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004431-24,,,,,,
111,399851,2022-10-12 12:05:13.557013,Neurostatus-SMARTCARE in Comparison to Standard Neurostatus-EDSS®,"<b>Condition</b>:    Multiple Sclerosis (MS)<br /><b>Interventions</b>:    Other: Neurostatus-SMARTCARE;   Other: Standard Neurostatus-EDSS<br /><b>Sponsors</b>:    University Hospital, Basel, Switzerland;   Novartis Pharma AG, Basel, Switzerland<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05575843?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-10-11 12:00:00.000000,,,,,
112,397230,2022-10-07 13:05:19.200393,Effect of Arm Ergometer Exercise Training on Upper Extremity Function in People With Multiple Sclerosis.,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: exercise<br /><b>Sponsor</b>:    Dokuz Eylul University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05571631?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-10-07 12:00:00.000000,,,,,
113,397229,2022-10-07 13:05:19.193478,Effectiveness of Telerehabilitation Interventions in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: telerehabilitation<br /><b>Sponsor</b>:    Dokuz Eylul University<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05571826?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-10-07 12:00:00.000000,,,,,
114,395367,2022-10-04 12:35:16.781424,Study Evaluating Kesimpta® Treatment Effects and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Other Disease Modifying Therapies,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Ofatumumab<br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05566756?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-10-04 12:00:00.000000,,,,,
115,394699,2022-10-03 13:45:16.832507,"""Evaluation of Usability and Safety of the Self-balancing Walking System Atalante in Patients With Multiple Sclerosis""",<b>Conditions</b>:    Multiple Sclerosis;   Ataxia;   Paraplegia<br /><b>Intervention</b>:    Device: Atalante<br /><b>Sponsor</b>:    Multiple Sclerosis Center of Catalonia<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05563402?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-10-03 12:00:00.000000,,,,,
116,392448,2022-09-30 12:40:12.831847,Prediction of Non-motor Symptoms in Fully Ambulatory MS Patients Using Vocal Biomarkers,"<b>Condition</b>:    Multiple Sclerosis, Vocal Biomarkers, Non Motor Symptoms<br /><b>Intervention</b>:    Other: Voice analysis<br /><b>Sponsors</b>:    University Hospital Inselspital, Berne;   AUDEERING GMBH<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05561621?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-30 12:00:00.000000,,,,,
117,392446,2022-09-30 12:40:12.826069,Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis - Impact on Spasticity and Pain,"<b>Conditions</b>:    Multiple Sclerosis;   Spasticity, Muscle;   Pain, Chronic<br /><b>Interventions</b>:    Device: FlowOx 2.0;   Device: FlowOx2.0 (Sham)<br /><b>Sponsor</b>:    Otivio AS<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05562453?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-30 12:00:00.000000,,,,,
118,392445,2022-09-30 12:40:12.823145,Transient and Immediate Motor Effects of Exercise in Progressive Multiple Sclerosis: A Pilot Study.,"<b>Conditions</b>:    Multiple Sclerosis, Chronic Progressive;   High-Intensity Interval Training;   Motor Symptoms<br /><b>Interventions</b>:    Behavioral: HIIT;   Behavioral: MCT<br /><b>Sponsor</b>:    Klinik Valens<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05562414?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-30 12:00:00.000000,,,,,
119,391648,2022-09-29 12:35:19.146318,The Effect of Transcranial Direct Current Stimulation on Fatigue Among Multiple Sclerosis Patients.Patients,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Device: a-tDCS<br /><b>Sponsor</b>:    Assiut University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05560139?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-29 12:00:00.000000,,,,,
120,391460,2022-09-29 06:05:13.299425,The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus,"<p>EudraCT Number: 2021-001144-98<br />Sponsor Protocol Number: LUB-COV-2021-01<br />Sponsor Name: Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie<br />Start Date: 2021-04-20<br />Medical condition: SARS-CoV-2 infection with one or more of the following symptoms: fever, cough, muscle aches, mild breathlessness, chest pain, diarrhea, nausea, vomiting, anosmia, lack of taste, sore throat, nasal ...<br />Disease: <br />Version: 23.1<br />SOC Term: 100000004848<br />Classification Code: 10084355<br />Term: COVID-19 virus test positive<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001144-98/PL"">PL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-001144-98,,,,,,
121,391452,2022-09-29 06:05:13.287465,"A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav...","<p>EudraCT Number: 2012-003176-39<br />Sponsor Protocol Number: 205MS303<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2013-05-31<br />Medical condition: Relapsing-remitting Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/IT"">IT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/IE"">IE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/FI"">FI</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/GR"">GR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/DK"">DK</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-003176-39,,,,,,
122,391003,2022-09-28 14:15:14.249469,Effect of the Vojta Therapy in Patients Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Randomized clinical trial.<br /><b>Sponsors</b>:    Aymara Abreu Corrales;   University of Salamanca<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05558683?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-28 12:00:00.000000,,,,,
123,388063,2022-09-23 12:25:18.584554,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH OCRELIZUMAB IN ADULT PATIENTS WITH PRIMARY PR...","<p>EudraCT Number: 2019-003919-53<br />Sponsor Protocol Number: GN41791<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2020-12-17<br />Medical condition: Primary Progressive multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003919-53/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-003919-53,,,,,,
124,385651,2022-09-19 13:30:17.667371,EMRESERVA to Enhance Cognitive Reserve in Multiple Sclerosis,<b>Condition</b>:    Cognitive Change<br /><b>Intervention</b>:    Behavioral: EMRESERVA<br /><b>Sponsor</b>:    Fundación Pública Andaluza para la gestión de la Investigación en Sevilla<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05546424?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-19 12:00:00.000000,,,,,
125,384566,2022-09-17 16:52:59.582237,Real World Study to Evaluate Patient and Care Partner Ratings on Early Experience of Injection and Device for KESIMPTA® (Ofatumumab) Indicated for Multiple Sclerosis,,https://www.novartis.com//clinicaltrials/study/nct05334472,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
126,384166,2022-09-17 00:10:14.971105,"A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes(PRO) in patients with relapsing multiple sclerosis (RMS) transi...","<p>EudraCT Number: 2019-001341-40<br />Sponsor Protocol Number: COMB157G23101<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2020-05-07<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/SI"">SI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/LV"">LV</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001341-40,,,,,,
127,383892,2022-09-16 14:10:13.594162,"In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases",<b>Conditions</b>:    Autoimmune Diseases;   Inflammatory Disease;   Acquired Bone Marrow Aplasia;   Systemic Lupus Erythematosus;   Multiple Sclerosis;   Gvhd;   Rheumatoid Arthritis;   Autoimmune Thyroiditis;   Vitiligo;   Alopecia;   Atopic Dermatitis<br /><b>Intervention</b>:    Other: Blood sample taken at a single time point<br /><b>Sponsor</b>:    Assistance Publique - Hôpitaux de Paris<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05544448?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-16 12:00:00.000000,,,,,
128,383890,2022-09-16 14:10:13.588187,Cognitive Markers in Prodromal MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Device: Active tDCS<br /><b>Sponsors</b>:    NYU Langone Health;   National Multiple Sclerosis Society<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05543915?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-16 12:00:00.000000,,,,,
129,383885,2022-09-16 14:10:13.573490,The Effects of Action Observation Therapy (AOT) on Balance and Gait in Patients With Multiple Sclerosis.,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Action Observation Therapy<br /><b>Sponsor</b>:    Shiraz University of Medical Sciences<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05543213?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-16 12:00:00.000000,,,,,
130,383310,2022-09-15 10:45:15.934300,The Effect of Reflexology and Pelvic Floor Muscle Exercises (Kegel) on Urinary Incontinence in MS Patients,<b>Conditions</b>:    Multiple Sclerosis;   Reflexology;   Urinary Incontinence<br /><b>Intervention</b>:    Other: Reflexology and kegel exercises<br /><b>Sponsor</b>:    Ondokuz Mayıs University<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05541965?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-15 12:00:00.000000,,,,,
131,382897,2022-09-14 15:35:19.909417,Vancomycin Study in Multiple Sclerosis (MS),<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Vancomycin;   Drug: Placebo<br /><b>Sponsors</b>:    Icahn School of Medicine at Mount Sinai;   Doris Duke Charitable Foundation<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05539729?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-14 12:00:00.000000,,,,,
132,380247,2022-09-09 15:00:11.488291,DECISIve - DiagnosE Using the Central veIn SIgn v1.0,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Diagnostic Test: Lumbar puncture;   Diagnostic Test: MRI<br /><b>Sponsor</b>:    Nottingham University Hospitals NHS Trust<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05533905?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-09 12:00:00.000000,,,,,
133,379693,2022-09-08 13:20:18.373479,A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    Drug: Natalizumab<br /><b>Sponsor</b>:    Biogen<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05532163?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-08 12:00:00.000000,,,,,
134,379691,2022-09-08 13:20:18.369338,Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Biological: Allogeneic umbilical cord mesenchymal stem cells;   Biological: Control group<br /><b>Sponsor</b>:    Ever Supreme Bio Technology Co., Ltd.<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05532943?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-08 12:00:00.000000,,,,,
135,379244,2022-09-07 14:40:13.228894,High Intensity Interval Gait Training in Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis,Gait, Exercise<br /><b>Interventions</b>:    Behavioral: Moderate paced continuous gait training;   Behavioral: High Intensity Interval gait training<br /><b>Sponsor</b>:    City University of New York<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05529498?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-07 12:00:00.000000,,,,,
136,378779,2022-09-06 14:55:13.287943,Risk Perception in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: High Efficacy Therapy (HET);   Other: Non High Efficacy Therapy (Non-HET)<br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05528666?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-05 12:00:00.000000,,,,,
137,376552,2022-09-02 15:55:22.461574,Effects of Dual-Task Training in People With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Dual-Task Training;   Other: Home Exercise Program<br /><b>Sponsor</b>:    Ege University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05526287?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-09-02 12:00:00.000000,,,,,
138,375907,2022-09-01 12:35:18.990114,A 2-year Prospective Study to Assess Health-related Quality of Life in Subjects with Highly-Active Relapsing Multiple Sclerosis Treated with Mavenclad®,"<p>EudraCT Number: 2017-002632-17<br />Sponsor Protocol Number: MS700568_0021<br />Sponsor Name: Merck KGaA<br />Start Date: 2018-01-30<br />Medical condition: Relapsing multiple sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/LT"">LT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/DK"">DK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/GR"">GR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002632-17,,,,,,
139,375273,2022-08-31 14:55:12.096764,Effect of Acupuncture on Heart Rate Variability in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Acupuncture Active;   Other: Acupuncture Sham<br /><b>Sponsor</b>:    University of Sao Paulo<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05523466?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-31 12:00:00.000000,,,,,
140,374738,2022-08-30 19:15:12.856445,"Development, Reliability and Validity of the Telerehabilitation Satisfaction Questionnaire- TSQ","<b>Condition</b>:    Neurological Disease<br /><b>Intervention</b>:    Other: Development of the Telerehabilitation Satisfaction Questionnaire<br /><b>Sponsor</b>:    Gazi University<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05520554?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-30 12:00:00.000000,,,,,
141,373795,2022-08-29 12:20:12.112100,Peer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-remitting<br /><b>Intervention</b>:    Other: Peer support<br /><b>Sponsor</b>:    Nantes University Hospital<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05519553?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-29 12:00:00.000000,,,,,
142,370859,2022-08-25 12:45:08.900676,"A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing (EID) of Natalizumab (BG00002) in Subjects With Rela...","<p>EudraCT Number: 2018-002145-11<br />Sponsor Protocol Number: 101MS329<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2019-03-21<br />Medical condition: Relapsing-remitting multiple sclerosis (RRMS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002145-11/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002145-11/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002145-11/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002145-11/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002145-11/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002145-11/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002145-11,,,,,,
143,370808,2022-08-25 11:05:08.383517,"Examining the Effects of a Remotely-delivered, Racially-tailored Exercise Training Program for Immediate and Sustained Improvements in Walking Dysfunction, Symptoms, and Health-related Quality of Life (HRQOL) Among African-Americans With Multiple Sclerosis (MS) Residing in Rural Environments.",<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Guidelines for Exercise in Multiple Sclerosis (GEMS);   Behavioral: FLEX Stretching and Toning Program<br /><b>Sponsors</b>:    University of Illinois at Chicago;   University of Alabama at Birmingham;   Bristol-Myers Squibb Foundation<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05516537?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-25 12:00:00.000000,,,,,
144,370807,2022-08-25 11:05:08.380598,Pharmacogenetics of Liver Toxicity in Patients With Multiple Sclerosis Treated With Fingolimod,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Genetic: Genetic polymorphism;   Diagnostic Test: Measurement of fingolimod and fingolimod-phosphate concentrations<br /><b>Sponsor</b>:    University Hospital, Caen<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05516303?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-25 12:00:00.000000,,,,,
145,369103,2022-08-23 06:00:10.564226,"An open-label, adaptive design study in patients with amyotrophic lateral sclerosis (ALS) to characterize safety, tolerability and brain microglia response, as measured by TSPO binding, following m...","<p>EudraCT Number: 2019-000826-22<br />Sponsor Protocol Number: CBLZ945C12201<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2019-09-17<br />Medical condition: Amyotrophic lateral sclerosis (ALS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10002026<br />Term: Amyotrophic lateral sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000826-22/SE"">SE</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000826-22/FI"">FI</a> (Restarted)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000826-22,,,,,,
146,368478,2022-08-22 12:55:10.890711,Multiparametric Assessment to Investigate Prognostic Factors for Disease Evolution a nd Evolutionary Patterns of Cognitive Status in RRMS,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    Other: Multiparametric assessment<br /><b>Sponsors</b>:    University Hospital of Mont-Godinne;   Saint-Luc University Hospital<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05510817?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-22 12:00:00.000000,,,,,
147,368474,2022-08-22 12:55:10.884001,Who Benefits Most From Cognitive Rehabilitation for Multiple Sclerosis?,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Cognitive Rehabilitation<br /><b>Sponsors</b>:    University of Nottingham;   MS Society;   University of Lincoln<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05509426?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-22 12:00:00.000000,,,,,
148,364489,2022-08-17 12:50:07.394575,"A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Subcutaneous...","<p>EudraCT Number: 2015-000922-12<br />Sponsor Protocol Number: TV44400-CNS-40083<br />Sponsor Name: Teva Pharmaceutical Industries, Ltd<br />Start Date: 2016-01-04<br />Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)<br />Disease: <br />Version: 18.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/IE"">IE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/HR"">HR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000922-12/IT"">IT</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-000922-12,,,,,,
149,364474,2022-08-17 12:50:07.035462,"The Effect of Backward Walking Training on Balance, Gait and Functional Mobility in Patients With Multiple Sclerosis",<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Exercise training<br /><b>Sponsors</b>:    Saglik Bilimleri Universitesi;   Ankara University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05505383?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-17 12:00:00.000000,,,,,
150,364469,2022-08-17 12:15:16.361992,"Open-Label, Multicenter, Multiple-Dose Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis Aged 10 to 17 Years","<p>EudraCT Number: 2014-005003-24<br />Sponsor Protocol Number: 109MS202<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2015-06-01<br />Medical condition: Relapsing-Remitting Multiple Sclerosis<br />Disease: <br />Version: 17.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029205<br />Term: Nervous system disorders<br />Level: SOC<br />Version: 17.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005003-24/LV"">LV</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005003-24/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005003-24/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005003-24/BG"">BG</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005003-24/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005003-24/BE"">BE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-005003-24,,,,,,
151,363697,2022-08-16 11:20:12.715644,A Measurement Study of TIS-modNV and AccuGait Force Platform in People With MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsors</b>:    Nordlandssykehuset HF;   Nord University;   Helse Nord<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05503628?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-16 12:00:00.000000,,,,,
152,363692,2022-08-16 11:20:12.701964,Finding Patterns In Clinical Study Experiences of Multiple Sclerosis Patients,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Power Life Sciences Inc.<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05503524?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-16 12:00:00.000000,,,,,
153,363672,2022-08-16 10:15:16.351517,"A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY...","<p>EudraCT Number: 2012-002714-40<br />Sponsor Protocol Number: RPC01-201<br />Sponsor Name: Receptos, Inc.<br />Start Date: 2013-05-09<br />Medical condition: RELAPSING MULTIPLE SCLEROSIS<br />Disease: <br />Version: 14.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/IT"">IT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/BG"">BG</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/GR"">GR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/HR"">HR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002714-40,,,,,,
154,362944,2022-08-15 10:45:08.852519,Reducing Fatigue in People With Multiple Sclerosis by Treatment With TENS,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Device: Transcutaneous electrical nerve stimulation<br /><b>Sponsor</b>:    University of Colorado, Boulder<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05500963?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-15 12:00:00.000000,,,,,
155,361659,2022-08-13 12:42:11.120527,Clemastine fumarate as remyelinating treatment in internuclear ophthalmoparesis and multiple sclerosis,"<p>EudraCT Number: 2021-003677-66<br />Sponsor Protocol Number: RESTORE<br />Sponsor Name: Amsterdam University Medical Center<br />Start Date: 2022-02-14<br />Medical condition: Multiple sclerosis (MS)
Internuclear ophthalmoparesis (INO)<br />Disease: <br />Version: 21.0<br />SOC Term: 100000004852<br />Classification Code: 10080865<br />Term: Multiple sclerosis lesion<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003677-66/NL"">NL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-003677-66,,,,,,
156,361454,2022-08-13 04:12:37.212398,"A 12-month, Open-label, Prospective, Multicenter, Interventional, Single-arm Study Assessing the Efficacy and Safety of Ofatumumab 20 mg Subcutaneous (s.c.) Injection in Relapsing Multiple Sclerosis (RMS) Patients in China",,https://www.novartis.com//clinicaltrials/study/nct05199571,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
157,360541,2022-08-11 12:55:08.944779,A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis,"<b>Condition</b>:    Relapsing Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Mitoxantrone Hydrochloride Liposome Injection<br /><b>Sponsor</b>:    CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05496894?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-11 12:00:00.000000,,,,,
158,360540,2022-08-11 12:55:08.935585,Exercise and Progressive Multiple Sclerosis,<b>Condition</b>:    Progressive Multiple Sclerosis<br /><b>Interventions</b>:    Other: Exercise Group 1;   Other: Exercise Group 2;   Other: Exercise Group 3<br /><b>Sponsors</b>:    University of Regina;   First Steps Wellness Centre;   Saskatchewan Health Research Foundation;   University of Saskatchewan<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05496881?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-11 12:00:00.000000,,,,,
159,360050,2022-08-10 08:48:55.200584,Exploring the Characteristics and Profiles of Relapsing Multiple Sclerosis Patients Initiated on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf Region,,https://www.novartis.com//clinicaltrials/study/nct05266469,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
160,360049,2022-08-10 08:48:55.199298,"AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Naïve, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes.",,https://www.novartis.com//clinicaltrials/study/nct05084638,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
161,359663,2022-08-09 12:40:08.602077,"A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS","<p>EudraCT Number: 2018-001511-73<br />Sponsor Protocol Number: WA40404<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2019-12-23<br />Medical condition: <br />Disease: <br />Population Age: <br />Gender: <br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/IE"">IE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/HR"">HR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001511-73,,,,,,
162,359658,2022-08-09 12:40:08.319270,Clinical and Instrumental Treatment's Predictors in Subjects With Neurological Diseases Using G-EO Robotic System,<b>Conditions</b>:    Multiple Sclerosis;   Stroke;   Parkinson Disease;   Acquired Brain Injury<br /><b>Intervention</b>:    Device: Robotic Assisted Gait Training with G-EO system<br /><b>Sponsor</b>:    Fondazione Don Carlo Gnocchi Onlus<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05493514?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-09 12:00:00.000000,,,,,
163,359450,2022-08-09 00:30:12.873049,A randomised controlled trial to compare ocrelizumab or alemtuzumab with autologous hematopoietic stem cell transplantation (aHSCT) in high inflammatory multiple sclerosis (COAST),"<p>EudraCT Number: 2016-001166-29<br />Sponsor Protocol Number: inims-009<br />Sponsor Name: University Medical Centre Hamburg-Eppendorf<br />Start Date: 2020-03-18<br />Medical condition: relapsing-remitting multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001166-29/DE"">DE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-001166-29,,,,,,
164,359260,2022-08-08 11:25:14.909900,MRI Biomarkers Predictive of Disability Progression in Patients With Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Magnetic Resonance Spectroscopy<br /><b>Intervention</b>:    Other: magnetic resonance spectroscopy<br /><b>Sponsor</b>:    Poitiers University Hospital<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05491031?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-08 12:00:00.000000,,,,,
165,357196,2022-08-01 14:05:08.992058,Common and Specific Information From Neuroimaging and Smartphone,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: eGait<br /><b>Sponsors</b>:    Nantes University Hospital;   Rennes University Hospital<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05482906?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-01 12:00:00.000000,,,,,
166,357195,2022-08-01 14:05:08.989228,Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Interventions</b>:    Other: Autologous hematopoietic stem cell transplantation;   Drug: Cyclophosphamide/ATG;   Drug: Cyclophosphamide/Rituximab<br /><b>Sponsor</b>:    Scripps Health<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05482542?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-08-01 12:00:00.000000,,,,,
167,357132,2022-08-01 11:55:08.693864,"A Double Blind, Randomised, Placebo Controlled Study Investigating Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis in patients treated with Copaxone...","<p>EudraCT Number: 2006-001827-21<br />Sponsor Protocol Number: CoSim-01<br />Sponsor Name: Glostrup Hospital, Dep. of Neurology<br />Start Date: 2009-03-06<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 9.1<br />SOC Term: <br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001827-21/DK"">DK</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001827-21,,,,,,
168,355015,2022-07-29 15:12:09.261553,"A 32-week, patient- and rater-blinded, randomized, multi-center, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from...","<p>EudraCT Number: 2011-001442-15<br />Sponsor Protocol Number: CFTY720D2324<br />Sponsor Name: Novartis Pharma Services AG<br />Start Date: 2011-08-26<br />Medical condition: relapsing remitting multiple sclerosis<br />Disease: <br />Version: 14.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/DE"">DE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/GR"">GR</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/AT"">AT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/FI"">FI</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001442-15/IT"">IT</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-001442-15,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
169,354001,2022-07-29 07:55:06.859149,"A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of Multiple Sclerosis","<p>EudraCT Number: 2005-001567-55<br />Sponsor Protocol Number: DAC-1012<br />Sponsor Name: Protein Design Labs, Inc.<br />Start Date: 2006-06-23<br />Medical condition: This study is performed in patients with relapsing forms of Multiple Sclerosis. Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS), thought ...<br />Disease: <br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001567-55/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001567-55/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001567-55/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001567-55/ES"">ES</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001567-55,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
170,353998,2022-07-29 07:55:06.854174,"A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis.","<p>EudraCT Number: 2004-002571-16<br />Sponsor Protocol Number: MBP8298-01 Amendment 04<br />Sponsor Name: BioMS Technology Corp<br />Start Date: 2007-06-29<br />Medical condition: Secondary progressive multiple sclerosis<br />Disease: <br />Version: 8.1<br />SOC Term: <br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002571-16/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002571-16/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002571-16/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002571-16/DK"">DK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002571-16/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002571-16/EE"">EE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002571-16/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002571-16/LT"">LT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002571-16/LV"">LV</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002571-16,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
171,351469,2022-07-28 11:11:55.735831,FATIMS - Fampyra and T cell Immunity in Multiple Sclerosis; a study of the Fampyra induced immunomodulatory T cell responses in MS,"<p>EudraCT Number: 2013-001409-10<br />Sponsor Protocol Number: FATIMS1.0<br />Sponsor Name: Odense University Hospital<br />Start Date: 2013-08-08<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 14.1<br />SOC Term: 100000004852<br />Classification Code: 10039720<br />Term: Sclerosis multiple<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001409-10/DK"">DK</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-001409-10,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
172,351201,2022-07-28 08:25:12.318980,Methylphenidate modified release as treatment option of MS-associated fatigue. A single-center randomized double-blind placebo-controlled trial.,"<p>EudraCT Number: 2012-003418-15<br />Sponsor Protocol Number: SSP<br />Sponsor Name: Medizinische Universität Wien<br />Start Date: 2012-10-23<br />Medical condition: Fatigue is a very common symptom in multiple sclerosis. Its management comprises nonpharmacologic approaches like exercise, cooling procedures and energy conservation programs and as second step ph...<br />Disease: <br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003418-15/AT"">AT</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-003418-15,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
173,345885,2022-07-26 12:25:09.652859,"Effect of Tai Chi on Balance, Mood, Cognition, and Quality of Life in Patients With Multiple Sclerosis","<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: ""Tai-chi"" - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes<br /><b>Sponsor</b>:    Comenius University<br /><b>Completed</b>",https://clinicaltrials.gov/ct2/show/NCT05474209?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-26 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
174,334452,2022-07-22 14:20:11.040205,"A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open label long...","<p>EudraCT Number: 2022-000049-34<br />Sponsor Protocol Number: ACT16753<br />Sponsor Name: Sanofi-aventis recherche & développement<br />Start Date: 2022-07-21<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000049-34/ES"">ES</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2022-000049-34,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
175,334055,2022-07-22 11:15:09.382328,GentleCath™ Air for Men Intermittent Catheter With FeelClean™ Technology,<b>Conditions</b>:    Bladder Outlet Obstruction;   Multiple Sclerosis;   Cauda Equina Syndrome;   Enlarged Prostate With Lower Urinary Tract Symptoms;   Parkinson Disease;   Lower Urinary Tract Symptoms;   Detrusor Underactivity;   Spinal Cord Injuries<br /><b>Intervention</b>:    Device: Intermittent self-catheterisation<br /><b>Sponsor</b>:    ConvaTec Inc.<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05470751?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-22 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
176,334052,2022-07-22 11:15:09.375567,Lower Extremities Closed Kinetic Chain Exercises for People With MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Combination Product: Telko plus conventional physical therapy (CPT)<br /><b>Sponsor</b>:    Anas Radi Hassan Alashram<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05460299?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-15 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
177,333284,2022-07-22 05:28:03.917167,An Open-label Multicenter Study to Assess Response to COVID-19 Vaccine in Participants With Multiple Sclerosis Treated With Ofatumumab 20 mg Subcutaneously,,https://www.novartis.com//clinicaltrials/study/nct04878211,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
178,330654,2022-07-21 10:50:05.623200,Hybrid Rehabilitation Approach Through Group Exercise and Telerehabilitation in Patients With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Circuit training followed by telerehabilitation;   Other: Usual care<br /><b>Sponsor</b>:    Brno University Hospital<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05469568?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-21 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
179,327489,2022-07-20 11:50:06.632653,RELAXaHEAD for Headache Patients (Phase II),"<b>Conditions</b>:    Migraine;   Headache;   Multiple Sclerosis;   Insomnia<br /><b>Interventions</b>:    Behavioral: Smartphone-Based Progressive Muscle Relaxation Therapy (PMR);   Behavioral: Monitored Usual Care (MUC)<br /><b>Sponsors</b>:    NYU Langone Health;   Center for Advancing Point of Care Technologies;   National Heart, Lung, and Blood Institute (NHLBI)<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05466682?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-20 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
180,327361,2022-07-20 10:50:07.508940,"An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and its Effect on Immune Tolerance in Subjects with Relapsing Multiple Sclerosis","<p>EudraCT Number: 2013-002916-28<br />Sponsor Protocol Number: EMR200166-001<br />Sponsor Name: Merck KGaA<br />Start Date: 2013-12-12<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10067063<br />Term: Progressive relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002916-28/LV"">LV</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002916-28,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
181,321804,2022-07-18 10:35:05.909973,Memory Rehabilitation Strategies in Patients With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Cognitive Rehabilitation;   Behavioral: Combined Rehabilitation;   Behavioral: Motor Rehabilitation<br /><b>Sponsor</b>:    I.R.C.C.S. Fondazione Santa Lucia<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05462678?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-18 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
182,314260,2022-07-15 12:45:06.942727,Long-term follow-up study to monitor the growth and development of pediatric patients previously treated with everolimus in study CRAD001M2301,"<p>EudraCT Number: 2013-003795-13<br />Sponsor Protocol Number: CRAD001M2305<br />Sponsor Name: Novartis Pharma Services AG<br />Start Date: 2014-12-10<br />Medical condition: Subependymal Giant Cell Astrocytoma (SEGA) associated with Tuberous Sclerosis Complex (TSC)<br />Disease: <br />Version: 21.0<br />SOC Term: 100000004850<br />Classification Code: 10045138<br />Term: Tuberous sclerosis<br />Level: LLT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003795-13/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003795-13/PL"">PL</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-003795-13,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
183,314057,2022-07-15 11:25:10.311767,Lower Extremities Closed Kinetic Chain Training for People With MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Combination Product: Telko plus conventional physical therapy (CPT)<br /><b>Sponsor</b>:    Anas Radi Hassan Alashram<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05460299?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-15 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
184,310358,2022-07-14 11:07:07.912983,Fatigue and Sleep Quality in Multiple Sclerosis Patients,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Reiki<br /><b>Sponsor</b>:    Istanbul Sabahattin Zaim University<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05456464?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-13 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
185,309308,2022-07-11 10:45:06.450197,Deep Brain Stimulation for Refractory Trigeminal Neuralgia With a Demyelinating Pontine Lesion,<b>Condition</b>:    Trigeminal Neuralgia<br /><b>Intervention</b>:    Device: Deep brain stimulation<br /><b>Sponsor</b>:    Université de Sherbrooke<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05451251?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-11 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
186,309305,2022-07-11 10:45:06.447701,"Effects of CT-100, a DiNaMo Component on Cognitive Functioning and Mood Symptoms","<b>Conditions</b>:    Multiple Sclerosis;   Mild Cognitive Impairment;   Cancer<br /><b>Interventions</b>:    Other: CT-100 DiNaMo;   Other: Care-as-Usual<br /><b>Sponsor</b>:    Click Therapeutics, Inc.<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05438147?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-29 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
187,309294,2022-07-11 10:45:06.438306,"Neurofilament Light Chain ,Chitinase-3 Like-1 Proteins and Plasmacytoid Dendritic Cells in Multiple Sclerosis","<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Diagnostic Test: Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic plasmacytoid Dendritic Cells<br /><b>Sponsor</b>:    Assiut University<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05451069?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-11 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
188,308231,2022-07-11 05:50:07.081428,"A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT...","<p>EudraCT Number: 2015-003471-30<br />Sponsor Protocol Number: D-FR-52120-222<br />Sponsor Name: Ipsen Innovation<br />Start Date: 2016-09-26<br />Medical condition: Urinary incontinence (UI) caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10038359 - Renal and urinary disorders<br />Classification Code: 10046543<br />Term: Urinary incontinence<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003471-30/RO"">RO</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003471-30/PT"">PT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003471-30/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003471-30/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003471-30/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003471-30/PL"">PL</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-003471-30,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
189,294370,2022-07-08 13:50:08.133008,Psychometric Evaluation in Patients With Brain Damage During Neuroinflammation (NeuroPsyc),<b>Conditions</b>:    Multiple Sclerosis;   Epilepsy;   Parkinson Disease;   Dementia;   Stroke<br /><b>Intervention</b>:    Behavioral: Psychometric Evaluations<br /><b>Sponsor</b>:    Neuromed IRCCS<br /><b>Enrolling by invitation</b>,https://clinicaltrials.gov/ct2/show/NCT05450237?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-08 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
190,294362,2022-07-08 13:50:08.051654,Sensory Integration Disorders in Patients With MS Including Disease Advancement and Relapses in the Last Year,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Diagnostic Test: Scale for the Assessment of Sensory Integration in Adults<br /><b>Sponsor</b>:    Pomeranian Medical University Szczecin<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05449574?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-08 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
191,289503,2022-07-07 13:50:06.032417,Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Exercise Program;   Telerehabilitation;   Autoimmune Disorder<br /><b>Interventions</b>:    Other: Fatigue Severity Scale;   Other: Berg Balance Test;   Other: Time up and go- 25 steps walking test;   Other: Multiple Sclerosis Quality of Life;   Other: Brief International Cognitive Assessment for MS (BICAMS);   Other: Beck Depression and Anxiety Scale<br /><b>Sponsor</b>:    Muğla Sıtkı Koçman University<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05447143?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-07 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
192,288222,2022-07-07 07:10:07.376837,Long-term extension safety and efficacy study of SAR442168 in participants with relapsing multiple sclerosis,"<p>EudraCT Number: 2018-004731-76<br />Sponsor Protocol Number: LTS16004<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2019-04-18<br />Medical condition: Relapsing multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10067063<br />Term: Progressive relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004731-76/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004731-76/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004731-76/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004731-76/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004731-76/NL"">NL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004731-76,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
193,284701,2022-07-06 13:46:51.450978,Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimE,<b>Condition</b>:    Relapsing Remitting Multiple Sclerosis<br /><b>Intervention</b>:    Other: Clinical assessment<br /><b>Sponsors</b>:    NHS Greater Glasgow and Clyde;   Biogen<br /><b>Enrolling by invitation</b>,https://clinicaltrials.gov/ct2/show/NCT05446285?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-06 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
194,283085,2022-07-06 04:45:53.980722,"A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety &amp; Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament ...",,https://www.novartis.com//clinicaltrials/study/nct05090371,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
195,280201,2022-07-05 13:10:06.441708,Effects of CT-100 DiNaMo Components on Cognitive Functioning and Mood Symptoms,"<b>Conditions</b>:    Multiple Sclerosis;   Mild Cognitive Impairment;   Cancer<br /><b>Interventions</b>:    Other: CT-100 DiNaMo;   Other: Care-as-Usual<br /><b>Sponsor</b>:    Click Therapeutics, Inc.<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05438147?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-29 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
196,279539,2022-07-05 09:45:08.278074,"A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's Disease","<p>EudraCT Number: 2016-001634-10<br />Sponsor Protocol Number: M15-566<br />Sponsor Name: AbbVie Deutschland GmbH & Co. KG<br />Start Date: 2017-08-23<br />Medical condition: Alzheimer's Disease<br />Disease: <br />Version: 20.0<br />SOC Term: 100000004852<br />Classification Code: 10001896<br />Term: Alzheimer's disease<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001634-10/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001634-10/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001634-10/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001634-10/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001634-10/DK"">DK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001634-10/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001634-10/IT"">IT</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-001634-10,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
197,278959,2022-07-05 06:31:52.363008,An open-label multicenter study to assess response to SARS-CoV-2 modRNA vaccines in participants with secondary progressive multiple sclerosis treated with Mayzent (siponimod) (AMA-VACC),"<p>EudraCT Number: 2020-005752-38<br />Sponsor Protocol Number: CBAF312ADE03<br />Sponsor Name: Novartis Pharma GmbH<br />Start Date: 2021-03-18<br />Medical condition:  secondary progressive multiple sclerosis (SPMS) <br />Disease: <br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005752-38/DE"">DE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005752-38,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
198,266994,2022-07-01 14:47:06.185610,Trial of eHealth Wellness Behavioral Interventions and Patient-reported Outcomes,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Wellness Patient Message<br /><b>Sponsor</b>:    Johns Hopkins University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05442112?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-01 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
199,266988,2022-07-01 14:47:06.178929,Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis,<b>Condition</b>:    Progressive Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Placebo;   Drug: Masitinib (4.5)<br /><b>Sponsor</b>:    AB Science<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05441488?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-07-01 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
200,266340,2022-07-01 08:36:50.661441,Discontinuation of first-line disease modifying treatment (DMT) in long-term full responders MS patients: a multicentre randomized clinical trial.,"<p>EudraCT Number: 2016-004819-12<br />Sponsor Protocol Number: FullResponders<br />Sponsor Name: OSPEDALE SAN RAFFAELE<br />Start Date: 2018-01-10<br />Medical condition: Relapsing-Remitting multiple sclerosis (RR-MS),<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004819-12/IT"">IT</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004819-12,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
201,263953,2022-06-30 15:05:07.894115,A Study of LP-168 in Healthy Volunteers,<b>Conditions</b>:    Multiple Sclerosis;   NMO Spectrum Disorder<br /><b>Interventions</b>:    Drug: LP-168 tablet;   Drug: LP-168 Placebo tablet<br /><b>Sponsor</b>:    Guangzhou Lupeng Pharmaceutical Company LTD.<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05432713?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-27 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
202,263952,2022-06-30 15:05:07.892856,Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women,<b>Conditions</b>:    Multiple Sclerosis;   Dysuria;   Lower Urinary Tract Symptoms;   Voiding Dysfunction;   Urinary Retention<br /><b>Interventions</b>:    Drug: Tamsulosin;   Drug: Placebo<br /><b>Sponsor</b>:    Centre Hospitalier Universitaire de Nīmes<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05439902?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-30 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
203,263946,2022-06-30 15:05:07.887310,"Delayed Diagnosis of Multiple Sclerosis, Treatment Initiation and Non-adherence in Upper Egypt","<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    doaa mokhtar mahmoud<br /><b>Completed</b>",https://clinicaltrials.gov/ct2/show/NCT05438693?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-30 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
204,263720,2022-06-30 13:10:07.429058,"Multicenter, randomized, double-blind, parallel-group extension to study AC 058B201 to investigate the long-term safety, tolerability, and efficacy of 10, 20, and 40 mg/day ponesimod, an oral S1P1 ...","<p>EudraCT Number: 2009-011470-15<br />Sponsor Protocol Number: AC-058B202<br />Sponsor Name: ACTELION Pharmaceuticals Ltd<br />Start Date: 2010-03-30<br />Medical condition: relapsing-remitting multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011470-15/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011470-15,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
205,260469,2022-06-29 14:10:57.251228,Effects of a CT-100 DiNaMo Components on Cognitive Functioning and Mood Symptoms,"<b>Conditions</b>:    Multiple Sclerosis;   Mild Cognitive Impairment;   Cancer<br /><b>Interventions</b>:    Other: CT-100 DiNaMo;   Other: Care-as-Usual<br /><b>Sponsor</b>:    Click Therapeutics, Inc.<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05438147?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-29 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
206,260463,2022-06-29 14:10:57.224724,A Therapeutic Experience Program (TEP) Study for Improvement of Gait in People With Multiple Sclerosis (MS),<b>Condition</b>:    Gait Impairment Due to Mild/Moderate Multiple Sclerosis (MS)<br /><b>Intervention</b>:    Device: PoNS®<br /><b>Sponsor</b>:    Helius Medical Inc<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05437276?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-29 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
207,259738,2022-06-29 08:20:14.299583,The effect of medical cannabis on neuropathic pain and spasticity in patients with Multiple Sclerosis and in patients with spinal cord injury. A multicenter national placebo-controlled trial,"<p>EudraCT Number: 2018-002315-98<br />Sponsor Protocol Number: MedicalcannabisMSSCI2018<br />Sponsor Name: Aarhus Universitetshospital<br />Start Date: 2018-12-06<br />Medical condition: Central neuropathic pain and spasticity<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028335<br />Term: Muscle spasticity<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10077975<br />Term: Central neuropathic pain<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002315-98/DK"">DK</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002315-98,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
208,259594,2022-06-29 07:25:28.997346,"A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis","<p>EudraCT Number: 2019-002625-29<br />Sponsor Protocol Number: GWSP19066<br />Sponsor Name: GW Pharma Limited<br />Start Date: 2020-01-14<br />Medical condition: Symptomatic treatment of spasticity in patients with multiple sclerosis (MS)<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028335<br />Term: Muscle spasticity<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002625-29/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002625-29/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002625-29/CZ"">CZ</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002625-29,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
209,259020,2022-06-29 02:45:53.850455,Impact of Mayzent (Siponimod) on Active Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study in Italy,,https://www.novartis.com//clinicaltrials/study/nct05376579,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
210,257014,2022-06-28 13:35:06.755691,Qualitative Study Patient & Physician Experiences Botox COVID-19,<b>Conditions</b>:    Chronic Brain Injury;   Cerebral Stroke;   MS (Multiple Sclerosis)<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    East Kent Hospitals University NHS Foundation Trust<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05435404?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-28 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
211,253330,2022-06-27 13:30:06.503597,A Phase I Study of LP-168 in Healthy Volunteers,<b>Conditions</b>:    Multiple Sclerosis;   NMO Spectrum Disorder<br /><b>Interventions</b>:    Drug: LP-168 tablet;   Drug: LP-168 Placebo tablet<br /><b>Sponsor</b>:    Guangzhou Lupeng Pharmaceutical Company LTD.<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05432713?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-27 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
212,253327,2022-06-27 13:30:06.499720,Blood Flow Restriction And Veterans With MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Low-Load Exercise with Blood Flow Restriction;   Other: Low-Load Exercise Control Group<br /><b>Sponsor</b>:    VA Office of Research and Development<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05433103?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-27 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
213,253321,2022-06-27 13:30:06.486520,Figure of 8 Walk Test in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Assesment<br /><b>Sponsor</b>:    Kahramanmaras Sutcu Imam University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05433714?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-27 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
214,252595,2022-06-27 07:10:07.122661,"Multicenter, non-comparative extension to study AC-058B301, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with relapsing multiple sclerosis","<p>EudraCT Number: 2016-004719-10<br />Sponsor Protocol Number: AC-058B303<br />Sponsor Name: Actelion Pharmaceuticals Ltd.<br />Start Date: 2017-10-02<br />Medical condition: relapsing multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/HR"">HR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004719-10/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004719-10,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
215,248011,2022-06-25 12:51:53.078174,Tracking the Immune Response to SARS-CoV-2 modRNA Vaccines in an Open-label Multicenter Study in Participants With Relapsing Multiple Sclerosis Treated With Ofatumumab s.c. (KYRIOS),,https://www.novartis.com//clinicaltrials/study/nct04869358,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
216,238945,2022-06-22 14:05:06.715126,A Pilot Project for Multifidus Muscle Evaluation in Patients With Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Back Pain<br /><b>Intervention</b>:    Other: home - exercise program<br /><b>Sponsor</b>:    University of Arkansas<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05427045?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-22 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
217,238944,2022-06-22 14:05:06.713734,Artificial Intelligence in Predicting Progression in Multiple Sclerosis Study,<b>Conditions</b>:    Multiple Sclerosis;   Multiple Sclerosis Lesion;   Multiple Sclerosis Brain Lesion<br /><b>Intervention</b>:    <br /><b>Sponsors</b>:    University of Ljubljana;   Novartis;   General and Teaching Hospital Celje;   University Medical Centre Ljubljana;   University Medical Centre Maribor;   General Hospital Izola<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05426980?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-22 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
218,235662,2022-06-21 14:30:07.076364,"Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt",<b>Condition</b>:    Relapsing-Remitting Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Fingolimod<br /><b>Sponsor</b>:    Hikma Pharmaceuticals LLC<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05423769?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-20 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
219,220059,2022-06-16 12:41:47.930743,PTNS for Female Patients Suffering From Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Overactive Bladder<br /><b>Interventions</b>:    Device: PTNS Treatment;   Device: Sham PTNS Treatment<br /><b>Sponsor</b>:    William Beaumont Hospitals<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05422625?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-16 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
220,218958,2022-06-16 05:44:17.796074,Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients (Prevention of Relapses and Delay of Progression of Physical Disability in Secondary Progressive Multiple Sclerosis),,https://www.novartis.com//clinicaltrials/study/nct04593927,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
221,215828,2022-06-15 11:10:05.936487,Designing Virtual Reality-based Software for People With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Exergaming<br /><b>Sponsors</b>:    Yuzuncu Yıl University;   Dokuz Eylul University<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05420532?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-15 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
222,215160,2022-06-15 06:55:08.370544,"An open-label, multi-center long-term safety roll-over study in patients with tuberous sclerosis complex (TSC) and refractory seizures who are judged by the Investigator to benefit from continued t...","<p>EudraCT Number: 2016-002977-37<br />Sponsor Protocol Number: CRAD001M2X02B<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2017-08-25<br />Medical condition: Refractory seizures associated with tuberous sclerosis complex<br />Disease: <br />Version: 20.0<br />SOC Term: 10010331 - Congenital, familial and genetic disorders<br />Classification Code: 10045138<br />Term: Tuberous sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18, Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002977-37/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002977-37/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002977-37/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002977-37/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002977-37/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002977-37/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002977-37/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002977-37,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
223,213658,2022-06-14 21:05:12.251263,"AttackMS - Treatment of People With Inflammatory Demyelination Suggestive of MS, or Definite MS, at First Presentation",<b>Conditions</b>:    Multiple Sclerosis;   Clinically Isolated Syndrome of Demyelination<br /><b>Interventions</b>:    Drug: Tysabri Injectable Product;   Drug: Placebo<br /><b>Sponsor</b>:    Queen Mary University of London<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05418010?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-14 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
224,213655,2022-06-14 21:05:12.248120,Study of IMCY-0141 in Recent Onset of Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Interventions</b>:    Drug: IMCY-0141;   Drug: Placebo;   Drug: Dimethyl Fumarate<br /><b>Sponsor</b>:    Imcyse SA<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05417269?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-14 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
225,208909,2022-06-13 15:16:50.808302,Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM),"<b>Condition</b>:    Demyelinating Diseases of the Central Nervous System (DDC)<br /><b>Intervention</b>:    Other: Traditional Chinese medicine (TCM)<br /><b>Sponsor</b>:    Dongzhimen Hospital, Beijing<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05415579?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-13 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
226,208903,2022-06-13 15:16:50.804072,"""Outwalk MS"" - Benefits of Outdoor Walking in Multiple Sclerosis",<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Walking exercise therapy<br /><b>Sponsors</b>:    University of Aarhus;   The Danish MS Society<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05415956?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-13 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
227,208299,2022-06-13 11:15:08.487235,"COMBAT-MS (COMparison Between All immunoTherapies for Multiple Sclerosis)

A prospective long-term cohort study of safety, efficacy and patient’s satisfaction of MS disease modulatory treatments in...","<p>EudraCT Number: 2016-003587-39<br />Sponsor Protocol Number: COMBAT-MS<br />Sponsor Name: Karolinska Institutet<br />Start Date: 2017-05-22<br />Medical condition: Relapsing-remitting multiple sclerosis (RRMS) that has started on their first or second immunomodulatory drug at the earliest 2011-01-01 and at the latest 2018-06-30. The clinical course and respon...<br />Disease: <br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003587-39/SE"">SE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003587-39,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
228,198045,2022-06-10 11:50:06.588618,Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases,<b>Conditions</b>:    Multiple Sclerosis;   Neuromyelitis Optica Spectrum Disorder;   Demyelinating Diseases of the Central Nervous System<br /><b>Intervention</b>:    Drug: Ofatumumab<br /><b>Sponsor</b>:    Tianjin Medical University General Hospital<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05414487?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-10 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
229,194704,2022-06-09 10:17:19.493858,"Fatigability in Persons With Multiple Sclerosis: Inputs From Cognition, Walking and Coordination","<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Dance therapy;   Other: Psychometric properties (Validity, Reliability) of interlimb coordination- and cognitive-fatigability<br /><b>Sponsors</b>:    Hasselt University;   Revalidatie & MS Centrum Overpelt;   National MS Center Melsbroek<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05412043?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-09 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
230,192026,2022-06-08 11:01:18.533754,The Effects of Vestibular Exercise and Cervical Stabilization Exercise Training on Balance and Gait in MS Patients,<b>Conditions</b>:    Multiple Sclerosis;   Vestibular;   Exercises<br /><b>Intervention</b>:    Other: Exercises<br /><b>Sponsor</b>:    Sanko University<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05409599?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-08 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
231,189746,2022-06-07 14:25:07.321561,Accelerated Brain Volume Loss in People With Multiple Sclerosis,<b>Condition</b>:    Retrospective Study<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    National MS Center Melsbroek<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05408767?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-07 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
232,188818,2022-06-07 05:55:06.748331,"A PHASE IV MULTICENTER, OPEN-LABEL STUDY EVALUATING B CELL LEVELS IN INFANTS POTENTIALLY EXPOSED TO OCRELIZUMAB DURING PREGNANCY – THE MINORE STUDY","<p>EudraCT Number: 2021-000062-14<br />Sponsor Protocol Number: MN42988<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2021-10-08<br />Medical condition: Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications]<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10071068<br />Term: Clinically isolated syndrome<br />Level: PT<br /><br />Population Age: In utero, Under 18, Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000062-14/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000062-14/DE"">DE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000062-14,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
233,186918,2022-06-06 12:50:08.897335,"Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with
Progressive Multiple Sclerosis","<p>EudraCT Number: 2021-000048-23<br />Sponsor Protocol Number: P2-IMU-838-PMS<br />Sponsor Name: Immunic AG<br />Start Date: 2021-11-04<br />Medical condition: Progressive forms of Multiple Sclerosis <br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10053395<br />Term: Progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000048-23,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
234,178960,2022-06-03 10:36:19.788888,The Effect of Covid-19 on the Disease Course of Multiple Sclerosis :Belgian Lessons Learned From Rocky I to Rocky IV,<b>Condition</b>:    COVID-19<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Marie D'hooghe<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05403463?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-03 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
235,178111,2022-06-03 03:07:38.574526,"A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib",,https://www.novartis.com//clinicaltrials/study/nct05156281,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
236,178110,2022-06-03 03:07:38.548580,"An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis",,https://www.novartis.com//clinicaltrials/study/nct03650114,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
237,178109,2022-06-03 03:07:38.545757,"A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety &amp; Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase",,https://www.novartis.com//clinicaltrials/study/nct01892722,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
238,176526,2022-06-02 14:30:06.875405,Aerobic Exercise in Persons With Multiple Sclerosis With Restless Legs Syndrome,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Aerobic exercise<br /><b>Sponsor</b>:    Dokuz Eylul University<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05402956?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-02 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
239,176523,2022-06-02 14:30:06.868908,Lifestyle Intervention for Patients With Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Lifestyle intervention program ""Leef! met MS""<br /><b>Sponsors</b>:    Amsterdam UMC, location VUmc;   National MS Foundation, The Netherlands;   Voeding Leeft<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05402501?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-06-02 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
240,173628,2022-06-01 13:40:06.832946,COVID-19 on Disease Activity in Radiologically Isolated Syndrome Cohort,<b>Conditions</b>:    Multiple Sclerosis;   COVID-19<br /><b>Intervention</b>:    Other: NO intervention<br /><b>Sponsor</b>:    Centre Hospitalier Universitaire de Nice<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05387395?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-24 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
241,173583,2022-06-01 01:07:37.471620,"A Non-interventional Study Evaluating Injectable Treatments (Ofatumumab, Glatiramer Acetate and Interferon β1) in Patients With Relapsing Multiple Sclerosis [AIOLOS]",,https://www.novartis.com//clinicaltrials/study/nct05344469,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
242,173080,2022-05-26 15:40:06.590034,Intravoxel Incoherent Motion(IVIM) Magnetic Resonance Imaging in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Diffusion-weighted magnetic resonance imaging<br /><b>Sponsor</b>:    Chinese University of Hong Kong<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05391906?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-26 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
243,173078,2022-05-26 15:40:06.587955,The Effect of an Interactive Web-based Program in the Management of Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Yönetebilirim<br /><b>Sponsor</b>:    Selcuk University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05393765?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-26 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
244,165545,2022-05-24 11:15:10.283607,COVID 19 on Disease Activity in Radiologically Isolated Syndrome Cohort,<b>Conditions</b>:    Multiple Sclerosis;   COVID-19<br /><b>Intervention</b>:    Other: NO intervention<br /><b>Sponsor</b>:    Centre Hospitalier Universitaire de Nice<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05387395?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-24 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
245,165544,2022-05-24 11:15:10.281955,RIS International Cohort,<b>Conditions</b>:    Multiple Sclerosis;   Radiologically Isolated Syndrome<br /><b>Intervention</b>:    Other: No intervention<br /><b>Sponsor</b>:    Centre Hospitalier Universitaire de Nice<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05388331?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-24 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
246,162447,2022-05-23 14:52:03.985805,MUSCLE - Nordic Walking in MUltiple SCLErosis,"<b>Conditions</b>:    Multiple Sclerosis, Chronic Progressive;   Multiple Sclerosis;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary Progressive<br /><b>Interventions</b>:    Other: Nordic Walking (NWG);   Other: Free Walking (FWG);   Other: Health Education (HEG)<br /><b>Sponsors</b>:    Leonardo A. Peyré-Tartaruga;   Aline Nogueira Haas;   Flávia Gomes Martinez<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05385731?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-23 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
247,162441,2022-05-23 14:52:03.980540,"An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis",<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Biological: BCD-132;   Drug: Teriflunomide<br /><b>Sponsor</b>:    Biocad<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05385744?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-23 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
248,155972,2022-05-20 15:37:08.289294,Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study (KOSMOS),,https://www.novartis.com//clinicaltrials/study/nct05285904,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
249,152103,2022-05-19 10:50:08.503581,"Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction",<b>Conditions</b>:    Neurogenic Dysfunction of the Urinary Bladder;   Multiple Sclerosis;   Sacral Neuromodulation;   Bowel Dysfunction;   Sexual Dysfunction;   Quality of Life<br /><b>Interventions</b>:    Device: Turning ON the neuromodulator;   Device: Turning OFF the neuromodulator<br /><b>Sponsor</b>:    Odense University Hospital<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05380856?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-19 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
250,152097,2022-05-19 10:50:08.498583,Clinical Correlates of Psychiatric Comorbidities in Patients With Multiple Sclerosis,<b>Condition</b>:    Patients With Multiple Sclerosis<br /><b>Intervention</b>:    Other: hospital anxiety and depression scale<br /><b>Sponsor</b>:    Sohag University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05382195?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-19 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
251,148510,2022-05-18 10:30:07.168634,Ketamine for Multiple Sclerosis Fatigue,<b>Condition</b>:    Multiple Sclerosis Fatigue<br /><b>Interventions</b>:    Drug: Ketamine;   Drug: Midazolam<br /><b>Sponsors</b>:    Johns Hopkins University;   United States Department of Defense<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05378100?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-18 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
252,148506,2022-05-18 10:30:06.026248,Prospective Randomized Endovascular Therapy in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Venous Angioplasty;   Other: Sham Angioplasty<br /><b>Sponsors</b>:    University at Buffalo;   Volcano Corporation<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05380362?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-18 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
253,148000,2022-05-18 07:00:06.804299,A long-term extension of Study GNC-401 with temelimab in patients with Relapsing forms of Multiple Sclerosis (RMS) under treatment with rituximab,"<p>EudraCT Number: 2021-001973-21<br />Sponsor Protocol Number: GNC-402<br />Sponsor Name: GeNeuro Innovation SAS<br />Start Date: 2021-07-09<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001973-21/SE"">SE</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-001973-21,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
254,147941,2022-05-18 06:30:06.835832,"A Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with familial amyot...","<p>EudraCT Number: 2020-005971-11<br />Sponsor Protocol Number: AP101-02<br />Sponsor Name: AL-S Pharma, AG<br />Start Date: 2021-12-22<br />Medical condition: Amyotrophic Lateral Sclerosis  (ALS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10002026<br />Term: Amyotrophic lateral sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005971-11/DE"">DE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005971-11,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
255,144834,2022-05-17 10:40:08.627939,Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy,<b>Condition</b>:    Active Secondary Progressive Multiple Sclerosis<br /><b>Intervention</b>:    Other: siponimod<br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05376579?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-17 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
256,144828,2022-05-17 10:40:08.623870,Investigation of the Effects of Motor Imagery and Action Observation Training in Individuals With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Motor Imagery training;   Other: Action Observation training;   Other: standard rehabilitation<br /><b>Sponsor</b>:    Hacettepe University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05377476?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-17 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
257,141456,2022-05-16 12:00:08.079361,"The Relationship of Neuropathic Pain With Incontinence, Disability and Life Quality in Multiple Sclerosis Patients","<b>Conditions</b>:    Multiple Sclerosis;   Disabilities Multiple;   Quality of Life;   Incontinence, Urinary;   Incontinence Bowel;   Neuropathic Pain<br /><b>Intervention</b>:    Other: Neuropathic Pain<br /><b>Sponsor</b>:    Istanbul University-Cerrahpasa<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05374811?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-16 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
258,141452,2022-05-16 12:00:08.075231,An Online Lifestyle Modification Course for People With Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Lifestyle modification;   Behavioral: Standard-care<br /><b>Sponsor</b>:    University of Melbourne<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05374473?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-16 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
259,131496,2022-05-13 10:40:06.705926,Multiple Sclerosis Intimacy and Sexuality Questionnaire,<b>Conditions</b>:    Multiple Sclerosis;   Sexual Dysfunction;   Questionnaires<br /><b>Intervention</b>:    Other: descriptive study<br /><b>Sponsor</b>:    Bozok University<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05374031?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-13 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
260,131406,2022-05-13 09:55:08.556701,"A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary pro...","<p>EudraCT Number: 2012-003056-36<br />Sponsor Protocol Number: CBAF312A2304<br />Sponsor Name: Novartis Pharma Services AG<br />Start Date: 2012-10-31<br />Medical condition: Secondary progressive multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/IE"">IE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/SK"">SK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003056-36/FR"">FR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-003056-36,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
261,127431,2022-05-12 07:25:10.203912,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) as Monotherapy in Patients With Neuromyelitis Optica (NMO) and...","<p>EudraCT Number: 2015-005431-41<br />Sponsor Protocol Number: BN40900(SA-309JG)<br />Sponsor Name: F. Hoffmann-La Roche Ltd.<br />Start Date: 2017-10-16<br />Medical condition: Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD)<br />Disease: <br />Version: 20.0<br />SOC Term: 100000004852<br />Classification Code: 10029322<br />Term: Neuromyelitis optica<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005431-41/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005431-41/HR"">HR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005431-41,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
262,124335,2022-05-11 11:50:06.264836,"TIME™ at Home Feasibility Study: Evaluation of a Virtually Delivered, Community-based, Task-oriented Exercise Program","<b>Conditions</b>:    Mobility Limitation;   Balance Impairment<br /><b>Intervention</b>:    Other: TIME™ at Home<br /><b>Sponsors</b>:    University of Toronto;   March of Dimes, Canada<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05369741?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-11 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
263,120726,2022-05-10 12:31:31.474909,"A two-year, double-blind, randomized, multicenter, active controlled
study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ...","<p>EudraCT Number: 2011-005677-23<br />Sponsor Protocol Number: CFTY720D2311<br />Sponsor Name: Novartis Farma<br />Start Date: 2013-04-02<br />Medical condition: Relapsing multiple sclerosis<br />Disease: <br />Version: 15.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/DE"">DE</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/RO"">RO</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/EE"">EE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/HR"">HR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-005677-23,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
264,120464,2022-05-10 10:55:05.903145,In-phase Bilateral Exercises in People With Relapsing Remitting Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: In-phase Bilateral Exercises of the upper limbs<br /><b>Sponsors</b>:    Cyprus University of Technology;   The Cyprus Foundation for Muscular Dystrophy Research<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05367947?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-10 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
265,120096,2022-05-10 08:45:06.974682,"A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis","<p>EudraCT Number: 2021-005746-15<br />Sponsor Protocol Number: MN43964<br />Sponsor Name: Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd<br />Start Date: 2022-05-09<br />Medical condition: Primary Progressive Multiple Sclerosis (PPMS)
Relapsing Multiple Sclerosis (RMS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/ES"">ES</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-005746-15,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
266,119091,2022-05-10 02:29:12.588096,"A Randomized, Sham-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Intrathecal OAV101 in Patients Type 2 Spinal Muscular Atrophy (SMA) Who Are ≥ 2 to &lt; 18 Years of Age, Treatment Naive, Sitting, and Never Ambulatory",,https://www.novartis.com//clinicaltrials/study/nct05089656,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
267,117349,2022-05-09 16:29:12.061311,"Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Homozygous ...",,https://www.novartis.com//clinicaltrials/study/nct04659863,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
268,116515,2022-05-09 11:40:07.349614,Physical Training for People With Parkinson's Disease and Multiple Sclerosis: Effect on Mind and Body,"<b>Conditions</b>:    Parkinson Disease;   Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: High Intensity Interval Training (HIIT);   Behavioral: Continuous Aerobic Training (CAT);   Behavioral: Movement Advice<br /><b>Sponsors</b>:    Amsterdam UMC, location VUmc;   Netherlands Brain Foundation<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05357638?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-03 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
269,116288,2022-05-09 10:45:06.925336,A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-remitting<br /><b>Intervention</b>:    Other: No Intervention<br /><b>Sponsor</b>:    Eisai Korea Inc.<br /><b>Completed</b>",https://clinicaltrials.gov/ct2/show/NCT05366036?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-09 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
270,114748,2022-05-09 01:29:11.385415,A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting (VICTORION-Implement),,https://www.novartis.com//clinicaltrials/study/nct05362903,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
271,114733,2022-05-09 01:29:11.368480,"A Phase Ib&#x2F;II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation",,https://www.novartis.com//clinicaltrials/study/nct04699188,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
272,114712,2022-05-09 01:29:11.066436,"A 52 Week, Multi-center, Randomized, Double-blind Placebo-controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (QGE031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy",,https://www.novartis.com//clinicaltrials/study/nct04984876,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
273,104550,2022-05-06 16:10:07.230610,"An Open-Label, Randomized, Multicenter, Active-Controlled,
Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in
Pediatric Subjects Aged 10 to Less Than 18 Years f...","<p>EudraCT Number: 2018-003008-38<br />Sponsor Protocol Number: 105MS306<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2019-06-17<br />Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS) <br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029205<br />Term: Nervous system disorders<br />Level: SOC<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/HR"">HR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003008-38,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
274,104154,2022-05-06 14:15:07.338074,Interest of Immersive Virtual Reality on Stress During Botulinum Toxin Injections in Spasticity (RVTOX),"<b>Condition</b>:    Central Neurogical Impairment<br /><b>Intervention</b>:    Device: DEEPSEN virtual reality mask<br /><b>Sponsor</b>:    University Hospital, Clermont-Ferrand<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05364203?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-06 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
275,99301,2022-05-05 14:25:07.059543,"Exopulse Mollii Suit, Spasticity & Tissue Oxygenation",<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Device: Exopulse Mollii Suit;   Device: Exopulse Mollii suit (sham)<br /><b>Sponsor</b>:    Institut De La Colonne Vertebrale Et Des Neurosciences<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05362006?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-05 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
276,95975,2022-05-04 21:09:11.652272,"EPIK-P2: A Phase II Double-blind Study With an Upfront, 16-week Randomized, Placebo-controlled Period, to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum ( ...",,https://www.novartis.com//clinicaltrials/study/nct04589650,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
277,95971,2022-05-04 21:09:11.647591,"A Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)",,https://www.novartis.com//clinicaltrials/study/nct05030428,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
278,95958,2022-05-04 21:09:11.637203,"An Open-label, Multi-center, ph II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With SOC Anti-cancer Therapy for the 2L Treatment of Metastatic Colorectal Cancer (mCRC)",,https://www.novartis.com//clinicaltrials/study/nct04952753,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
279,95954,2022-05-04 21:09:11.606332,"An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors",,https://www.novartis.com//clinicaltrials/study/nct04857372,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
280,95948,2022-05-04 21:09:11.599454,"EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Partic ...",,https://www.novartis.com//clinicaltrials/study/nct04899349,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
281,94231,2022-05-04 12:05:07.043552,Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy,"<b>Conditions</b>:    Multiple Sclerosis (MS);   Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Chronic Progressive;   Multiple Sclerosis Relapse;   Multiple Sclerosis Brain Lesion;   Multiple Sclerosis Benign<br /><b>Interventions</b>:    Drug: Clemastine Fumarate;   Drug: Placebo<br /><b>Sponsors</b>:    University of California, San Francisco;   United States Department of Defense<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05359653?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-04 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
282,94036,2022-05-04 11:09:11.866512,"Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Heterozygou ...",,https://www.novartis.com//clinicaltrials/study/nct04652726,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
283,94028,2022-05-04 11:09:11.856147,The Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis,,https://www.novartis.com//clinicaltrials/study/nct01285479,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
284,94024,2022-05-04 11:09:11.851733,"A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea&#x2F;Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive ...",,https://www.novartis.com//clinicaltrials/study/nct03474965,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
285,94020,2022-05-04 11:09:11.847179,"A Randomized, Controlled, Multicenter, Open-label Trial Comparing a Hospital Post-discharge Care Pathway Involving Aggressive LDL-C Management That Includes Inclisiran With Usual Care Versus Usual Care Alone in Patients With a Recent Acute Coronary S ...",,https://www.novartis.com//clinicaltrials/study/nct04873934,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
286,94016,2022-05-04 11:09:11.841289,"Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India (SPOTLIGHT)",,https://www.novartis.com//clinicaltrials/study/nct05020873,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
287,94015,2022-05-04 11:09:11.839247,"A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositi ...",,https://www.novartis.com//clinicaltrials/study/nct04251533,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
288,94001,2022-05-04 11:09:11.714905,"EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no ...",,https://www.novartis.com//clinicaltrials/study/nct04729387,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
289,94000,2022-05-04 11:09:11.710619,"A Randomized, Double-blind, Phase III Study, Comparing NIS793 in Combination With Gemcitabine and Nab-paclitaxel Versus (vs.) Placebo Combined With Gemcitabine and Nab-paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma ...",,https://www.novartis.com//clinicaltrials/study/nct04935359,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
290,92248,2022-05-04 01:09:11.499411,A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography (OCT) Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections,,https://www.novartis.com//clinicaltrials/study/nct04662944,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
291,92246,2022-05-04 01:09:11.497587,"A 96-week, Two-arm, Randomized, Single-masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy",,https://www.novartis.com//clinicaltrials/study/nct04278417,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
292,92242,2022-05-04 01:09:11.494242,"A Single-center, Randomized, Open-label, Three-period Crossover Study to Investigate the Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation, and the Food Effect of Alpelisib Granule Formulation in Adult Healthy Volunteers",,https://www.novartis.com//clinicaltrials/study/nct05195892,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
293,92237,2022-05-04 01:09:11.489874,"Multicenter, Open-label, Single-arm Study to Evaluate the PK, Safety, Tolerability and Efficacy of a New Artemether:Lumefantrine (2.5 mg:30 mg) Dispersible Tablet in the Treatment of Infants and Neonates &lt;5 kg Body Weight With Acute Uncomplicated Pla ...",,https://www.novartis.com//clinicaltrials/study/nct04300309,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
294,92233,2022-05-04 01:09:11.485987,"A 12-week Parallel Group, Randomized, Placebo-controlled, Double-blinded, Multi-center Study to Evaluate Efficacy and Safety of 2 Concentrations of SAF312 Eye Drops (5 mg&#x2F;ml and 15 mg&#x2F;ml) Used Twice-daily in the Treatment of Post-operative Corneal In ...",,https://www.novartis.com//clinicaltrials/study/nct04630158,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
295,90424,2022-05-03 15:09:11.568795,"An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)",,https://www.novartis.com//clinicaltrials/study/nct04720157,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
296,90410,2022-05-03 15:09:11.564555,A Phase II Study to Evaluate the Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1),,https://www.novartis.com//clinicaltrials/study/nct04980833,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
297,90406,2022-05-03 15:09:11.346630,"A Placebo-controlled, Patient and Investigator Blinded, Randomized Parallel Cohort Study to Assess Pharmacodynamics, Pharmacokinetics, Safety, Tolerability and Preliminary Clinical Efficacy of VAY736 and CFZ533 in Patients With Systemic Lupus Erythem ...",,https://www.novartis.com//clinicaltrials/study/nct03656562,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
298,90107,2022-05-03 13:36:31.600135,Novel Imaging Markers in SPMS,"<b>Conditions</b>:    Secondary Progressive Multiple Sclerosis;   Multiple Sclerosis, Secondary Progressive;   Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Ferumoxytol infusion;   Drug: Gadoteridol;   Diagnostic Test: MRI Brain and Cervical Spine<br /><b>Sponsor</b>:    University of Utah<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05357833?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-03 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
299,90106,2022-05-03 13:36:31.598811,Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?,"<b>Conditions</b>:    Hypogammaglobulinemia;   Multiple Sclerosis;   Fatigue<br /><b>Intervention</b>:    Diagnostic Test: Laboratory test<br /><b>Sponsor</b>:    University Hospital Inselspital, Berne<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05357781?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-03 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
300,90102,2022-05-03 13:36:31.594773,Physical Training for People With Parkinsons Disease and Multiple Sclerosis: Effect on Mind and Body,"<b>Conditions</b>:    Parkinson Disease;   Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: High Intensity Interval Training (HIIT);   Behavioral: Continuous Aerobic Training (CAT);   Behavioral: Movement Advice<br /><b>Sponsors</b>:    Amsterdam UMC, location VUmc;   Netherlands Brain Foundation<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05357638?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-03 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
301,89189,2022-05-03 07:57:01.149149,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICACY OF OCRELIZUMAB IN COMPARISON WITH FINGOLIMOD IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTI...","<p>EudraCT Number: 2020-004128-41<br />Sponsor Protocol Number: WN42086<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2021-08-24<br />Medical condition: Relapsing-Remitting Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004128-41/BE"">BE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004128-41,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
302,87936,2022-05-03 00:09:10.567239,"One Year, Single Arm, Open Label, Multicenter, Phase IV Study Using Multimodal Imaging to Guide Disease Activity Assessment Through Innovative Early Predictive Anatomical Biomarkers of Fluid Resolution in wAMD Patients Treated With Brolucizumab- IMAG ...",,https://www.novartis.com//node/14326,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
303,87928,2022-05-03 00:09:10.560117,A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Radiotherapy With or Without Temozolomide and in Recurrent Glioblastoma as Single Agent,,https://www.novartis.com//node/14491,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
304,87924,2022-05-03 00:09:10.554883,"A Real-world, Prospective, Multi-center, Open-label, Phase IV Clinical Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)",,https://www.novartis.com//node/14481,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
305,87919,2022-05-03 00:09:10.551196,"PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer",,https://www.novartis.com//node/13421,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
306,87909,2022-05-03 00:09:10.542839,"A Randomized, Placebo-controlled, Double-masked, Multi-center, Dose-ranging Study to Evaluate the Safety, and Efficacy of UNR844 in Subjects With Presbyopia",,https://www.novartis.com//node/13326,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
307,87908,2022-05-03 00:09:10.540163,"A 12-week Randomized, participant-and Investigator-blinded, Placebo-controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics, Safety, and Pharmacokinetics of Two Doses of Inhaled CSJ117 in Adults With Chronic Obstructive Pulmonary D ...",,https://www.novartis.com//node/13231,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
308,87905,2022-05-03 00:09:10.490100,"A Randomized, Active-controlled, Patient and Investigator-masked, Multiple Dose Proof-of-concept Study of Intravitreal LKA651 in Patients With Diabetic Macular Edema",,https://www.novartis.com//node/13936,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
309,85561,2022-05-02 10:41:27.133466,Cognitive-motor Telerehabilitation in MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Cognitive training;   Behavioral: Motor training<br /><b>Sponsors</b>:    Universitair Ziekenhuis Brussel;   National MS Center Melsbroek;   Research Foundation Flanders<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05355389?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-05-02 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
310,73437,2022-04-29 10:45:06.089101,Validation of Ella Platform for Serum Nfl And GFAP Measures In Multiple Sclerosis Patients,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Biomarker quantification<br /><b>Sponsor</b>:    Centre Hospitalier Universitaire de Nīmes<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05352971?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-29 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
311,72756,2022-04-29 06:45:07.743813,"Estudio prospectivo Fase III, multicéntrico, randomizado, doble ciego, de dos grupos paralelos, controlado con placebo y de 96 semanas de duración, para comparar la eficacia y seguridad de masitini...","<p>EudraCT Number: 2010-021219-17<br />Sponsor Protocol Number: AB07002<br />Sponsor Name: AB Science<br />Start Date: 2011-09-12<br />Medical condition: Pacientes con esclerosis múltiple primaria progresiva o secundaria progresiva sin recidiva<br />Disease: <br />Version: 14.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br />Version: 14.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021219-17/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021219-17/DE"">DE</a> (Prohibited by CA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021219-17/SK"">SK</a> (Prohibited by CA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021219-17/GR"">GR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021219-17/BG"">BG</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-021219-17,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
312,69697,2022-04-28 11:38:12.160658,"An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomog ...",,https://www.novartis.com//clinicaltrials/study/nct04066244,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
313,69693,2022-04-28 11:38:12.154692,An Open Label Cryptosporidium Controlled Human Infection Model (CHIM) to Assess the Efficacy and Safety of ABO809 in Healthy Participants,,https://www.novartis.com//clinicaltrials/study/nct05036668,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
314,69689,2022-04-28 11:38:12.148570,"A Randomized, Open-label, Phase I&#x2F;II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients",,https://www.novartis.com//clinicaltrials/study/nct04097821,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
315,69685,2022-04-28 11:38:12.141544,"International, Non-interventional, Post-Authorization Long-Term Safety Study of Lutathera, in Patients With Unresectable or Metastatic, Well-Differentiated, Somatostatin Receptor Positive, Gastroenteropancreatic Neuroendocrine Tumours",,https://www.novartis.com//clinicaltrials/study/nct03691064,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
316,69530,2022-04-28 10:50:07.021247,Exercise on Contactin-1 and Contactin-2 Level in Persons With Multiple Sclerosis,<b>Condition</b>:    Relapsing Remitting Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Firat University<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05351411?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-28 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
317,69524,2022-04-28 10:50:06.243383,Dry Needling for Treating Spasticity in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Procedure: Dry needling<br /><b>Sponsor</b>:    Hospital Universitario de Canarias<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05351957?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-28 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
318,67206,2022-04-27 20:38:12.296045,"A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy",,https://www.novartis.com//clinicaltrials/study/nct04150029,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
319,67204,2022-04-27 20:38:12.290492,"A Multi-center, Open-label Study to Determine the Dose and Safety of Oral Asciminib in Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP), Previously Treated With One or More Tyrosine Kinas ...",,https://www.novartis.com//clinicaltrials/study/nct04925479,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
320,67201,2022-04-27 20:38:12.287776,"Two Steps Italian Prospective obsErvationAL Study Assessing the Effectiveness and Outcomes Associated With LUtathera (177Lu) Oxodotreotide Treatment in Adult Subjects With Unresectable or Metastatic, Progressive, Well Differentiated (G1 and G2), Soma ...",,https://www.novartis.com//clinicaltrials/study/nct04727723,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
321,67192,2022-04-27 20:38:12.278163,"A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient-reported Outcomes (PRO) in Patients With Relapsing Multiple Sclerosis (RMS) Transitioning From Fumarate-based RMS Approved Therapies o ...",,https://www.novartis.com//clinicaltrials/study/nct04353492,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
322,67190,2022-04-27 20:38:12.272063,"A Three-period Multicenter Study, With a Randomized-withdrawal, Double-blinded, Placebo-controlled Design in Period 2 to Evaluate the Clinical Efficacy, Safety, and Tolerability of MAS825 in NLRC4-GOF Patients",,https://www.novartis.com//clinicaltrials/study/nct04641442,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
323,67184,2022-04-27 20:38:12.269757,"A 12-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Study to Assess the Efficacy and Safety of CSJ117, When Added to Existing Asthma Therapy in Patients ≥ 18 Years of Age With Severe Uncontrolled Asthma.",,https://www.novartis.com//clinicaltrials/study/nct04410523,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
324,67181,2022-04-27 20:38:12.265744,"A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Ensovibep (MP0420) in Ambulatory Patients With Symptomatic COVID-19 - The &quot;EMPATHY&quot; Trial",,https://www.novartis.com//clinicaltrials/study/nct04828161,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
325,67180,2022-04-27 20:38:12.267535,"EPIK-B5: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With HR-positive, HER2-negative Advanced Breast Cancer With a PIK3CA Mutation, Who Progressed on or ...",,https://www.novartis.com//clinicaltrials/study/nct05038735,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
326,65668,2022-04-27 11:41:07.818769,Metformin Treatment in Progressive Multiple Sclerosis,"<b>Conditions</b>:    Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Metformin 500 Mg Oral Tablet, up to 4 tablets a day;   Drug: Placebo oral tablet identical to metformin, up to 4 tablets a day<br /><b>Sponsor</b>:    University of California, Los Angeles<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05349474?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-27 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
327,61737,2022-04-26 12:15:31.025176,CSF Free Kappa Light Chain for The Diagnosis of Demyelinating Disorders,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Diagnostic Test: Kappa Free Light Chain (K-FLC)<br /><b>Sponsor</b>:    Aga Khan University<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05347277?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-26 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
328,58025,2022-04-25 14:10:07.002410,Effect of Computerized Cognitive Training in Persons With MS,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Interventions</b>:    Device: BrainHQ cognitive training;   Device: BrainHQ control games<br /><b>Sponsor</b>:    University of Nebraska<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05345288?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-25 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
329,58016,2022-04-25 14:10:06.991055,Remote Exercise Effects on Cognitive Processing Speed in Multiple Sclerosis: A Pilot Trial,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Remotely Delivered and Supported Aerobic Walking Exercise Training;   Behavioral: Remotely Delivered and Supported Stretching and Toning Exercise Training<br /><b>Sponsor</b>:    Kessler Foundation<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05344040?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-25 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
330,58013,2022-04-25 14:10:06.986482,A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis,<b>Condition</b>:    Relapsing Multiple Sclerosis<br /><b>Interventions</b>:    Other: ofatumumab;   Other: glatiramer acetate;   Other: interferon β1<br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05344469?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-25 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
331,57609,2022-04-25 11:50:07.595172,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects with Mild Cognitive Impairment due to Alzheimer’s Disease ...","<p>EudraCT Number: 2017-002901-37<br />Sponsor Protocol Number: 251AD201<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2018-06-04<br />Medical condition: Mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) or mild AD<br />Disease: <br />Version: 20.0<br />SOC Term: 100000004852<br />Classification Code: 10001896<br />Term: Alzheimer's disease<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002901-37/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002901-37/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002901-37/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002901-37/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002901-37/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002901-37/FR"">FR</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002901-37,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
332,45848,2022-04-22 12:30:07.387904,Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis,"<b>Conditions</b>:    Multiple Sclerosis, Relapsing-Remitting;   Adult ALL;   Vitamin D3 Deficiency<br /><b>Interventions</b>:    Dietary Supplement: 25(OH)D3;   Dietary Supplement: vitamin D3<br /><b>Sponsors</b>:    Tehran University of Medical Sciences;   Boston University<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05340985?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-22 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
333,45846,2022-04-22 12:30:07.386002,Kinesiotape on Balance in With Multiple Sclerosis,<b>Conditions</b>:    Individuals With Multiple Sclerosis;   With Ataxia Symptoms;   No Secondary Disease Affecting Balance<br /><b>Intervention</b>:    Other: Kinesiotape<br /><b>Sponsor</b>:    Firat University<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05341895?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-22 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
334,45838,2022-04-22 12:30:07.379209,Proprioceptive Neuromuscular Facilitation in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: PNF;   Other: Breathing exercises<br /><b>Sponsor</b>:    Biruni University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05342025?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-22 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
335,45220,2022-04-22 08:35:07.871592,Tracking the immune response to SARS-CoV-2 modRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS),"<p>EudraCT Number: 2021-000307-20<br />Sponsor Protocol Number: COMB157GDE01<br />Sponsor Name: Novartis Pharma Vertriebs GmbH <br />Start Date: 2021-04-28<br />Medical condition: relapsing multiple sclerosis <br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000307-20/DE"">DE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000307-20,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
336,45216,2022-04-22 08:35:07.865057,"A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Onc...","<p>EudraCT Number: 2011-005249-12<br />Sponsor Protocol Number: EFC11759<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2014-08-13<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 17.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/EE"">EE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/GR"">GR</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/FR"">FR</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/LT"">LT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/3rd"">Outside EU/EEA</a>, <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/IE"">IE</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/NL"">NL</a> (Restarted), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/SI"">SI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005249-12/IT"">IT</a> (Not Authorised)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-005249-12,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
337,42025,2022-04-21 11:11:45.684532,Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis,"<b>Conditions</b>:    Multiple Sclerosis;   Internuclear Ophthalmoplegia<br /><b>Interventions</b>:    Drug: Clemastine Fumarate;   Drug: Placebo<br /><b>Sponsor</b>:    Amsterdam UMC, location VUmc<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05338450?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-21 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
338,34597,2022-04-19 14:11:14.287635,"A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)","<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Bristol-Myers Squibb<br /><b>Recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05335031?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-19 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
339,34590,2022-04-19 14:11:14.278624,A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Kesimpta<br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05334472?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-19 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
340,33622,2022-04-19 08:45:09.604716,"A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of Satralizumab (SA237) in patients with neuromyelitis...","<p>EudraCT Number: 2013-003752-21<br />Sponsor Protocol Number: BN40898(SA-307JG)<br />Sponsor Name: F. Hoffmann-La Roche Ltd.<br />Start Date: 2014-05-19<br />Medical condition: Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD)<br />Disease: <br />Version: 20.0<br />SOC Term: 100000004852<br />Classification Code: 10029322<br />Term: Neuromyelitis optica<br />Level: LLT<br /><br />Population Age: Adolescents, Under 18, Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003752-21/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003752-21/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003752-21/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003752-21/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003752-21/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003752-21/ES"">ES</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-003752-21,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
341,30571,2022-04-18 14:45:08.112418,"A Phase 2, double-blind, randomized, placebo-controlled study assessing efficacy and safety of SAR441344, a CD40L-antagonist monoclonal antibody, in participants with relapsing multiple sclerosis","<p>EudraCT Number: 2020-004785-19<br />Sponsor Protocol Number: ACT16877<br />Sponsor Name: Sanofi-Aventis Recherche et Développement<br />Start Date: 2021-06-01<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004785-19/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004785-19/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004785-19/BG"">BG</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004785-19,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
342,30552,2022-04-18 14:35:08.041305,"A Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy and Safety of Nabiximols Oromucosal Spray as Add-on Therapy in Patients with Spasticity Due to Multiple Sclerosis","<p>EudraCT Number: 2019-002623-14<br />Sponsor Protocol Number: GWSP18023<br />Sponsor Name: GW Pharma Ltd<br />Start Date: 2020-03-17<br />Medical condition: Symptomatic relief of spasticity in Multiple Sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028335<br />Term: Muscle spasticity<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002623-14/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002623-14/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002623-14/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002623-14/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002623-14,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
343,30539,2022-04-18 14:30:07.566785,"A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)","<p>EudraCT Number: 2021-000028-36<br />Sponsor Protocol Number: P3-IMU-838-RMS-01<br />Sponsor Name: Immunic AG<br />Start Date: 2022-01-18<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000028-36/BG"">BG</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000028-36,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
344,30538,2022-04-18 14:30:07.564703,"Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by magnetic resonance imaging (MRI), as well as safety and t...","<p>EudraCT Number: 2018-001896-19<br />Sponsor Protocol Number: P2-IMU-838-MS<br />Sponsor Name: Immunic AG<br />Start Date: 2018-12-17<br />Medical condition: relapsing-remitting multiple sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001896-19/BG"">BG</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001896-19,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
345,30523,2022-04-18 14:25:07.924460,"A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis","<p>EudraCT Number: 2020-000637-41<br />Sponsor Protocol Number: EFC16033<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2020-07-31<br />Medical condition: Relapsing Multiple Sclerosis <br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/IT"">IT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/RO"">RO</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000637-41,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
346,30519,2022-04-18 14:25:07.572884,Study of Empathy in MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Interpersonal Reactivity Index<br /><b>Sponsor</b>:    Assistance Publique - Hôpitaux de Paris<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05332951?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-18 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
347,21883,2022-04-14 10:59:17.162522,Functional Outcomes From Diets in Multiple Sclerosis,<b>Conditions</b>:    Relapsing Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis<br /><b>Interventions</b>:    Behavioral: Glycemic load;   Behavioral: Calorie restriction;   Behavioral: Behavioral support<br /><b>Sponsors</b>:    University of Alabama at Birmingham;   Washington University School of Medicine;   United States Department of Defense<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05327322?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-14 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
348,21300,2022-04-13 11:59:18.445167,Effects of Telerehabilitation-Based Motor Imagery Training on Pain in People With Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Pain<br /><b>Intervention</b>:    Behavioral: Telerehabilitation-based motor imagery training<br /><b>Sponsors</b>:    Dokuz Eylul University;   Izmir Katip Celebi University<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05326711?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-13 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
349,21299,2022-04-13 11:59:18.443892,Defining an Immunological Signature Related to Lesion Location in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: cytof analysis<br /><b>Sponsor</b>:    Rennes University Hospital<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05326048?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-13 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
350,21298,2022-04-13 11:59:18.442353,L Test in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: L test<br /><b>Sponsor</b>:    Firat University<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05325359?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-13 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
351,20707,2022-04-12 12:59:17.118072,Therapeutic Effects of Line Dancing in People With MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: line dancing<br /><b>Sponsors</b>:    Gazi University;   Hacettepe University;   Fenerbahce University<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05322915?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-12 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
352,19941,2022-04-11 11:59:20.168812,TENS in Persons With MS,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Device: Trancutaneous Electrical Nerve Stimulation;   Other: Strength training;   Device: Sham stimulation<br /><b>Sponsor</b>:    University Medical Center Groningen<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05321927?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-11 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
353,19936,2022-04-11 11:59:20.140251,Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: MetFORMIN 1000 Mg Oral Tablet;   Drug: Interferon beta-1a<br /><b>Sponsor</b>:    German University in Cairo<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05298670?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-28 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
354,19935,2022-04-11 11:59:19.434725,Immersive Virtual Reality for Upper Limb Rehabilitation in Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Immersive Virtual Reality Intervention<br /><b>Sponsors</b>:    Glasgow Caledonian University;   MS Society, UK;   NHS Lanarkshire<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05320237?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-11 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
355,17697,2022-04-08 19:59:18.794374,Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients,<b>Conditions</b>:    Fatigue;   Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Ozanimod<br /><b>Sponsors</b>:    Brigham and Women's Hospital;   Bristol-Myers Squibb<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05319093?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-08 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
356,17415,2022-04-08 12:59:18.909630,"A phase III, multi-centre, randomised, double-blind, placebo-controlled, parallel-group clinical trial to investigate the efficacy and safety of BX-1 for the symptomatic relief of spasticity in pat...","<p>EudraCT Number: 2018-000001-23<br />Sponsor Protocol Number: DroSpas-1<br />Sponsor Name: Bionorica SE <br />Start Date: 2018-10-25<br />Medical condition: Symptomatic relief of spasticity in patients with multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029205<br />Term: Nervous system disorders<br />Level: SOC<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000001-23/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000001-23/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000001-23/ES"">ES</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000001-23,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
357,17383,2022-04-08 11:59:17.699002,Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY),"<p>EudraCT Number: 2017-000638-75<br />Sponsor Protocol Number: TG1101-RMS301<br />Sponsor Name: TG Therapeutics<br />Start Date: 2017-12-05<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029202<br />Term: Nervous system disorder<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000638-75/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000638-75/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000638-75/ES"">ES</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-000638-75,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
358,17382,2022-04-08 11:59:17.697319,Phase III: UbliTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY),"<p>EudraCT Number: 2017-000639-15<br />Sponsor Protocol Number: TG1101-RMS302<br />Sponsor Name: TG Therapeutics<br />Start Date: 2017-12-04<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029202<br />Term: Nervous system disorder<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000639-15/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000639-15/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000639-15/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000639-15/HR"">HR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-000639-15,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
359,17259,2022-04-08 09:59:17.158259,"An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis","<p>EudraCT Number: 2016-002937-31<br />Sponsor Protocol Number: MA30143<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2017-09-12<br />Medical condition: Relapsing remitting multiple sclerosis (RRMS)<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10039720<br />Term: Sclerosis multiple<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/NO"">NO</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/SI"">SI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/HR"">HR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002937-31/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002937-31,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
360,16302,2022-04-07 11:59:17.157547,"A 96-Weeks, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the T...","<p>EudraCT Number: 2021-000639-30<br />Sponsor Protocol Number: AB20009<br />Sponsor Name: AB Science<br />Start Date: 2022-01-12<br />Medical condition: Patients with primary progressive or secondary progressive multiple sclerosis without relapse<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000639-30/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000639-30/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000639-30/GR"">GR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000639-30,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
361,16099,2022-04-07 07:59:18.430043,"Post-authorization safety study to check the potential association between the safety
profile of beta interferon 1a and the body mass index or pharmacodynamics during the
titration phase","<p>EudraCT Number: 2006-000606-23<br />Sponsor Protocol Number: 26756<br />Sponsor Name: Merck, S.L.<br />Start Date: 2006-11-23<br />Medical condition: Not applicalbe<br />Disease: <br />Version: 14.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000606-23/ES"">ES</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000606-23,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
362,15179,2022-04-06 12:59:16.692334,Exercise and Pregnancy in People With Multiple Sclerosis,<b>Conditions</b>:    Multiple Sclerosis;   Pregnancy<br /><b>Intervention</b>:    Other: Moderate-intensity cardiovascular exercise<br /><b>Sponsor</b>:    University of Alberta<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05313204?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-06 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
363,14013,2022-04-05 12:59:19.301730,"A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by...","<p>EudraCT Number: 2020-005929-89<br />Sponsor Protocol Number: CLOU064C12302<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2022-02-01<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/SI"">SI</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005929-89,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
364,13981,2022-04-05 12:59:18.848290,Multiple Sclerosis and Overactive Bladder Treatment,<b>Condition</b>:    Neurogenic Bladder Dysfunction<br /><b>Interventions</b>:    Device: Repetitive Transcranial Magnetic Stimulation;   Device: Transcutaneous Posterior Tibial Nerve Stimulation<br /><b>Sponsor</b>:    Istanbul Medipol University Hospital<br /><b>Enrolling by invitation</b>,https://clinicaltrials.gov/ct2/show/NCT05312138?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-04-05 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
365,12975,2022-04-04 15:59:16.854905,The effect of Tecfidera® (Dimethyl Fumarate) on the gut microbiota as a causal factor for GI associated adverse events.,"<p>EudraCT Number: 2015-001197-18<br />Sponsor Protocol Number: NOR-BGT-14-10665<br />Sponsor Name: Biogen Idec Norway<br />Start Date: 2015-05-20<br />Medical condition: multiple sclerosis<br />Disease: <br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001197-18/NO"">NO</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-001197-18,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
366,12825,2022-04-04 12:59:16.573010,Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis,"<p>EudraCT Number: 2018-004557-24<br />Sponsor Protocol Number: UKM17_0056<br />Sponsor Name: Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel <br />Start Date: 2019-07-29<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004557-24/DE"">DE</a> (Temporarily Halted)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004557-24,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
367,12768,2022-04-04 11:59:20.156553,"A Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients with Re...","<p>EudraCT Number: 2019-004822-15<br />Sponsor Protocol Number: GNC-401<br />Sponsor Name: GeNeuro Innovation SAS<br />Start Date: 2020-05-18<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004822-15/SE"">SE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-004822-15,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
368,12682,2022-04-04 09:59:19.594712,"A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (...","<p>EudraCT Number: 2014-001579-30<br />Sponsor Protocol Number: TV5600-CNS-20006<br />Sponsor Name: Teva Pharmaceutical Industries Ltd.<br />Start Date: 2014-11-27<br />Medical condition: Primary Progressive Multiple Sclerosis<br />Disease: <br />Version: 19.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001579-30/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001579-30/IT"">IT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001579-30/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001579-30/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001579-30/NL"">NL</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-001579-30,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
369,12615,2022-04-04 07:59:17.530399,"Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis","<p>EudraCT Number: 2021-000048-23<br />Sponsor Protocol Number: P2-IMU-838-PMS<br />Sponsor Name: Immunic AG<br />Start Date: 2021-10-28<br />Medical condition: Progressive forms of Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10053395<br />Term: Progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000048-23/NL"">NL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000048-23,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
370,9544,2022-04-01 13:59:17.901179,"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)","<p>EudraCT Number: 2020-000645-14<br />Sponsor Protocol Number: EFC16035<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2020-10-13<br />Medical condition: Primary Progressive Multiple Sclerosis <br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000645-14/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000645-14,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
371,9537,2022-04-01 13:59:17.893220,"A 24 week, MRI based, double-blind, randomised, placebo-controlled, modified dose-escalation trial to evaluate the safety, efficacy and pharmacokinetics of BIRT 2584 XX tablets at doses of 100, 300...","<p>EudraCT Number: 2005-005985-35<br />Sponsor Protocol Number: 1206.15<br />Sponsor Name: Boehringer Ingelheim<br />Start Date: 2006-08-29<br />Medical condition: Relapsing forms of Multiple Sclerosis<br />Disease: <br />Version: 8.1<br />SOC Term: <br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005985-35/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005985-35/CZ"">CZ</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005985-35,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
372,9498,2022-04-01 12:59:18.787053,"A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lu...","<p>EudraCT Number: 2015-000392-28<br />Sponsor Protocol Number: 1199.214<br />Sponsor Name: Boehringer Ingelheim bv<br />Start Date: 2015-11-02<br />Medical condition: Patients with Systemic Sclerosis and associated Interstitial Lung Disease<br />Disease: <br />Version: 19.1<br />SOC Term: 100000004859<br />Classification Code: 10012977<br />Term: Diffuse systemic sclerosis<br />Level: LLT<br />Version: 19.1<br />SOC Term: 100000004859<br />Classification Code: 10036814<br />Term: Progressive systemic sclerosis<br />Level: LLT<br />Version: 19.1<br />SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders<br />Classification Code: 10042954<br />Term: Systemic sclerosis pulmonary<br />Level: PT<br />Version: 19.1<br />SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders<br />Classification Code: 10025109<br />Term: Lung involvement in systemic sclerosis<br />Level: LLT<br />Version: 19.1<br />SOC Term: 100000004859<br />Classification Code: 10042953<br />Term: Systemic sclerosis<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/PT"">PT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/DK"">DK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/GR"">GR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/IE"">IE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/NO"">NO</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/HU"">HU</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000392-28/IT"">IT</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-000392-28,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
373,9448,2022-04-01 11:59:16.905992,"Multicenter, open-label, 12 weeks,
phaseIV pRospectivE randomized study aimed at evaLuating whether sc IFN beta 1a
(Rebif®) administered In the morning may affEct the severity of Flu-like syndrom...","<p>EudraCT Number: 2013-004450-21<br />Sponsor Protocol Number: EMR200136-570<br />Sponsor Name: Merck Serono S.p.A.<br />Start Date: 2014-02-07<br />Medical condition: relapsing multiple sclerosis<br />Disease: <br />Version: 14.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004450-21/IT"">IT</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-004450-21,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
374,9442,2022-04-01 11:59:16.901447,"A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.","<p>EudraCT Number: 2004-000762-13<br />Sponsor Protocol Number: TV-5010/202<br />Sponsor Name: TEVA ITALIA srl<br />Start Date: 2004-08-31<br />Medical condition: Subject with relapsing remitting Multiple Sclerosis. Subject must have at least one documented relapse within one year prior to screening visit.<br />Disease: <br />Version: 15.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000762-13/IT"">IT</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000762-13,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
375,9371,2022-04-01 09:59:16.534523,"An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o...","<p>EudraCT Number: 2005-004061-41<br />Sponsor Protocol Number: 101-MS-321<br />Sponsor Name: BIOGEN IDEC LTD<br />Start Date: 2006-06-01<br />Medical condition: Multiple sclerosis (MS)<br />Disease: <br />Version: 14.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/GB"">GB</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/BE"">BE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/FI"">FI</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/IE"">IE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/DE"">DE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/AT"">AT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/SE"">SE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/HU"">HU</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/DK"">DK</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/CZ"">CZ</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/ES"">ES</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/IT"">IT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/GR"">GR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004061-41,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
376,9369,2022-04-01 09:59:16.532908,"A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis","<p>EudraCT Number: 2016-004935-18<br />Sponsor Protocol Number: GNC-004<br />Sponsor Name: GeNeuro SA<br />Start Date: 2017-04-12<br />Medical condition: Multiple Sclerosis (MS)<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004935-18/HU"">HU</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004935-18/DE"">DE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004935-18/CZ"">CZ</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004935-18/ES"">ES</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004935-18/PL"">PL</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004935-18/BG"">BG</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004935-18/HR"">HR</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004935-18/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004935-18,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
377,9364,2022-04-01 09:59:16.529268,"A multicentre, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of subcutaneously administered r-hIFN beta-1a (Rebif) using clone 484-39 in the treatment of subjects...","<p>EudraCT Number: 2004-000337-12<br />Sponsor Protocol Number: 24810<br />Sponsor Name: Serono International SA<br />Start Date: 2004-07-23<br />Medical condition: MS with 2 or more relapses within the last 2 years <br />Disease: <br />Version: 7.0<br />SOC Term: <br />Classification Code: 10028245<br />Term: <br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000337-12/HU"">HU</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000337-12,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
378,9302,2022-04-01 08:59:22.275820,Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAM...,"<p>EudraCT Number: 2009-011088-35<br />Sponsor Protocol Number: PACAMUS<br />Sponsor Name: Philipps-Universität Marburg<br />Start Date: 2010-03-24<br />Medical condition: Patients with Multiple Sclerosis (MS) or Clinically isolated syndrome suggestive for MS (CIS) are investigated. The main objective is to conserve data about changes in the VIP/PACAP (vasoactive int...<br />Disease: <br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011088-35/DE"">DE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011088-35,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
379,9294,2022-04-01 08:59:22.269992,"A 3-year, multi-center study to evaluate optical coherence tomography as an outcome measure in patients with multiple sclerosis","<p>EudraCT Number: 2011-001437-16<br />Sponsor Protocol Number: CFTY720D2319<br />Sponsor Name: Novartis Pharma Services AG<br />Start Date: 2012-09-19<br />Medical condition: multiple sclerosis<br />Disease: <br />Version: 15.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001437-16/DE"">DE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-001437-16,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
380,8416,2022-03-31 16:25:00.344899,"Intra-individual, randomized multicentric comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in patients with Multiple Sclerosis at 3T","<p>EudraCT Number: 2009-014857-34<br />Sponsor Protocol Number: FAU-001<br />Sponsor Name: Universitätsklinikum Erlangen<br />Start Date: 2010-02-01<br />Medical condition: Patients with clinically definite MS or a clinically isolated episode of CNS involvement and disease dissemination in space, according to the McDonald’s criteria<br />Disease: <br />Version: 12.0<br />SOC Term: <br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014857-34/DE"">DE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-014857-34,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
381,8412,2022-03-31 16:24:59.950968,A Study for Tysabri Participant Preference,<b>Condition</b>:    Relapsing-Remitting Multiple Sclerosis (RRMS)<br /><b>Intervention</b>:    Drug: Natalizumab<br /><b>Sponsor</b>:    Biogen<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05304520?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-31 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
382,8411,2022-03-31 16:24:59.948202,Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05301907?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-31 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
383,8278,2022-03-31 14:56:29.614852,Effect of MD1003 in spinal progressive multiple sclerosis: a pivotal randomized double blind placebo controlled study,"<p>EudraCT Number: 2013-002113-35<br />Sponsor Protocol Number: MD1003CT2013-02MS-SPI<br />Sponsor Name: MEDDAY SAS<br />Start Date: Information not available in EudraCT<br />Medical condition: Progressive spinal multiple sclerosis<br />Disease: <br />Version: 18.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10053395<br />Term: Progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002113-35/FR"">FR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002113-35,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
384,8237,2022-03-31 13:56:27.068531,Effect of MD1003 in chronic visual loss related to optic neuritis in multiple sclerosis: a pivotal randomized double masked placebo controlled study,"<p>EudraCT Number: 2013-002112-27<br />Sponsor Protocol Number: MD1003CT2013-01MS-ON<br />Sponsor Name: MEDDAY SAS<br />Start Date: Information not available in EudraCT<br />Medical condition: chronic visual loss related to optic neuritis in multiple sclerosis<br />Disease: <br />Version: 18.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 18.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10030942<br />Term: Optic neuritis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002112-27/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002112-27/GB"">GB</a> (GB - no longer in EU/EEA)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002112-27,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
385,8153,2022-03-31 10:56:31.359538,"A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respira...","<p>EudraCT Number: 2006-006299-39<br />Sponsor Protocol Number: 191622-082-01<br />Sponsor Name: Allergan<br />Start Date: 2008-04-23<br />Medical condition: Patients with urinary incontinence due to neurogenic detrusor overactivity as a result of spinal cord injury or multiple sclerosis who have not been adequately managed with anticholinergic therapy ...<br />Disease: <br />Version: 8.1<br />SOC Term: <br />Classification Code: 10046543<br />Term: Urinary incontinence<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006299-39/NL"">NL</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006299-39/FR"">FR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-006299-39,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
386,8104,2022-03-31 09:56:28.720059,"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis","<p>EudraCT Number: 2020-000647-30<br />Sponsor Protocol Number: EFC16645<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2020-08-27<br />Medical condition: Non-relapsing Secondary Progressive Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000647-30/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000647-30,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
387,8086,2022-03-31 08:56:29.209455,"A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dos...","<p>EudraCT Number: 2010-018273-38<br />Sponsor Protocol Number: D1950C00011<br />Sponsor Name: AstraZeneca AB<br />Start Date: 2010-03-22<br />Medical condition: Alzheimer's Disease<br />Disease: <br />Version: 12.1<br />SOC Term: <br />Classification Code: 10001896<br />Term: Alzheimer's disease<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018273-38/FR"">FR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-018273-38,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
388,7434,2022-03-30 11:56:31.283489,"Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of...","<p>EudraCT Number: 2007-001377-28<br />Sponsor Protocol Number: 27577<br />Sponsor Name: Merck Serono International S.A.<br />Start Date: 2008-06-11<br />Medical condition: Adult patients with moderate to severe chronic plaque psoriasis 
-- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosp...<br />Disease: <br />Version: 9.1<br />SOC Term: <br />Classification Code: 10061664<br />Term: Autoimmune disorder<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10025139<br />Term: Lupus erythematosus systemic<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10047888<br />Term: Wegener's granulomatosis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10002817<br />Term: Antiphospholipid syndrome<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10040767<br />Term: Sjogren's syndrome<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10039073<br />Term: Rheumatoid arthritis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10045228<br />Term: Type I diabetes mellitus<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10011401<br />Term: Crohn's disease<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10009900<br />Term: Colitis ulcerative<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10003827<br />Term: Autoimmune hepatitis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10049046<br />Term: Autoimmune thyroiditis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10003822<br />Term: Autoimmune haemolytic anaemia NOS<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10034697<br />Term: Pernicious anemia<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10028417<br />Term: Myasthenia gravis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10018620<br />Term: Goodpasture's syndrome<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10018766<br />Term: Guillain Barre syndrome<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10043554<br />Term: Thrombocytopenia<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10037153<br />Term: Psoriasis<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/FR"">FR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/DE"">DE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/AT"">AT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/NL"">NL</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/PT"">PT</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001377-28,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
389,7429,2022-03-30 11:56:31.279154,"A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes in patients with relapsing multiple sclerosis transitioning fro...","<p>EudraCT Number: 2019-001341-40<br />Sponsor Protocol Number: COMB157G23101<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2020-05-07<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/SI"">SI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001341-40/LV"">LV</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001341-40,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
390,7395,2022-03-30 10:56:26.571489,"A PHASE III, NON-INFERIORITY, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND RADIOLOGICAL AND CLINICAL EFFECTS OF SUBCUT...","<p>EudraCT Number: 2020-005448-48<br />Sponsor Protocol Number: CN42097<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2022-03-15<br />Medical condition: Multiple Sclerosis (MS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005448-48/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005448-48/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005448-48/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005448-48/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005448-48,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
391,7356,2022-03-30 09:56:28.367759,"A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis","<p>EudraCT Number: 2010-020338-25<br />Sponsor Protocol Number: WA25046<br />Sponsor Name: F.Hoffmann-La Roche<br />Start Date: 2010-11-02<br />Medical condition: Primary Progressive Multiple Sclerosis (PPMS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/FI"">FI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/BG"">BG</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/DK"">DK</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020338-25/PL"">PL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020338-25,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
392,6978,2022-03-29 22:12:24.271901,Effect of infliximab on inflammatory and fibrous lesions in patients with intestinal Crohn’s disease,"<p>EudraCT Number: 2006-004784-58<br />Sponsor Protocol Number: MRI-0143<br />Sponsor Name: University of Leuven<br />Start Date: 2007-06-22<br />Medical condition: Crohn's disease<br />Disease: <br />Version: 8.1<br />SOC Term: <br />Classification Code: 10011401<br />Term: Crohn's disease<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004784-58/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004784-58/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004784-58/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004784-58/GB"">GB</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004784-58,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
393,6977,2022-03-29 22:12:24.270224,"Ensayo de fase III, multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, sobre la eficacia y la seguridad del bapineuzumab (AAB-001, ELN115727) en pacientes co...","<p>EudraCT Number: 2007-005994-79<br />Sponsor Protocol Number: 3133K1-3000-WW<br />Sponsor Name: Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development<br />Start Date: 2008-05-13<br />Medical condition: Enfermedad de Alzheimer

Alzheimer Disease<br />Disease: <br />Version: 9.1<br />SOC Term: <br />Classification Code: 10012271<br />Term: Dementia Alzheimer's type<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/ES"">ES</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/IE"">IE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/GB"">GB</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/DE"">DE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/FI"">FI</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/SE"">SE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/IT"">IT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/PT"">PT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/AT"">AT</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/NL"">NL</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005994-79/DK"">DK</a> (Prematurely Ended)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005994-79,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
394,6976,2022-03-29 22:12:24.269551,"A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS)","<p>EudraCT Number: 2020-000579-19<br />Sponsor Protocol Number: MAGNET<br />Sponsor Name: Stichting TRICALS Foundation<br />Start Date: 2021-06-25<br />Medical condition: Amyotrophic Lateral Sclerosis<br />Disease: <br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000579-19/NL"">NL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000579-19,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
395,6975,2022-03-29 22:12:24.268675,"An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT-physician’s choi...","<p>EudraCT Number: 2020-004505-32<br />Sponsor Protocol Number: COMB157G3301<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2021-06-09<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004505-32/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004505-32/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004505-32/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004505-32,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
396,6974,2022-03-29 22:12:24.267781,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSIN...","<p>EudraCT Number: 2020-001168-28<br />Sponsor Protocol Number: GN42272<br />Sponsor Name: F. Hoffman-La Roche<br />Start Date: 2021-03-01<br />Medical condition: Relapsing multiple sclerosis (RMS)<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001168-28/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001168-28/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001168-28/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001168-28,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
397,6973,2022-03-29 22:12:24.267083,"A Scandinavian, randomized, rater-blinded study of single and double-dose (2x250 mcg e.o.d.) Betaferon in patients with early secondary progressive multiple sclerosis.","<p>EudraCT Number: 2005-001540-23<br />Sponsor Protocol Number: 309560<br />Sponsor Name: Schering Nordiska AB<br />Start Date: 2006-03-03<br />Medical condition: Early Secondary Progressive Multiple Sclerosis<br />Disease: <br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001540-23/SE"">SE</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001540-23/DK"">DK</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001540-23,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
398,6972,2022-03-29 22:12:24.266425,"Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters.
A cross-over, double-blinded, placebo-controlled study.","<p>EudraCT Number: 2012-005076-34<br />Sponsor Protocol Number: BEL-FMP-12-10325<br />Sponsor Name: Cliniques Universitaires Saint-Luc, Neurologie<br />Start Date: 2013-01-03<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005076-34/BE"">BE</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-005076-34,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
399,6971,2022-03-29 22:12:24.265589,"A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN
PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSO...","<p>EudraCT Number: 2017-004886-29<br />Sponsor Protocol Number: MN39158<br />Sponsor Name: Roche Farma SA (Soc unipersonal) que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche Ltd<br />Start Date: 2018-05-22<br />Medical condition: Multiple sclerosis (MS)<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10039720<br />Term: Sclerosis multiple<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/ES"">ES</a> (Prematurely Ended), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/IE"">IE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/FI"">FI</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/SI"">SI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004886-29/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004886-29,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
400,6970,2022-03-29 22:12:24.264629,"A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS","<p>EudraCT Number: 2020-000893-69<br />Sponsor Protocol Number: BN42082<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2020-10-28<br />Medical condition: Relapsing Multiple Sclerosis (MS)<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10039720<br />Term: Sclerosis multiple<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/GB"">GB</a> (GB - no longer in EU/EEA), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/NL"">NL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000893-69/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000893-69,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
401,6969,2022-03-29 22:12:24.263390,"Randomized autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab for patients with relapsing remitting Multiple Sclerosis","<p>EudraCT Number: 2017-001362-25<br />Sponsor Protocol Number: RAM-MS<br />Sponsor Name: Helse Bergen HF, Haukeland University Hospital<br />Start Date: 2018-05-02<br />Medical condition: Relapsing remitting multiple sclerosis.<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001362-25/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001362-25/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001362-25/NL"">NL</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001362-25,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
402,6968,2022-03-29 22:12:24.262728,"A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis","<p>EudraCT Number: 2015-002500-91<br />Sponsor Protocol Number: RPC01-3001<br />Sponsor Name: Celgene International II Sàrl (CIS II)<br />Start Date: 2015-10-12<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/GB"">GB</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/SE"">SE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/HR"">HR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002500-91/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002500-91,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
403,6967,2022-03-29 22:12:24.261935,"A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Scleros...","<p>EudraCT Number: 2019-004980-36<br />Sponsor Protocol Number: MS200527-0082<br />Sponsor Name: Merck Healthcare KGaA<br />Start Date: 2020-09-21<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/GR"">GR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/BG"">BG</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/NO"">NO</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/SI"">SI</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004980-36/IT"">IT</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-004980-36,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
404,6966,2022-03-29 22:12:24.260701,Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously ...,"<p>EudraCT Number: 2019-000069-19<br />Sponsor Protocol Number: MS700568_0026<br />Sponsor Name: Merck KGaA<br />Start Date: 2019-07-12<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029205<br />Term: Nervous system disorders<br />Level: SOC<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/SE"">SE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/PT"">PT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/EE"">EE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/BG"">BG</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/AT"">AT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/LT"">LT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/HR"">HR</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000069-19/RO"">RO</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000069-19,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
405,6965,2022-03-29 22:12:24.260078,A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409),"<p>EudraCT Number: 2013-003884-71<br />Sponsor Protocol Number: LPS13649<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2015-02-05<br />Medical condition: Relapsing-remitting multiple sclerosis<br />Disease: <br />Version: 17.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003884-71/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003884-71/NL"">NL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003884-71/CZ"">CZ</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003884-71/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003884-71/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003884-71/IT"">IT</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003884-71/DK"">DK</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003884-71/HR"">HR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-003884-71,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
406,6964,2022-03-29 22:12:24.259067,"A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followe...","<p>EudraCT Number: 2020-002700-39<br />Sponsor Protocol Number: CBAF312D2301<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2021-09-10<br />Medical condition: Multiple Sclerosis in pediatric patients<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/DE"">DE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/PT"">PT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/EE"">EE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/FR"">FR</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/BE"">BE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/LT"">LT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/AT"">AT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/SK"">SK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/LV"">LV</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002700-39/HR"">HR</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002700-39,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
407,6963,2022-03-29 22:12:24.258411,A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis,"<p>EudraCT Number: 2015-005160-41<br />Sponsor Protocol Number: ALK8700-A301<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2016-07-27<br />Medical condition: Relapsing Remitting Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005160-41/DE"">DE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005160-41/BE"">BE</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005160-41/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005160-41/ES"">ES</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005160-41/BG"">BG</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005160-41,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
408,6962,2022-03-29 22:12:24.257643,Antelope: Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS),"<p>EudraCT Number: 2018-004751-20<br />Sponsor Protocol Number: PB006-03-01<br />Sponsor Name: Polpharma Biologics S.A.<br />Start Date: 2019-07-22<br />Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004751-20/PL"">PL</a> (Completed), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004751-20/HR"">HR</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004751-20,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
409,6961,2022-03-29 22:12:24.256139,"AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS","<p>EudraCT Number: 2017-001313-93<br />Sponsor Protocol Number: MN39159<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2018-05-03<br />Medical condition: Progressive multiple sclerosis (PMS)<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10053395<br />Term: Progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/IE"">IE</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/DK"">DK</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/ES"">ES</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/PL"">PL</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/CZ"">CZ</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/HU"">HU</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/IT"">IT</a> (Ongoing), <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/DE"">DE</a> (Ongoing)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001313-93,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
410,6960,2022-03-29 22:12:23.976789,"A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis","<p>EudraCT Number: 2008-003098-42<br />Sponsor Protocol Number: 108MS303<br />Sponsor Name: Biogen Idec Ltd<br />Start Date: 2009-01-06<br />Medical condition: To evaluate the immunogenicity of Avonex® 30 mcg when administered SC to interferon-naïve subjects with relapsing Multiple Sclerosis<br />Disease: <br />Version: 9.1<br />SOC Term: <br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=""https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003098-42/CZ"">CZ</a> (Completed)</p>",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-003098-42,,15.0,,15.0,European Clinical Trials Register,https://www.clinicaltrialsregister.eu/ctr-search/rest/feed/bydates?query=multiple+AND+sclerosis
411,6533,2022-03-28 11:41:38.700399,Structural and Functional Impairment of Multiple Organs in Patients With Systemic Sclerosis: A MR Imaging Study,<b>Conditions</b>:    Systemic Sclerosis;   Multisystem Disorder<br /><b>Intervention</b>:    Other: MRI<br /><b>Sponsors</b>:    Tsinghua University;   Peking Union Medical College Hospital<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05297474?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-28 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
412,6530,2022-03-28 11:41:38.697822,Gait Analysis in Multiple Sclerosis Patients,<b>Conditions</b>:    Multiple Sclerosis;   3D Gait Analysis;   Vestibular Rehabilitation<br /><b>Interventions</b>:    Other: Vestibular exercises;   Other: Standard neurorehabilitation exercises<br /><b>Sponsors</b>:    Istanbul Kültür University;   Istanbul University-Cerrahpasa<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05299151?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-28 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
413,6526,2022-03-28 11:41:38.693998,Drug Repurposing for Improving the Therapeutic Outcome in Multiple Sclerosis Patients,"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Metformin 1000 mg (Cidophage® 1000 mg tablets, CID, Giza, Egypt) tablet;   Drug: Interferon beta-1a<br /><b>Sponsor</b>:    German University in Cairo<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05298670?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-28 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
414,5579,2022-03-25 11:41:38.145928,B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    Drug: Ocrelizumab<br /><b>Sponsor</b>:    VU University Medical Center<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05296161?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-25 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
415,5005,2022-03-23 14:40:22.014022,An Assistive Powered Wheelchair: Stage 2 Trial,<b>Conditions</b>:    Multiple Sclerosis;   Stroke;   Cystic Fibrosis;   Motor Neurone Disease;   Craniocerebral Trauma;   Guillain-Barre Syndrome<br /><b>Intervention</b>:    Device: Powered Wheelchair Obstacle Alerting System<br /><b>Sponsors</b>:    East Kent Hospitals University NHS Foundation Trust;   University of Kent;   Sussex Community NHS Foundation Trust;   KU Leuven;   l'Institut supérieur de l'électronique et du numérique (ISEN) Lille<br /><b>Completed</b>,https://clinicaltrials.gov/ct2/show/NCT05292690?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-23 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
416,4667,2022-03-22 12:37:56.690857,Cellular microRNA Signatures in Multiple Sclerosis,"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    Genetic: 50 ml blodd sampling<br /><b>Sponsors</b>:    Institut Pasteur;   Höpital La Pitié-Salpêtrière<br /><b>Not yet recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05290688?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-22 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
417,3318,2022-03-18 12:44:44.032425,Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients,"<b>Conditions</b>:    Multiple Sclerosis;   Autoimmune Blistering Disease;   B-Cell Deficiency<br /><b>Intervention</b>:    Biological: COVID19 vaccine<br /><b>Sponsors</b>:    Yale University;   National Institute of Allergy and Infectious Diseases (NIAID);   Robert Leet and Clara Guthrie Patterson Trust<br /><b>Active, not recruiting</b>",https://clinicaltrials.gov/ct2/show/NCT05286242?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-18 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
418,3310,2022-03-18 12:44:44.026375,Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Ofatumumab<br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05285904?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-18 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
419,3308,2022-03-18 12:44:43.303079,Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Biological: Ocrelizumab;   Drug: Placebo for Ocrelizumab<br /><b>Sponsors</b>:    National Institute of Allergy and Infectious Diseases (NIAID);   Autoimmunity Centers of Excellence (ACE)<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05285891?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-18 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
420,2987,2022-03-17 12:44:43.883950,Famciclovir in Multiple Sclerosis,<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Famciclovir<br /><b>Sponsor</b>:    Queen Mary University of London<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05283551?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-17 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
421,2434,2022-03-15 19:19:40.664680,A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers,<b>Condition</b>:    Amyotrophic Lateral Sclerosis<br /><b>Interventions</b>:    Drug: prosetin;   Drug: placebo<br /><b>Sponsors</b>:    ProJenX;   Worldwide Clinical Trials<br /><b>Recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05279755?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-15 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
422,2049,2022-03-14 13:19:41.179332,Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis,<b>Conditions</b>:    Clinically Isolated Syndrome;   Relapsing Remitting Multiple Sclerosis<br /><b>Intervention</b>:    Device: Eye-tracking<br /><b>Sponsors</b>:    McGill University;   Innodem Neurosciences<br /><b>Not yet recruiting</b>,https://clinicaltrials.gov/ct2/show/NCT05277740?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-14 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
423,1286,2022-03-12 06:20:41.569236,Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis),,https://www.novartis.com//clinicaltrials/study/nct04940065,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
424,1214,2022-03-12 01:20:39.024812,,,https://www.novartis.com/,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
425,1175,2022-03-11 20:20:41.491487,"A 52-week, Two Arm, Randomized, Open-label, Multicenter Study Assessing the Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens for Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration",,https://www.novartis.com//clinicaltrials/study/nct04679935,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
426,1150,2022-03-11 20:20:41.430654,"Exploratory PLatform Trial on Anti-Inflammatory Agents in Alzheimer&#39;s Disease (EXPLAIN-AD): A Randomized, Placebo-controlled, Multicenter Platform Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Various Anti-inflammatory ...",,https://www.novartis.com//clinicaltrials/study/nct04795466,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
427,1088,2022-03-11 14:47:23.013971,Neuromodulation in MS Using Translingual Stimulation,<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Combination Product: PT plus translingual stimulation device;   Combination Product: PT plus translingual stimulation control device<br /><b>Sponsors</b>:    University of Saskatchewan;   Memorial University of Newfoundland<br /><b>Enrolling by invitation</b>,https://clinicaltrials.gov/ct2/show/NCT05275049?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-11 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
428,1074,2022-03-11 11:30:33.550145,Pronesimod no tratamento de Esclerose Múltipla Recidivante,,https://www.cuf.pt/cuf-academic-center/ensaios-clinicos/pronesimod-no-tratamento-de-esclerose-multipla-recidivante,,14.0,,14.0,CUF,https://www.cuf.pt/cuf-academic-center/ensaios-clinicos?combine=&unidade=&estado=All&patologia=2346&especialidade=
429,1070,2022-03-11 11:30:24.347794,"An Open-label, Single Arm Phase II Study of DFV890 to Assess the Safety, Tolerability and Efficacy in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)",,https://www.novartis.com//clinicaltrials/study/nct04868968,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
430,1066,2022-03-11 11:30:24.340166,"A 24-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Extension Study to Assess the Safety of CSJ117, When Added to Existing Standard of Care Asthma Therapy in Patients ≥18 Years of Age",,https://www.novartis.com//clinicaltrials/study/nct04946318,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
431,1062,2022-03-11 11:30:24.331596,Special Drug Use-results Surveillance of Tabrecta Tablets (MET Exon 14 Skipping Mutation-positive Unresectable Advanced&#x2F;Recurrent Non-small Cell Lung Cancer),,https://www.novartis.com//clinicaltrials/study/nct04575025,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
432,1058,2022-03-11 11:30:24.316439,"A One-Year, Randomized, Double-Masked, Multicenter, Phase III, Two-Arm Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Chinese Patients With Visual Impairment Due to Diabetic Macular Edema",,https://www.novartis.com//clinicaltrials/study/nct04058067,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
433,1054,2022-03-11 11:30:24.307013,"A Single-arm, Open-label, Phase II Study of Sabatolimab in Combination With Azacitidine and Venetoclax in Adult Participants With High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria",,https://www.novartis.com//clinicaltrials/study/nct04812548,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
434,1050,2022-03-11 11:30:24.300229,"A Prospective, Open Label, Multicenter, Single Arm, Phase 2 Study of 177Lu-PSMA-617 in the Treatment of Participants With Progressive PSMA- Positive Metastatic Castration-resistant Prostate Cancer (mCRPC) in Japan",,https://www.novartis.com//clinicaltrials/study/nct05114746,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
435,1049,2022-03-11 11:30:24.295763,More locations,,https://www.novartis.com/,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
436,1046,2022-03-11 11:30:24.290363,"A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension",,https://www.novartis.com//clinicaltrials/study/nct04926818,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
437,1045,2022-03-11 11:30:24.282894,A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab (6mg) in Patients With Neovascular Age-related Macular Degeneration (nAMD),,https://www.novartis.com//clinicaltrials/study/nct04632056,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
438,1038,2022-03-11 11:30:24.269299,"Special Drug Use Surveillance for Entresto Tablets (Chronic Heart Failure, CLCZ696B1401)",,https://www.novartis.com//clinicaltrials/study/nct04781881,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
439,1034,2022-03-11 11:30:23.276296,"A Randomized, Open-label, Multi-center, Phase II Study of Asciminib Versus Best Available Therapy in Chinese Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors",,https://www.novartis.com//clinicaltrials/study/nct04795427,,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
440,706,2022-03-09 00:29:14.458003,A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Drug: OcrelizumabSponsor :    Hoffmann-La RocheNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05269004?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-07 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
441,593,2022-03-08 15:25:06.601663,Function Magnetic Resonance Imaging to Assess Two Therapeutic Strategies in Multiple Sclerosis (NeuroRehEM).,Condition:    Multiple SclerosisInterventions:    Behavioral: N-back Cognitive Training;   Behavioral: Virtual Reality Motor and Cognitive TrainingSponsor :    Universitat Jaume IRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05270239?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-08 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
442,592,2022-03-08 15:25:06.599812,Covid-19 Vaccine Immune Response in Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Other: Blood Test 1;   Other: Blood Test 2Sponsor :    University Hospitals of North Midlands NHS TrustRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05269888?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-08 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
443,591,2022-03-08 15:25:06.595685,Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype,"Conditions:    Multiple Sclerosis;   Sleep;   PainInterventions:    Drug: Cannabidiol (CBD);   Drug: Tetrahydrocannabinol (THC);   Drug: Placebo CBD;   Drug: Placebo THCSponsors :    Tiffany J. Braley, MD, MS;   National Center for Complementary and Integrative Health (NCCIH)Not yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05269628?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-08 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
444,427,2022-03-04 17:22:45.000000,Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf,Condition:    Relapsing Multiple SclerosisInterventions:    Other: Ofatumumab;   Other: OcrelizumabSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05266469?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-04 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
445,426,2022-03-03 12:52:45.000000,"A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis","Condition:    Multiple Sclerosis, Relapsing-RemittingIntervention:    Drug: NatalizumabSponsor :    BiogenNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05265728?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-03-03 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
446,425,2022-02-28 22:52:11.000000,Exploring Cortical Remyelination in Children With Multiple Sclerosis,Condition:    Children With Multiple SclerosisIntervention:    Other: MRI without injection of contrast productSponsor :    Assistance Publique - Hôpitaux de ParisNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05258396?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-28 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
447,424,2022-02-23 16:12:11.000000,Optimizing Detection and Prediction of Changes in Cognitive Function in Multiple Sclerosis (MS),Condition:    Multiple SclerosisIntervention:    Sponsors :    University of Michigan;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Wayne State University;   University of WashingtonNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05252195?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-23 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
448,423,2022-02-21 23:55:32.000000,Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan,,https://www.novartis.com/clinicaltrials/study/nct05114746,2022-02-21 23:55:32.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
449,422,2022-02-21 23:55:32.000000,"Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors",,https://www.novartis.com/clinicaltrials/study/nct04795427,2022-02-21 23:55:32.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
450,421,2022-02-21 13:32:11.000000,Study of Gynecological Follow-up Concerning Women With Multiple Sclerosis,"Condition:    Multiple SclerosisIntervention:    Behavioral: QuestionnaireSponsors :    University Hospital, Bordeaux;   Merck Sharp & Dohme Corp.Not yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05248438?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-21 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
451,420,2022-02-19 21:55:32.000000,Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma,,https://www.novartis.com/clinicaltrials/study/nct04417621,2022-02-19 21:55:32.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
452,419,2022-02-19 21:55:32.000000,"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4&#x2F;6 Inhibitor and an Aromatase Inhibitor.",,https://www.novartis.com/clinicaltrials/study/nct05038735,2022-02-19 21:55:32.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
453,418,2022-02-19 01:55:33.000000,A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP,,https://www.novartis.com/clinicaltrials/study/nct04346654,2022-02-19 01:55:33.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
454,417,2022-02-19 01:55:33.000000,Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1),,https://www.novartis.com/clinicaltrials/study/nct04980833,2022-02-19 01:55:33.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
455,416,2022-02-19 01:55:33.000000,Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy,,https://www.novartis.com/clinicaltrials/study/nct04816214,2022-02-19 01:55:33.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
456,415,2022-02-19 01:55:33.000000,"Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer",,https://www.novartis.com/clinicaltrials/study/nct04940052,2022-02-19 01:55:33.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
457,414,2022-02-19 01:55:33.000000,Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies,,https://www.novartis.com/clinicaltrials/study/nct04000529,2022-02-19 01:55:33.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
458,413,2022-02-18 13:53:27.000000,The Effect of Iyengar Yoga Practice on Patients With Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Iyengar Yoga;   Yoga;   EDSSIntervention:    Other: The effect of Iyengar yoga practice on patients with multiple sclerosisSponsor :    University Hospital, MotolActive, not recruiting ",https://clinicaltrials.gov/ct2/show/NCT05247372?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-18 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
459,412,2022-02-17 20:46:49.000000,Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2,,https://www.novartis.com/clinicaltrials/study/nct04935359,2022-02-17 20:46:49.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
460,411,2022-02-17 12:33:27.000000,Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study,Conditions:    Relapsing-Remitting Multiple Sclerosis (RRMS);   Neuromyelitis Optica;   HealthyIntervention:    Procedure: Peripheral blood withdrawalSponsors :    Neuromed IRCCS;   University of Rome Tor VergataNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05245344?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-17 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
461,410,2022-02-17 12:33:27.000000,Sensing Physical Activity to Evaluate and Monitor a Routine Aftercare Program (SensE-M),Condition:    Disease With a Risk for ChronicityIntervention:    Sponsors :    University of Zurich;   Kliniken ValensNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05243407?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-17 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
462,409,2022-02-17 05:46:47.000000,A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines,,https://www.novartis.com/clinicaltrials/study/nct05030311,2022-02-17 05:46:47.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
463,407,2022-02-16 14:23:27.000000,Telemonitoring and Connected Care Applied to Multiple Sclerose,"Condition:    Multiple SclerosisInterventions:    Device: MSmonitor, a self-management/education program with e-health interventions;   Device: Video calling program ""Better-close"";   Device: Researchmanager programSponsor :    IsalaRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05242731?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-16 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
464,406,2022-02-16 14:23:27.000000,Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis,"Condition:    Relapsing Remitting Multiple Sclerosis (RRMS)Interventions:    Drug: Pegylated interferon beta-1a;   Drug: Interferon Beta-1A Prefilled SyringeSponsor :    CinnagenActive, not recruiting ",https://clinicaltrials.gov/ct2/show/NCT05242133?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-16 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
465,405,2022-02-15 03:46:48.000000,To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema,,https://www.novartis.com/clinicaltrials/study/nct04058067,2022-02-15 03:46:48.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
466,404,2022-02-15 03:46:48.000000,Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA),,https://www.novartis.com/clinicaltrials/study/nct05089656,2022-02-15 03:46:48.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
467,403,2022-02-15 03:46:48.000000,"Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant",,https://www.novartis.com/clinicaltrials/study/nct04899349,2022-02-15 03:46:48.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
468,402,2022-02-11 19:46:49.000000,Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria,,https://www.novartis.com/clinicaltrials/study/nct04747613,2022-02-11 19:46:49.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
469,401,2022-02-11 14:03:27.000000,TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants,"Condition:    Multiple SclerosisIntervention:    Drug: NatalizumabSponsors :    Biogen;   Association for Functional Rehabilitation, Recreation and Applied Kinesiology ImpulseRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05236777?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-11 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
470,400,2022-02-10 23:46:50.000000,An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study,,https://www.novartis.com/clinicaltrials/study/nct04597632,2022-02-10 23:46:50.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
471,399,2022-02-10 23:46:50.000000,Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD),,https://www.novartis.com/clinicaltrials/study/nct04268823,2022-02-10 23:46:50.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
472,398,2022-02-10 23:46:50.000000,"A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China",,https://www.novartis.com/clinicaltrials/study/nct04894890,2022-02-10 23:46:50.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
473,397,2022-02-10 23:46:50.000000,Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia,,https://www.novartis.com/clinicaltrials/study/nct04784390,2022-02-10 23:46:50.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
474,396,2022-02-10 13:46:49.000000,A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED),,https://www.novartis.com/clinicaltrials/study/nct04737330,2022-02-10 13:46:49.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
475,395,2022-02-10 12:43:27.000000,The Feasibility of Frame Running as an Exercise Option for People With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: Frame RunningSponsors :    Queen Margaret University;   Multiple Sclerosis SocietyNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05234879?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-10 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
476,394,2022-02-10 12:43:27.000000,"A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis",Conditions:    Relapsing Multiple Sclerosis;   Primary Progressive Multiple SclerosisInterventions:    Drug: Ocrelizumab IV;   Drug: Ocrelizumab SC;   Drug: Methylprednisolone IV;   Drug: Diphenhydramine IV;   Drug: Dexamethasone given orally;   Drug: Desloratadine given orallySponsor :    Hoffmann-La RocheNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05232825?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-10 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
477,393,2022-02-10 03:46:48.000000,"A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+&#x2F;HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia",,https://www.novartis.com/clinicaltrials/study/nct04943497,2022-02-10 03:46:48.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
478,392,2022-02-10 03:46:48.000000,Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant,,https://www.novartis.com/clinicaltrials/study/nct04862143,2022-02-10 03:46:48.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
479,391,2022-02-10 03:46:48.000000,STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS,,https://www.novartis.com/clinicaltrials/study/nct04878432,2022-02-10 03:46:48.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
480,390,2022-02-09 17:46:50.000000,Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma,,https://www.novartis.com/clinicaltrials/study/nct04903197,2022-02-09 17:46:50.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
481,389,2022-02-09 17:46:50.000000,CLCZ696B2319E1 OL Extension Study to Evaluate Long-term Safety of Sacubitril&#x2F;Valsartan in Pediatric Patients With HF,,https://www.novartis.com/clinicaltrials/study/nct03785405,2022-02-09 17:46:50.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
482,388,2022-02-09 07:46:49.000000,Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease,,https://www.novartis.com/clinicaltrials/study/nct05030428,2022-02-09 07:46:49.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
483,387,2022-02-08 21:46:49.000000,Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy,,https://www.novartis.com/clinicaltrials/study/nct04984876,2022-02-08 21:46:49.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
484,386,2022-02-08 21:46:49.000000,"Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.",,https://www.novartis.com/clinicaltrials/study/nct05078580,2022-02-08 21:46:49.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
485,385,2022-02-08 21:46:49.000000,Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation,,https://www.novartis.com/clinicaltrials/study/nct04699188,2022-02-08 21:46:49.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
486,384,2022-02-08 13:13:27.000000,The Influence of HIIT Versus MCT on Cardiorespiratory Fitness in PPMS,"Conditions:    Primary Progressive Multiple Sclerosis;   Exercise;   Cardiorespiratory FitnessInterventions:    Behavioral: HIIT;   Behavioral: MCTSponsors :    Klinik Valens;   Technische Universität Dortmund, GermanyNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05229861?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-08 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
487,383,2022-02-07 20:46:47.000000,Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients,,https://www.novartis.com/clinicaltrials/study/nct03656562,2022-02-07 20:46:47.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
488,382,2022-02-07 20:46:47.000000,Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection,,https://www.novartis.com/clinicaltrials/study/nct04838626,2022-02-07 20:46:47.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
489,381,2022-02-07 15:03:27.000000,3D OPTIMIZED WMN MPRAGE Increased Detection of Focal Spinal Cord Lesion in Multiple Sclerosis (WHINUME),"Condition:    Multiple SclerosisIntervention:    Device: 3D OPTIMIZED WMN MPRAGESponsor :    University Hospital, BordeauxNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05227092?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-07 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
490,380,2022-02-05 10:10:47.000000,Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer&#39;s Disease,,https://www.novartis.com/clinicaltrials/study/nct04795466,2022-02-05 10:10:47.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
491,378,2022-02-05 10:10:47.000000,Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.,,https://www.novartis.com/clinicaltrials/study/nct04774926,2022-02-05 10:10:47.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
492,377,2022-02-05 00:10:44.000000,Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects,,https://www.novartis.com/clinicaltrials/study/nct04129528,2022-02-05 00:10:44.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
493,376,2022-02-05 00:10:44.000000,A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070&#x2F;Branaplam in Early Manifest Huntington&#39;s Disease,,https://www.novartis.com/clinicaltrials/study/nct05111249,2022-02-05 00:10:44.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
494,375,2022-02-05 00:10:44.000000,A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration,,https://www.novartis.com/clinicaltrials/study/nct04239027,2022-02-05 00:10:44.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
495,373,2022-02-04 15:47:25.000000,Providing Emotional Support Around the Point of Multiple Sclerosis Diagnosis: PrEliMS 2,Condition:    Multiple SclerosisIntervention:    Other: Acceptance and Commitment TherapySponsor :    University of NottinghamNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05225012?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-04 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
496,372,2022-02-01 14:57:18.000000,Evaluation of Relapse Presence in Multiple Sclerosis,"Conditions:    Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis RelapseIntervention:    Diagnostic Test: in-vivo Corneal Confocal MicroscopySponsor :    Marmara UniversityCompleted ",https://clinicaltrials.gov/ct2/show/NCT05218317?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-01 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
497,371,2022-02-01 14:57:18.000000,Effectiveness of Cryotherapy on the Fatigue of Patients With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Device: partial-body cryotherapy chamber sessionSponsors :    Fondation Ildys;   Lille Catholic UniversityNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05219201?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-02-01 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
498,370,2022-01-28 15:57:18.000000,Promoting Aerobic Training in Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Behavioral: Aerobic exercise;   Behavioral: Task-oriented upper-limb training;   Behavioral: Sport events participationSponsors :    Fondazione Italiana Sclerosi Multipla;   University of Genoa;   University Grenoble AlpsRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05212805?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-28 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
499,369,2022-01-27 17:47:18.000000,LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB,Condition:    Multiple SclerosisIntervention:    Drug: OcrelizumabSponsor :    Centre Hospitalier Universitaire de NiceNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05210621?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-27 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
500,368,2022-01-27 17:47:18.000000,Safety of Exposure to Natalizumab During Pregnancy,"Condition:    Multiple SclerosisIntervention:    Behavioral: QuestionnaireSponsors :    University Hospital, Bordeaux;   BiogenNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05209815?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-27 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
501,367,2022-01-26 13:17:18.000000,Development and Evaluation of the Self-management Module in Patients With Multiple Sclerosis,"Condition:    Self EfficacyIntervention:    Other: EducationSponsor :    Hacettepe UniversityActive, not recruiting ",https://clinicaltrials.gov/ct2/show/NCT05209113?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-26 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
502,366,2022-01-26 13:17:18.000000,A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Drug: OcrelizumabSponsor :    Hoffmann-La RocheRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05208840?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-26 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
503,365,2022-01-24 16:57:17.000000,MS-ResearchBiomarkerS,"Conditions:    Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary Progressive;   Clinically Isolated Syndrome;   Radiologically Isolated Syndrome;   Neuromyelitis Optica Spectrum Disorders;   Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease;   Neurologic Autoimmune Disease;   Neurologic Disorder;   Healthy AgingIntervention:    Sponsor :    Cedars-Sinai Medical CenterRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05204459?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-24 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
504,364,2022-01-21 14:40:27.000000,"Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis","Condition:    Multiple Sclerosis, Relapsing-RemittingInterventions:    Drug: IMU-838 tablets;   Drug: Placebo matching IMU-838 tabletsSponsor :    Immunic AGNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05201638?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-21 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
505,363,2022-01-20 16:30:27.000000,Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China,Condition:    Relapsing Multiple SclerosisIntervention:    Biological: OfatumumabSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05199571?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-20 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
506,362,2022-01-19 17:16:55.000000,Expression of PARP-1 in Multiple Sclerosis Patients,Condition:    Multiple SclerosisIntervention:    Genetic: Blood samplingSponsor :    Sohag UniversityRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05196425?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-19 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
507,361,2022-01-19 17:16:55.000000,Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study,Condition:    Multiple Sclerosis (MS)Intervention:    Sponsor :    BiogenRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05197699?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-19 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
508,360,2022-01-18 12:46:55.000000,Reinventing Yourself With Multiple Sclerosis (MS),Condition:    Multiple SclerosisIntervention:    Behavioral: Reinvention with MSSponsors :    Kessler Foundation;   Craig Hospital;   University of MinnesotaNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05195320?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-17 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
509,359,2022-01-12 15:40:19.000000,Validity and Reliability of the Dual-task Questionnaire,"Condition:    Multiple SclerosisIntervention:    Procedure: validity and reability studySponsor :    Gazi UniversityActive, not recruiting ",https://clinicaltrials.gov/ct2/show/NCT05188937?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-12 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
510,358,2022-01-11 17:30:19.000000,Investigating the Home-based RCTs of Pilates Exercises and Cognitive Rehabilitation Exercises for Executive Functions and Anxiety in MS.,Condition:    Multiple SclerosisInterventions:    Behavioral: Home-Based Pilates exercise;   Other: Home-based Cognitive Rehabilitation;   Other: waiting list groupSponsors :    Arak University of Medical Sciences;   Pardis Specialized Wellness InstituteRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05185986?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-11 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
511,357,2022-01-10 13:00:20.000000,Validity and Reliability of Turkish Version Leg Activity Measure,Conditions:    Spinal Cord Injuries;   Multiple Sclerosis;   StrokeIntervention:    Other: assessmentSponsor :    Kahramanmaras Sutcu Imam UniversityNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05182411?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-07 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
512,356,2022-01-10 13:00:19.000000,Validity and Reliability of the Modified Four Square Step Test in Multiple Sclerosis Patients,Condition:    Multiple SclerosisIntervention:    Other: AssesmentSponsor :    Kahramanmaras Sutcu Imam UniversityNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05182398?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-07 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
513,355,2022-01-06 23:30:19.000000,Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects,Condition:    Relapsing Remitting Multiple SclerosisInterventions:    Drug: Monomethyl Fumarate 190 Mg;   Drug: Diroximel Fumarate 462 mgSponsor :    Banner Life Sciences LLCCompleted ,https://clinicaltrials.gov/ct2/show/NCT05181215?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-06 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
514,354,2022-01-05 12:40:19.000000,Natalizumab and Chronic Inflammation,Condition:    Multiple SclerosisIntervention:    Drug: Natalizumab 300 MG in 15 ML InjectionSponsors :    Vanderbilt University Medical Center;   BiogenNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05177718?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-05 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
515,353,2022-01-05 12:40:19.000000,Low-Load Blood Flow Restriction on Patients With Multiple Sclerosis,Conditions:    Training Study;   Multiple Sclerosis;   Blood Flow RestrictionInterventions:    Other: Blood Flow Restriction;   Other: Standard of CareSponsors :    University of Central Florida;   AdventHealthRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05177952?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-05 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
516,352,2022-01-05 12:40:19.000000,A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis,"Condition:    SpasticityInterventions:    Drug: Arbaclofen;   Drug: PlaceboSponsor :    RVL Pharmaceuticals, Inc.Not yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05179577?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-05 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
517,351,2022-01-04 14:30:19.000000,Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis,"Conditions:    Multiple Sclerosis (MS);   Relapsing-remitting Multiple Sclerosis (RRMS);   Secondary-progressive Multiple Sclerosis (SPMS);   Primary Progressive Multiple Sclerosis (PPMS)Interventions:    Diagnostic Test: MRI;   Other: Neurocognitive examination for healthy subjects;   Other: blood samplingSponsors :    University Hospital, Basel, Switzerland;   Swiss National Science FoundationRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05177523?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2022-01-04 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
518,350,2022-01-03 16:20:19.000000,Adherence to Mediterranean Diet and Cardiovascular Health in Multiple Sclerosis Female Patients: a Case Control Study,"Condition:    Multiple SclerosisIntervention:    Other: Lifestyle interventionSponsors :    Iaso Maternity Hospital, Athens, Greece;   Harokopio University;   G.Gennimatas General HospitalCompleted ",https://clinicaltrials.gov/ct2/show/NCT05175378?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-12-31 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
519,349,2021-12-29 15:24:10.000000,Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment,Condition:    Relapsing Remitting Multiple SclerosisIntervention:    Drug: OfatumumabSponsors :    University of Southern California;   Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05171972?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-12-29 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
520,348,2021-12-29 15:24:10.000000,"Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab",Condition:    Relapsing-remitting Multiple Sclerosis (RRMS)Intervention:    Device: BeCare applicationSponsor :    Icahn School of Medicine at Mount SinaiRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05172466?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-12-29 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
521,347,2021-12-27 15:42:42.000000,A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring,Condition:    Multiple SclerosisIntervention:    Sponsor :    Bristol-Myers SquibbNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05170126?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-12-24 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
522,346,2021-12-23 15:29:41.000000,Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Secondary ProgressiveInterventions:    Combination Product: Extracorporeal Photopheresis;   Combination Product: MS standard of careSponsor :    Abu Dhabi Stem Cells CenterNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05168384?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-12-23 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
523,345,2021-12-21 15:17:55.000000,Impact Program for Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Behavioral: Impact of four week coaching program on dietary habitsSponsor :    University of Alabama at BirminghamNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05165238?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-12-21 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
524,344,2021-12-17 16:17:56.000000,Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation,Conditions:    Multiple Sclerosis;   HealthyIntervention:    Procedure: thoracic duct cannulationSponsors :    University of Pennsylvania;   Novartis Pharmaceuticals;   Novartis Institutes for BioMedical ResearchNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05162638?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-12-17 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
525,343,2021-12-14 12:17:55.000000,Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS),Condition:    Relapsing Multiple SclerosisInterventions:    Drug: Remibrutinib;   Drug: TeriflunomideSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05156281?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-12-14 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
526,342,2021-12-13 14:07:55.000000,Safety of Therapeutic Step-down in Neuromyelitis Optica,"Condition:    Neuromyelitis OpticaIntervention:    Sponsor :    University Hospital, Strasbourg, FranceRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05155644?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-12-13 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
527,341,2021-12-13 14:07:55.000000,China National Registry of CNS Inflammatory Demyelinating Diseases,Conditions:    Multiple Sclerosis;   NMO Spectrum Disorder;   Clinically Isolated Syndrome;   CNS Demyelinating Autoimmune Diseases;   Acute Disseminated EncephalomyelitisIntervention:    Drug: Intravenous steroidSponsor :    Beijing Tiantan HospitalNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05154370?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-12-13 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
528,340,2021-12-07 13:52:09.000000,Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis,Condition:    Relapsing Multiple SclerosisInterventions:    Drug: Remibrutinib;   Drug: TeriflunomideSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05147220?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-12-07 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
529,339,2021-12-07 13:52:09.000000,Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Investigating Individual Profiles of Myelin Repair and the Contribution of Neuroinflammation,Conditions:    Multiple Sclerosis;   Inflammatory DiseaseIntervention:    Procedure: PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714Sponsor :    Assistance Publique - Hôpitaux de ParisNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05147532?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-12-07 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
530,338,2021-12-02 15:12:45.000000,Impact of Fingolimod Adherence on Outcomes,Condition:    Multiple SclerosisIntervention:    Drug: FingolimodSponsor :    Novartis PharmaceuticalsCompleted ,https://clinicaltrials.gov/ct2/show/NCT05141669?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-12-02 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
531,337,2021-12-02 15:12:45.000000,Pilot Study on EEG and Behavioral Effects of Two Different Treatments on Sexual Life,"Conditions:    Multiple Sclerosis;   Spinal Cord InjuriesIntervention:    Behavioral: TherapySponsor :    IRCCS San Camillo, Venezia, ItalyRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05142111?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-12-02 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
532,336,2021-11-26 16:07:43.000000,"Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis",Condition:    Multiple SclerosisInterventions:    Drug: IMU-838 tablets;   Drug: Placebo matching IMU-838 tabletsSponsor :    Immunic AGNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05134441?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-25 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
533,335,2021-11-23 15:17:43.000000,"CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy",Condition:    Multiple SclerosisInterventions:    Drug: Metformin and clemastine in combination;   Drug: PlaceboSponsors :    Cambridge University Hospitals NHS Foundation Trust;   University of CambridgeNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05131828?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-23 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
534,334,2021-11-23 15:17:43.000000,"A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants",Condition:    Multiple SclerosisInterventions:    Drug: GSK3888130B;   Drug: PlaceboSponsor :    GlaxoSmithKlineRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05131971?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-23 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
535,333,2021-11-23 15:17:43.000000,Ocrelizumab Access by Socio-Economic Status,"Condition:    Multiple SclerosisIntervention:    Drug: OcrelizumabSponsors :    Brigham and Women's Hospital;   Genentech, Inc.;   Boston Medical CenterNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05131984?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-23 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
536,332,2021-11-22 13:57:43.000000,Improving Prospective Memory Via Telehealth,Condition:    Multiple SclerosisInterventions:    Behavioral: Prospective Memory Intervention;   Behavioral: EducationalSponsor :    Saint Francis CareRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05129293?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-22 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
537,331,2021-11-18 18:07:42.000000,An Individualized-health eLibrary App for People With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Device: SavvyHealthSponsor :    University of Illinois at Urbana-ChampaignRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05124600?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-18 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
538,330,2021-11-18 18:07:42.000000,A Health Action Process Approach Online Intervention for People With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Behavioral: MSPA eClassSponsor :    University of Illinois at Urbana-ChampaignRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05124522?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-18 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
539,329,2021-11-17 13:37:42.000000,Longitudinal Assessment of Iron Rims in MS Lesions,Condition:    Multiple SclerosisInterventions:    Biological: Blood sample provided;   Diagnostic Test: 7-T MRI scanSponsors :    Nottingham University Hospitals NHS Trust;   Johns Hopkins UniversityNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05123443?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-17 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
540,328,2021-11-17 13:37:42.000000,Respiratory Functions in Pediatric-Onset Multiple Sclerosis,"Condition:    Pediatric-onset Multiple SclerosisIntervention:    Other: Evaluation of respiratory capacity, respiratory muscle strength and fatigueSponsor :    Istanbul University-CerrahpasaRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05123924?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-17 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
541,327,2021-11-17 13:37:42.000000,A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis,Condition:    Relapsing-Remitting Multiple SclerosisInterventions:    Drug: Ocrelizumab;   Other: Ocrelizumab Placebo;   Drug: Fingolimod;   Other: Fingolimod PlaceboSponsors :    Hoffmann-La Roche;   PPDNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05123703?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-17 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
542,326,2021-11-16 12:17:42.000000,COVID-19 Vaccine Biomarker Study in Multiple Sclerosis,Conditions:    Multiple Sclerosis;   COVID-19Intervention:    Sponsors :    Columbia University;   NovartisRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05121662?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-16 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
543,325,2021-11-16 12:17:42.000000,Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary ProgressiveInterventions:    Drug: N-acetyl cysteine;   Drug: PlaceboSponsors :    Emmanuelle Waubant;   United States Department of DefenseNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05122559?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-16 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
544,324,2021-11-15 14:07:42.000000,A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS),Condition:    Relapsing Multiple SclerosisInterventions:    Drug: fenebrutinib;   Drug: placeboSponsor :    Hoffmann-La RocheNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05119569?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-15 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
545,323,2021-11-12 15:31:05.000000,A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants,,https://www.novartis.com/clinicaltrials/study/nct04812548,2021-11-12 15:31:05.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
546,322,2021-11-12 15:31:05.000000,Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia,,https://www.novartis.com/clinicaltrials/study/nct04925479,2021-11-12 15:31:05.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
547,321,2021-11-12 15:31:05.000000,"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients",,https://www.novartis.com/clinicaltrials/study/nct04635800,2021-11-12 15:31:05.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
548,320,2021-11-11 19:31:04.000000,Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH),,https://www.novartis.com/clinicaltrials/study/nct04147195,2021-11-11 19:31:04.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
549,319,2021-11-11 15:07:42.000000,Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Biological: HB-adMSCs;   Drug: PlaceboSponsor :    Hope Biosciences Stem Cell Research FoundationRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05116540?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-11 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
550,318,2021-11-11 09:31:04.000000,Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation,,https://www.novartis.com/clinicaltrials/study/nct04427072,2021-11-11 09:31:04.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
551,317,2021-11-10 23:31:04.000000,DFF332 as a Single Agent and in Combination With Everolimus &amp; Immuno-Oncology Agents in Advanced&#x2F;Relapsed Renal Cancer &amp; Other Malignancies,,https://www.novartis.com/clinicaltrials/study/nct04895748,2021-11-10 23:31:04.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
552,316,2021-11-10 13:31:04.000000,Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study,,https://www.novartis.com/clinicaltrials/study/nct04657822,2021-11-10 13:31:04.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
553,315,2021-11-10 13:31:04.000000,A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP,,https://www.novartis.com/clinicaltrials/study/nct04971226,2021-11-10 13:31:04.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
554,314,2021-11-10 13:31:04.000000,A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy,,https://www.novartis.com/clinicaltrials/study/nct04150029,2021-11-10 13:31:04.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
555,311,2021-11-09 12:26:59.000000,Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Diagnostic Test: Measurement of concentrations of orally-used DMDs;   Diagnostic Test: Genetic testing;   Diagnostic Test: Parameters for routine use of DMDs;   Other: Side effects of orally used DMDsSponsors :    University Hospital Ostrava;   University of OstravaNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05112484?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-09 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
556,310,2021-11-08 14:27:35.000000,"Electrical Stimulations on Pain, Functional Capacity and Quality of Life in Multiple Sclerosis",Condition:    Multiple SclerosisIntervention:    Other: ElectrotherapySponsor :    Kahramanmaras Sutcu Imam UniversityNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05110586?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-08 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
557,309,2021-11-08 14:27:34.000000,A Study to Evaluate White Matter Hyperintensities in Migraine,Conditions:    Migraine;   Small Vessel Ischemic Disease;   Multiple SclerosisIntervention:    Diagnostic Test: Brain NeuroimagingSponsor :    Mayo ClinicRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05112289?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-08 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
558,307,2021-11-07 17:02:39.000000,Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC,,https://www.novartis.com/clinicaltrials/study/nct04926831,2021-11-07 17:02:39.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
559,306,2021-11-07 17:02:39.000000,Asciminib Treatment Optimization in ≥ 3rd Line CML-CP.,,https://www.novartis.com/clinicaltrials/study/nct04948333,2021-11-07 17:02:39.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
560,305,2021-11-06 07:04:31.000000,"Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis",,https://www.novartis.com/clinicaltrials/study/nct04886258,2021-11-06 07:04:31.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
561,303,2021-11-04 20:04:29.000000,Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma,,https://www.novartis.com/clinicaltrials/study/nct04946318,2021-11-04 20:04:29.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
562,302,2021-11-04 20:04:29.000000,A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC,,https://www.novartis.com/clinicaltrials/study/nct04452877,2021-11-04 20:04:29.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
563,301,2021-11-04 20:04:29.000000,Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments,,https://www.novartis.com/clinicaltrials/study/nct04058756,2021-11-04 20:04:29.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
564,300,2021-11-04 20:04:29.000000,A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors,,https://www.novartis.com/clinicaltrials/study/nct04857372,2021-11-04 20:04:29.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
565,299,2021-11-03 12:21:08.000000,A Sub-Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage,Condition:    Multiple Sclerosis (MS)Intervention:    Device: Konectom platformSponsor :    BiogenNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05106465?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-03 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
566,298,2021-11-01 12:51:08.000000,Robotics for Mobility Rehabilitation in MS,Conditions:    Multiple Sclerosis;   MSIntervention:    Other: Balance exercise program using exoskeleton deviceSponsor :    East Kent Hospitals University NHS Foundation TrustCompleted ,https://clinicaltrials.gov/ct2/show/NCT05102682?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-11-01 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
567,297,2021-10-28 13:51:08.000000,"The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic","Conditions:    Alopecia Areata;   Alopecia Totalis;   Alopecia Universalis;   Alopecia Areata (& Ophiasis);   Alopecia Barbae;   Alopecia Diffuse;   Autoimmune Diseases;   Autoimmune Hyperthyroidism;   Autoimmune Hypothyroidism;   Diabetes Mellitus, Type 1;   Ulcerative Colitis;   Inflammatory Bowel Diseases;   Crohn Disease;   Rheumatoid Arthritis;   Down Syndrome;   Atopic Dermatitis;   Atopic Asthma;   Atopic Rhinitis;   Vitiligo;   Psoriasis;   Ankylosing Spondylitis;   Multiple Sclerosis;   Lupus Erythematosus;   COVID-19 Pandemic;   Vaccine Reaction;   Infections;   Anemia, PerniciousIntervention:    Other: Exposure of interestSponsor :    Faculty Hospital Kralovske VinohradyActive, not recruiting ",https://clinicaltrials.gov/ct2/show/NCT05098600?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-28 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
568,296,2021-10-25 13:01:08.000000,MS Spinal Mobilisation Study,Condition:    Multiple SclerosisInterventions:    Other: Spinal Mobilisation Intervention;   Other: General MassageSponsors :    Edinburgh Napier University;   Scottish Hospital Endowments Research Trust;   Pacla Medical LtdCompleted ,https://clinicaltrials.gov/ct2/show/NCT05090709?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-25 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
569,295,2021-10-25 13:01:07.000000,Cannabis as a Complementary Treatment in Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Drug: Cannabis oil vs placeboSponsors :    Centre hospitalier de l'Université de Montréal (CHUM);   Canadian Institutes of Health Research (CIHR);   Multiple Sclerosis Society of CanadaNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05092191?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-25 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
570,294,2021-10-22 12:11:07.000000,A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation,Condition:    Relapsing-Remitting Multiple SclerosisInterventions:    Drug: Ofatumumab;   Drug: Disease modifying treatment (DMT)Sponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05090371?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-22 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
571,293,2021-10-22 12:11:07.000000,Diagnosic and Pronostic Values of Kappa and Lambda Free Light Chains in Central Nervous System Inflammatory Diseases,Conditions:    Central Nervous System Diseases;   Multiple SclerosisIntervention:    Other: Biological collectionSponsor :    Centre Hospitalier Universitaire de NiceNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05088473?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-22 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
572,292,2021-10-22 12:11:07.000000,Characterizing the Use of Ofatumumab in a Real World Setting,Condition:    Relapsing Multiple SclerosisIntervention:    Other: ofatumumabSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05090033?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-22 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
573,291,2021-10-20 12:41:08.000000,"Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.",Condition:    Relapse Remitting Multiple SclerosisIntervention:    Drug: OfatumumabSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05084638?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-20 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
574,290,2021-10-19 13:59:14.000000,A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS),Condition:    Relapsing Forms of Multiple SclerosisIntervention:    Drug: Diroximel fumarateSponsor :    BiogenNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05083923?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-19 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
575,289,2021-10-18 12:39:14.000000,COVID-19 Booster Vaccination in Persons With Multiple Sclerosis,Condition:    PWMS Who Have Completed Vaccination Against COVID-19 and Test Negative for COVID-19 Spike Protein Antibodies Using a Commercial AssayInterventions:    Biological: Homologous booster;   Biological: Heterologous boosterSponsors :    Griffin Hospital;   Yale-Griffin Prevention Research CenterNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05081271?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-18 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
576,288,2021-10-18 12:39:14.000000,A Systems Approach to Understanding Disease Processes in Multiple Sclerosis,"Condition:    Multiple SclerosisIntervention:    Drug: All patients in the study will be treated with ocrelizumabSponsors :    Providence Health & Services;   Institute for Systems Biology;   Genentech, Inc.Recruiting ",https://clinicaltrials.gov/ct2/show/NCT05081700?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-18 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
577,287,2021-10-15 14:59:14.000000,Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis,"Conditions:    Multiple Sclerosis, Relapsing-Remitting;   Multiple SclerosisIntervention:    Biological: Tolerogenic FibroblastsSponsor :    FibroBiologicsCompleted ",https://clinicaltrials.gov/ct2/show/NCT05080270?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-15 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
578,286,2021-10-14 22:52:38.000000,Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.,,https://www.novartis.com/clinicaltrials/study/nct04817618,2021-10-14 22:52:38.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
579,285,2021-10-14 16:49:14.000000,Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Drug: RituximabSponsor :    St. Petersburg State Pavlov Medical UniversityRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05078177?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-14 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
580,284,2021-10-14 16:49:14.000000,Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis,Conditions:    Relapsing Multiple Sclerosis;   Multiple SclerosisIntervention:    Diagnostic Test: Cerebrospinal and Blood Serum Semaphorin 4A LevelsSponsors :    Providence Health & Services;   Milton S. Hershey Medical Center;   Bristol-Myers SquibbNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05077956?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-14 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
581,283,2021-10-13 13:56:18.000000,Multicenter Observational Study for the Evaluation in Clinical Practice of Urinary Disorders in Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Urinary Bladder, NeurogenicIntervention:    Other: Initial management of the urinary disorder/s identified during the screening phaseSponsor :    ASP 7 RagusaNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05075642?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-13 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
582,282,2021-10-12 15:46:14.000000,Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab,Condition:    Multiple SclerosisIntervention:    Biological: COVID-19 vaccinationSponsors :    Sheba Medical Center;   SanofiRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05075499?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-12 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
583,281,2021-10-12 00:09:39.000000,Study of Diagnostic Performance of [18F]CTT1057 in BCR,,https://www.novartis.com/clinicaltrials/study/nct04838613,2021-10-12 00:09:39.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
584,280,2021-10-11 14:26:14.000000,Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Diagnostic Test: CSF immunoglobulin (Ig) free light chains (FLC) dosageSponsor :    Francis CorazzaRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05072691?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-11 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
585,279,2021-10-11 14:26:14.000000,Telerehabilitation-based Upper Extremity Training in People With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: Telerehabilitation-based Upper Extremity TrainingSponsor :    Dokuz Eylul UniversityNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05073731?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-11 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
586,278,2021-10-10 08:09:39.000000,Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA),,https://www.novartis.com/clinicaltrials/study/nct04851873,2021-10-10 08:09:39.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
587,277,2021-10-09 12:10:27.000000,Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy,,https://www.novartis.com/clinicaltrials/study/nct04820530,2021-10-09 12:10:27.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
588,276,2021-10-08 16:09:38.000000,"Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis",,https://www.novartis.com/clinicaltrials/study/nct04396366,2021-10-08 16:09:38.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
589,275,2021-10-08 16:09:38.000000,Study of Efficacy of Oral Sacubitril&#x2F;Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy,,https://www.novartis.com/clinicaltrials/study/nct04164732,2021-10-08 16:09:38.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
590,274,2021-10-08 16:09:38.000000,Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D,,https://www.novartis.com/clinicaltrials/study/nct04491136,2021-10-08 16:09:38.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
591,273,2021-10-08 16:09:38.000000,"Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD",,https://www.novartis.com/clinicaltrials/study/nct04882124,2021-10-08 16:09:38.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
592,272,2021-10-08 16:09:38.000000,Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC),,https://www.novartis.com/clinicaltrials/study/nct04390763,2021-10-08 16:09:38.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
593,271,2021-10-07 12:16:14.000000,Lifestyle Weight Management Program: Interviews and Stakeholder Meetings.,Condition:    Paediatric Multiple Sclerosis and Neuromyelitis Optica Spectrum DisorderIntervention:    Behavioral: Observational Study.Sponsors :    Oxford Brookes University;   Great Ormond Street Hospital for Children NHS Foundation Trust;   Guy's and St Thomas' NHS Foundation Trust;   Oxford University Hospitals NHS TrustNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05070286?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-07 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
594,270,2021-10-01 10:56:35.000000,Neuromuscular Electrostimulation in Multiple Sclerosis People With Dysphagia,Conditions:    Deglutition Disorders;   Multiple SclerosisInterventions:    Device: Experimental: traditional dysphagia therapy plus Neuromuscular electrostimulation;   Device: Sham Comparator: Traditional dysphagia therapy plus sham Neuromuscular electrostimulationSponsor :    I.R.C.C.S. Fondazione Santa LuciaRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05063708?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-01 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
595,269,2021-10-01 10:56:35.000000,"A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis",Condition:    Multiple Sclerosis (MS)Intervention:    Drug: 11C-BMS-986196Sponsor :    Bristol-Myers SquibbNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05064436?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-10-01 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
596,268,2021-09-30 22:16:35.000000,PET Imaging of Cyclooxygenase-2 in Multiple Sclerosis,"Condition:    Multiple SclerosisIntervention:    Drug: 11C-MCISponsors :    National Institute of Mental Health (NIMH);   University of Maryland, College ParkRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05062083?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-09-30 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
597,267,2021-09-30 22:16:35.000000,Development and Validation of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Device: Eye-TrackingSponsor :    Innodem NeurosciencesNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05061953?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-09-30 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
598,266,2021-09-29 11:39:07.000000,COVID Vaccine Response in MS,Conditions:    Multiple Sclerosis;   HealthyIntervention:    Other: Blood drawSponsor :    Brigham and Women's HospitalRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05060354?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-09-29 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
599,265,2021-09-28 13:29:08.000000,MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study,Condition:    Multiple Sclerosis (MS)Intervention:    Sponsor :    BiogenRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05058729?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-09-28 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
600,264,2021-09-27 11:53:46.000000,Autoimmune Intervention Mastery Course Study,Conditions:    Multiple Sclerosis;   Clinically Isolated SyndromeInterventions:    Behavioral: Immediate Autoimmune Intervention Mastery Course;   Behavioral: Immediate Question and Answer sessions.;   Behavioral: Delayed Autoimmune Intervention Mastery Course;   Behavioral: Delayed Question and Answer sessionsSponsor :    Terry L. WahlsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05057676?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-09-27 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
601,263,2021-09-27 11:53:46.000000,"Functions, Physical Activity and Employment for Individuals With MS: A Pilot Feasibility Study",Condition:    Multiple SclerosisInterventions:    Behavioral: CoreDISTparticipation;   Behavioral: Standard careSponsors :    Nordlandssykehuset HF;   Nord University;   Hasselt University;   Helse NordEnrolling by invitation ,https://clinicaltrials.gov/ct2/show/NCT05057338?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-09-27 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
602,262,2021-09-23 17:49:58.000000,"Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis",Condition:    Multiple SclerosisInterventions:    Drug: IMU-838;   Drug: Placebo matching IMU-838Sponsor :    Immunic AGNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05054140?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-09-23 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
603,261,2021-09-23 17:49:58.000000,Ultrasound-Guided Percutaneous Neuromodulation in Spasticity,Condition:    Multiple SclerosisIntervention:    Procedure: Percutaneous Echoguided NeuromodulationSponsor :    Hospital Universitario de CanariasNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05053984?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-09-23 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
604,260,2021-09-21 13:11:04.000000,Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis,Conditions:    Multiple Sclerosis;   Major Depressive DisorderInterventions:    Behavioral: POWER-MS;   Behavioral: FLEX-MSSponsors :    University of Alabama at Birmingham;   Congressionally Directed Medical Research ProgramsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05051618?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-09-21 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
605,259,2021-09-17 15:00:09.000000,A Long-term Extension of Study GNC-401,Condition:    Multiple SclerosisInterventions:    Drug: Temelimab 18 mg/kg;   Drug: Temelimab 36mg/kg;   Drug: Temelimab 54 mg/kgSponsor :    GeNeuro Innovation SASRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05049161?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-09-17 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
606,258,2021-09-16 16:50:09.000000,The Effect of Cigarette Smoke on Sleep Quality and Physical Activity in People With Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Behavioral: Sleep quality and physical activity;   Genetic: Nicotine dependence;   Diagnostic Test: Nicotine and cotinine serum levels;   Behavioral: SmokingSponsor :    University of JordanNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05046535?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-09-16 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
607,257,2021-09-06 00:04:28.000000,Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs,,https://www.novartis.com/clinicaltrials/study/nct04711135,2021-09-06 00:04:28.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
608,256,2021-09-06 00:04:27.000000,A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA),,https://www.novartis.com/clinicaltrials/study/nct04814368,2021-09-06 00:04:27.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
609,255,2021-09-05 16:31:06.000000,Impact of the Modifications of Environmental Exposures and Health Care Access During COVID-19 Lockdown on Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: questionnaireSponsor :    Assistance Publique - Hôpitaux de ParisNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05033782?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-09-03 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
610,254,2021-09-02 23:31:19.000000,Dabrafenib and&#x2F;or Trametinib Rollover Study,,https://www.novartis.com/clinicaltrials/study/nct03340506,2021-09-02 23:31:19.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
611,253,2021-09-02 23:31:19.000000,"Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis",,https://www.novartis.com/clinicaltrials/study/nct04074590,2021-09-02 23:31:19.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
612,252,2021-09-02 23:31:19.000000,Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer,,https://www.novartis.com/clinicaltrials/study/nct03839823,2021-09-02 23:31:19.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
613,251,2021-09-02 23:31:19.000000,Special Drug Use-results Surveillance of Tabrecta Tablets,,https://www.novartis.com/clinicaltrials/study/nct04575025,2021-09-02 23:31:19.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
614,250,2021-09-02 23:31:19.000000,The Gilenya Pregnancy Registry,,https://www.novartis.com/clinicaltrials/study/nct01285479,2021-09-02 23:31:19.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
615,249,2021-09-01 16:27:57.000000,Development and Application of Tele-Neuro Rehabilitation System,Conditions:    Stroke;   Multiple Sclerosis;   Parkinson DiseaseInterventions:    Other: Telerehabilitaton;   Other: Home ExerciseSponsors :    Istanbul University-Cerrahpasa;   The Scientific and Technological Research Council of TurkeyRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05031403?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-09-01 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
616,248,2021-09-01 16:27:57.000000,Assessment of Quality of Life and Psychological Problems in Patients With Multiple Sclerosis,Condition:    Multiple Sclerosis Acute and ProgressiveIntervention:    Combination Product: investigations like MRI..Sponsor :    Assiut UniversityRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05029830?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-09-01 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
617,247,2021-09-01 02:31:19.000000,Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer,,https://www.novartis.com/clinicaltrials/study/nct04597411,2021-09-01 02:31:19.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
618,246,2021-09-01 02:31:19.000000,A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD,,https://www.novartis.com/clinicaltrials/study/nct04632056,2021-09-01 02:31:19.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
619,245,2021-09-01 02:31:19.000000,Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients,,https://www.novartis.com/clinicaltrials/study/nct04524442,2021-09-01 02:31:19.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
620,244,2021-09-01 02:31:19.000000,[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake,,https://www.novartis.com/clinicaltrials/study/nct03872778,2021-09-01 02:31:19.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
621,243,2021-08-31 15:55:08.000000,Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS,"Conditions:    Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Multiple SclerosisInterventions:    Drug: Intranasal Foralumab Solution;   Drug: PlaceboSponsor :    Tiziana Life Sciences, PLCNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05029609?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-31 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
622,242,2021-08-31 15:55:08.000000,Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden,"Conditions:    Multiple Sclerosis;   Multiple Sclerosis, Relapsing-RemittingIntervention:    Procedure: Autologous hematopoietic stem cell transplantationSponsors :    Uppsala University;   Karolinska University Hospital;   Sahlgrenska University Hospital, Sweden;   Uppsala University Hospital;   Skane University Hospital;   University Hospital, Linkoeping;   University Hospital, Umeå;   Region Örebro CountyRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05029206?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-31 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
623,241,2021-08-31 15:55:08.000000,The Effects of Trunk Stabilization and Aerobic Trainings in Multiple Sclerosis,Condition:    Physical TherapyInterventions:    Other: Combined exercise training;   Other: Aerobic trainingSponsor :    Ankara Yildirim Beyazıt UniversityCompleted ,https://clinicaltrials.gov/ct2/show/NCT05029700?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-31 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
624,240,2021-08-31 15:55:07.000000,Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy,"Conditions:    Multiple Sclerosis;   Multiple Sclerosis, Relapsing-RemittingInterventions:    Biological: Tetanus, diphtheria, and acellular pertussis vaccine;   Biological: Pneumococcal polysaccharide vaccine;   Biological: Seasonal influenza vaccineSponsor :    CelgeneNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05028634?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-31 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
625,239,2021-08-31 02:48:29.000000,An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients,,https://www.novartis.com/clinicaltrials/study/nct04662931,2021-08-31 02:48:29.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
626,238,2021-08-31 02:48:29.000000,Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP),,https://www.novartis.com/clinicaltrials/study/nct04630158,2021-08-31 02:48:29.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
627,237,2021-08-27 18:48:30.000000,A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections,,https://www.novartis.com/clinicaltrials/study/nct04662944,2021-08-27 18:48:30.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
628,236,2021-08-27 18:48:30.000000,"A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer&#39;s Type.",,https://www.novartis.com/clinicaltrials/study/nct02989402,2021-08-27 18:48:30.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
629,235,2021-08-27 18:48:30.000000,Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET,,https://www.novartis.com/clinicaltrials/study/nct03972488,2021-08-27 18:48:30.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
630,234,2021-08-26 20:34:56.000000,Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.,,https://www.novartis.com/clinicaltrials/study/nct04712721,2021-08-26 20:34:56.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
631,233,2021-08-26 20:34:56.000000,Special Drug Use Surveillance for Entresto Tablets,,https://www.novartis.com/clinicaltrials/study/nct04781881,2021-08-26 20:34:56.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
632,232,2021-08-26 20:34:56.000000,Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients,,https://www.novartis.com/clinicaltrials/study/nct04593927,2021-08-26 20:34:56.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
633,230,2021-08-26 00:47:17.000000,Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients,,https://www.novartis.com/clinicaltrials/study/nct03814746,2021-08-26 00:47:17.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
634,229,2021-08-26 00:47:17.000000,Study to Evaluate the Efficacy and Safety of MAS825 in NLRC4-GOF Patients,,https://www.novartis.com/clinicaltrials/study/nct04641442,2021-08-26 00:47:17.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
635,228,2021-08-26 00:47:17.000000,Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma,,https://www.novartis.com/clinicaltrials/study/nct04410523,2021-08-26 00:47:17.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
636,227,2021-08-24 18:47:17.000000,A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.,,https://www.novartis.com/clinicaltrials/study/nct04836858,2021-08-24 18:47:17.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
637,226,2021-08-24 18:47:16.000000,"Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum",,https://www.novartis.com/clinicaltrials/study/nct04589650,2021-08-24 18:47:16.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
638,225,2021-08-24 18:47:16.000000,"An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC",,https://www.novartis.com/clinicaltrials/study/nct04720157,2021-08-24 18:47:16.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
639,224,2021-08-24 18:47:16.000000,"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers",,https://www.novartis.com/clinicaltrials/study/nct03798626,2021-08-24 18:47:16.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
640,223,2021-08-24 13:43:55.000000,Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine,"Conditions:    Multiple Sclerosis, Relapsing-Remitting;   Vaccine Response ImpairedIntervention:    Biological: Most recent vaccine to seasonal influenzaSponsor :    Heinrich-Heine University, DuesseldorfRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05019248?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-24 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
641,221,2021-08-23 17:47:17.000000,A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.,,https://www.novartis.com/clinicaltrials/study/nct04806503,2021-08-23 17:47:17.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
642,220,2021-08-23 12:23:55.000000,Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD),"Conditions:    Optic Neuritis;   Transverse Myelitis;   Acute Disseminated Encephalomyelitis;   Multiple Sclerosis;   Neuromyelitis Optica Spectrum Disorder;   Anti-NMDAR Encephalitis;   Anti-GAD65 Associated Autoimmune Encephalitis;   Anti-AMPAR-1/2 Associated Autoimmune Encephalitis;   Anti-Lgi-1 Associated Autoimmune Encephalitis;   Anti-CASPR-2 Associated Autoimmune Encephalitis;   Anti-GABAR-1/2 Associated Autoimmune Encephalitis;   Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis;   Hashimoto Encephalitis;   CNS Vasculitis;   CNS Sarcoidosis;   CNS Lupus;   Rasmussen EncephalitisIntervention:    Sponsors :    University of Bern;   Schweizerische Multiple Sklerose Gesellschaft;   University Hospital Inselspital, Berne;   Roche Pharma (Switzerland) Ltd;   NovartisRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05017142?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-23 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
643,219,2021-08-23 12:23:55.000000,The Role of Social and Territorial Inequalities in the Management and Prognosis of Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Social and Territorial InequalitiesIntervention:    Sponsor :    Central Hospital, Nancy, FranceRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05017038?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-23 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
644,218,2021-08-19 22:19:09.000000,Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.,,https://www.novartis.com/clinicaltrials/study/nct04711902,2021-08-19 22:19:09.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
645,217,2021-08-19 22:19:09.000000,Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions,,https://www.novartis.com/clinicaltrials/study/nct04656223,2021-08-19 22:19:09.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
646,216,2021-08-19 15:05:47.000000,Hydroxychloroquine and Indapamide in SPMS,"Condition:    Multiple Sclerosis, Secondary ProgressiveIntervention:    Drug: Hydroxychloroquine and IndapamideSponsor :    University of CalgaryNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05013463?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-19 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
647,215,2021-08-19 15:05:47.000000,The Reliability of the Nine Hole Peg Test in Patients With Multiple Sclerosis,"Condition:    Motor ActivityIntervention:    Diagnostic Test: Nine Hole Peg TestSponsor :    Charles University, Czech RepublicNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05012241?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-19 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
648,214,2021-08-19 12:19:09.000000,A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,,https://www.novartis.com/clinicaltrials/study/nct04667117,2021-08-19 12:19:09.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
649,213,2021-08-19 12:19:09.000000,Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma,,https://www.novartis.com/clinicaltrials/study/nct03570892,2021-08-19 12:19:09.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
650,211,2021-08-19 12:19:09.000000,Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration,,https://www.novartis.com/clinicaltrials/study/nct04679935,2021-08-19 12:19:09.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
651,210,2021-08-19 12:19:09.000000,"Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis",,https://www.novartis.com/clinicaltrials/study/nct04864392,2021-08-19 12:19:09.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
652,208,2021-08-19 02:19:10.000000,Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab,,https://www.novartis.com/clinicaltrials/study/nct04210843,2021-08-19 02:19:10.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
653,207,2021-08-19 02:19:10.000000,Secukinumab Open Label Roll-over Extension Protocol,,https://www.novartis.com/clinicaltrials/study/nct04638647,2021-08-19 02:19:10.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
654,206,2021-08-19 02:19:10.000000,Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa,,https://www.novartis.com/clinicaltrials/study/nct04179175,2021-08-19 02:19:10.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
655,205,2021-08-19 02:19:10.000000,Study of Out of Specification for Tisagenlecleucel,,https://www.novartis.com/clinicaltrials/study/nct04094311,2021-08-19 02:19:10.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
656,203,2021-08-19 02:19:10.000000,"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up",,https://www.novartis.com/clinicaltrials/study/nct03781414,2021-08-19 02:19:10.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
657,202,2021-08-19 02:19:10.000000,"Efficacy, Safety and Tolerability of the Combination of Tropifexor &amp; Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.",,https://www.novartis.com/clinicaltrials/study/nct04065841,2021-08-19 02:19:10.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
658,201,2021-08-19 02:19:10.000000,Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis,,https://www.novartis.com/clinicaltrials/study/nct04732117,2021-08-19 02:19:10.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
659,200,2021-08-19 02:19:10.000000,A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism,,https://www.novartis.com/clinicaltrials/study/nct03938454,2021-08-19 02:19:10.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
660,199,2021-08-18 13:45:47.000000,Pregnancy Cohort in Multiple Sclerosis (MS),"Conditions:    Multiple Sclerosis (MS);   Clinically Isolated Syndrome (CIS)Intervention:    Sponsor :    Charite University, Berlin, GermanyRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05010902?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-18 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
661,198,2021-08-17 20:19:09.000000,Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy,,https://www.novartis.com/clinicaltrials/study/nct04278417,2021-08-17 20:19:09.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
662,195,2021-08-17 15:35:47.000000,DreaMS - Validation Study 1,"Condition:    Multiple SclerosisIntervention:    Device: dreaMS App R2.0Sponsors :    Research Center for Clinical Neuroimmunology and Neuroscience Basel;   Healios AG;   University Hospital, Basel, Switzerland;   University of Basel;   Innosuisse - Swiss Innovation Agency;   Novartis Pharmaceuticals;   Hoffmann-La RocheNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05009160?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-17 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
663,194,2021-08-17 00:19:09.000000,"Alpelisib Plus Olaparib in Platinum-resistant&#x2F;Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected",,https://www.novartis.com/clinicaltrials/study/nct04729387,2021-08-17 00:19:09.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
664,193,2021-08-17 00:19:09.000000,Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss,,https://www.novartis.com/clinicaltrials/study/nct04251533,2021-08-17 00:19:09.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
665,192,2021-08-17 00:19:09.000000,Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA),,https://www.novartis.com/clinicaltrials/study/nct04174157,2021-08-17 00:19:09.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
666,191,2021-08-17 00:19:09.000000,Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren&#39;s Syndrome,,https://www.novartis.com/clinicaltrials/study/nct03905525,2021-08-17 00:19:09.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
667,190,2021-08-17 00:19:09.000000,"Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration",,https://www.novartis.com/clinicaltrials/study/nct04864834,2021-08-17 00:19:09.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
668,189,2021-08-16 17:25:47.000000,Efficacy of Diet on Quality of Life in Multiple Sclerosis,"Condition:    Multiple Sclerosis, Relapsing-RemittingInterventions:    Dietary Supplement: BodyBio Balance Oil;   Dietary Supplement: Kirunal Fish Oil;   Dietary Supplement: BodyBio PC;   Behavioral: Modified Paleolithic Elimination diet;   Behavioral: Time Restricted Olive Oil Based (TROO) Ketogenic Diet;   Behavioral: Dietary Guidelines for Americans DietSponsor :    Terry L. WahlsNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05007483?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-16 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
669,187,2021-08-13 13:25:47.000000,A Teleheath tDCS Approach to Decrease Cannabis Use,Conditions:    Cannabis Use Disorder;   Multiple SclerosisInterventions:    Other: Transcranial Direct Current Stimulation (tDCS);   Other: Sham - Transcranial Direct Current Stimulation (tDCS);   Other: MindfulnessSponsor :    NYU Langone HealthNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT05005013?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-13 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
670,185,2021-08-12 20:19:09.000000,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",,https://www.novartis.com/clinicaltrials/study/nct03650114,2021-08-12 20:19:09.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
671,184,2021-08-12 15:19:08.000000,Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer,,https://www.novartis.com/clinicaltrials/study/nct04544189,2021-08-12 15:19:08.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
672,182,2021-08-12 15:19:08.000000,Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis,,https://www.novartis.com/clinicaltrials/study/nct01892722,2021-08-12 15:19:08.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
673,181,2021-08-12 15:19:08.000000,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab,,https://www.novartis.com/clinicaltrials/study/nct04353492,2021-08-12 15:19:08.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
674,180,2021-08-12 15:09:11.000000,"Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients.",,https://www.novartis.com/clinicaltrials/study/nct03623243,2021-08-12 15:09:11.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
675,179,2021-08-12 15:09:11.000000,Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients,,https://www.novartis.com/clinicaltrials/study/nct04667949,2021-08-12 15:09:11.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
676,178,2021-08-12 15:09:11.000000,Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.,,https://www.novartis.com/clinicaltrials/study/nct04623216,2021-08-12 15:09:11.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
677,177,2021-08-12 15:09:11.000000,A Randomized Study to Evaluate the Effect of an &quot;Inclisiran First&quot; Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE),,https://www.novartis.com/clinicaltrials/study/nct04929249,2021-08-12 15:09:11.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
678,176,2021-08-12 15:09:11.000000,"A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis",,https://www.novartis.com/clinicaltrials/study/nct04486716,2021-08-12 15:09:11.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
679,175,2021-08-12 15:09:11.000000,Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation,,https://www.novartis.com/clinicaltrials/study/nct04666259,2021-08-12 15:09:11.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
680,172,2021-08-12 15:09:11.000000,"Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy",,https://www.novartis.com/clinicaltrials/study/nct04539041,2021-08-12 15:09:11.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
681,170,2021-08-12 13:29:25.000000,Physiological Responses in Experimentally Induced Cognitive Fatigue in People With Multiple Sclerosis (MS),Conditions:    Multiple Sclerosis;   Fatigue;   StressIntervention:    Behavioral: High-challenging cognitive protocol to provoke stress and (cognitive) fatigueSponsors :    KU Leuven;   National MS Center MelsbroekRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05003375?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-12 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
682,169,2021-08-12 13:29:25.000000,"Efficacy of Cognitive Behavioral Therapy on Fatigue, Cognition and Inflammatory Biomarkers in MS Patients","Condition:    Multiple SclerosisInterventions:    Device: ""RehaCom"" computer-based cognitive training in addition to Conventional physical therapy program;   Other: Conventional physical therapy programSponsor :    Cairo UniversityCompleted ",https://clinicaltrials.gov/ct2/show/NCT05002062?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-12 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
683,168,2021-08-12 13:29:25.000000,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS,Condition:    Multiple SclerosisIntervention:    Biological: AlloRxSponsor :    The Foundation for Orthopaedics and Regenerative MedicineRecruiting ,https://clinicaltrials.gov/ct2/show/NCT05003388?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-12 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
684,167,2021-08-12 13:29:25.000000,Thalamic Nuclei Volumes in Multiple Sclerosis,"Condition:    Multiple SclerosisIntervention:    Sponsors :    University Hospital, Bordeaux;   Institut National de la Santé Et de la Recherche Médicale, FranceRecruiting ",https://clinicaltrials.gov/ct2/show/NCT05002764?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-12 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
685,166,2021-08-11 15:21:39.000000,COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders,"Conditions:    Rheumatoid Arthritis;   Systemic Lupus Erythematosus (SLE);   Pemphigus Vulgaris;   Multiple Sclerosis;   Systemic Sclerosis (SSc)Interventions:    Biological: Moderna mRNA-1273;   Biological: BNT162b2;   Biological: Ad26.COV2.S;   Drug: IS (MMF or MPA);   Drug: IS (MTX);   Biological: IS (B cell depletion therapy)Sponsors :    National Institute of Allergy and Infectious Diseases (NIAID);   Autoimmunity Centers of Excellence;   Rho Federal Systems Division, Inc.Not yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT05000216?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-11 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
686,165,2021-08-10 14:01:41.000000,A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy,Conditions:    Multiple Sclerosis;   Clinically Isolated SyndromeIntervention:    Drug: OcrelizumabSponsors :    Hoffmann-La Roche;   PPD;   LabCorp;   IllingworthNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04998812?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-10 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
687,164,2021-08-10 14:01:41.000000,A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab,Conditions:    Multiple Sclerosis;   Clinically Isolated SyndromeIntervention:    Drug: OcrelizumabSponsors :    Hoffmann-La Roche;   PPD;   LabCorp;   IllingworthNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04998851?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-10 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
688,163,2021-08-09 12:36:29.000000,Symptoms and Treatment Assessment of Ano-Rectal Disorders in Multiple Sclerosis Patients : STAR-Q,Conditions:    Multiple Sclerosis;   Constipation;   Fecal IncontinenceIntervention:    Other: Clinical interviewsSponsor :    Pierre and Marie Curie UniversityCompleted ,https://clinicaltrials.gov/ct2/show/NCT04996186?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-09 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
689,162,2021-08-09 12:36:29.000000,Neurophysiological Assessment in Patients With Multiple Sclerosis,Conditions:    Multiple Sclerosis;   Demyelinating Disease;   Inflammatory DiseaseInterventions:    Other: Neurophysiological assessment;   Other: clinical assessmentSponsor :    University of Roma La SapienzaNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04997343?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-09 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
690,161,2021-08-09 12:36:29.000000,Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS),"Condition:    Relapsing-Remitting Multiple SclerosisIntervention:    Sponsors :    Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   Merck Serono Limited, an affiliate of Merck KGaA, Darmstadt, GermanyNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04997148?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14,2021-08-09 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
691,160,2021-08-07 00:23:03.000000,Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment,,https://www.novartis.com/clinicaltrials/study/nct04587622,2021-08-07 00:23:03.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
692,159,2021-08-07 00:23:03.000000,Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD),,https://www.novartis.com/clinicaltrials/study/nct04443907,2021-08-07 00:23:03.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
693,158,2021-08-06 12:10:36.000000,Sensitivity of Motor Assessment in MS - a Prospective Cohort Study,"Conditions:    Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Secondary Progressive;   Multiple Sclerosis, Chronic ProgressiveIntervention:    Diagnostic Test: PASS-MSSponsors :    Friedemann Paul;   Roche Pharma AGActive, not recruiting ",https://clinicaltrials.gov/ct2/show/NCT04993274?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-08-06 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
694,157,2021-08-06 12:10:36.000000,Quantitative T1rho Magnetic Resonance Imaging in Healthy Subjects,Conditions:    Multiple Sclerosis;   Magnetic Resonance ImagingIntervention:    Diagnostic Test: T1rho imagingSponsor :    Chinese University of Hong KongNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04993196?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-08-06 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
695,156,2021-08-05 22:46:35.000000,Study of Safety and of the Mechanism of BLZ945 in ALS Patients,,https://www.novartis.com/clinicaltrials/study/nct04066244,2021-08-05 22:46:35.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
696,155,2021-08-05 22:46:35.000000,Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to &lt; 12 Years Old With Asthma,,https://www.novartis.com/clinicaltrials/study/nct04589663,2021-08-05 22:46:35.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
697,154,2021-08-05 22:46:35.000000,Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent,,https://www.novartis.com/clinicaltrials/study/nct04722666,2021-08-05 22:46:35.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
698,153,2021-08-05 22:46:35.000000,"Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis",,https://www.novartis.com/clinicaltrials/study/nct04064242,2021-08-05 22:46:35.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
699,151,2021-08-05 22:46:35.000000,Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients,,https://www.novartis.com/clinicaltrials/study/nct03876769,2021-08-05 22:46:35.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
700,150,2021-08-05 15:59:12.000000,Pronesimod no tratamento de Esclerose Múltipla Recidivante | CUF,,https://www.cuf.pt/cuf-academic-center/ensaios-clinicos/pronesimod-no-tratamento-de-esclerose-multipla-recidivante,2021-08-05 15:59:12.000000,14.0,,14.0,CUF,https://www.cuf.pt/cuf-academic-center/ensaios-clinicos?combine=&unidade=&estado=All&patologia=2346&especialidade=
701,149,2021-08-05 15:53:54.000000,177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer,,https://www.novartis.com/clinicaltrials/study/nct04689828,2021-08-05 15:53:54.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
702,148,2021-08-05 15:39:00.000000,Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients,,https://www.novartis.com//clinicaltrials/study/nct04578834,2021-08-05 15:39:00.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
703,147,2021-08-05 15:39:00.000000,Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI,,https://www.novartis.com//clinicaltrials/study/nct02859727,2021-08-05 15:39:00.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
704,146,2021-08-05 15:39:00.000000,"Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)",,https://www.novartis.com//clinicaltrials/study/nct04868968,2021-08-05 15:39:00.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
705,145,2021-08-05 15:39:00.000000,Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients,,https://www.novartis.com//clinicaltrials/study/nct04072887,2021-08-05 15:39:00.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
706,144,2021-08-05 15:39:00.000000,Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD,,https://www.novartis.com//clinicaltrials/study/nct04023552,2021-08-05 15:39:00.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
707,143,2021-08-05 15:39:00.000000,"A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation",,https://www.novartis.com//clinicaltrials/study/nct04582409,2021-08-05 15:39:00.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
708,142,2021-08-05 15:39:00.000000,Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome,,https://www.novartis.com//clinicaltrials/study/nct04873934,2021-08-05 15:39:00.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
709,141,2021-08-05 15:39:00.000000,Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment,,https://www.novartis.com//clinicaltrials/study/nct04558918,2021-08-05 15:39:00.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
710,139,2021-08-05 15:39:00.000000,Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia,,https://www.novartis.com//clinicaltrials/study/nct04652726,2021-08-05 15:39:00.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
711,137,2021-08-05 15:39:00.000000,Home,,https://www.novartis.com/,2021-08-05 15:39:00.000000,13.0,,13.0,Novartis,https://www.novartis.com/clinicaltrials/recruiting-trials?title=multiple%20sclerosis
712,136,2021-08-04 13:22:57.000000,Territorial Implementation and Evaluation of a Multiple Sclerosis Expert Patient Program,Conditions:    Multiple Sclerosis;   Quality of Life;   Patient Empowerment;   Patient Activation;   Fatigue;   Peer GroupIntervention:    Other: Multiple Sclerosis Expert Patient Program of CataloniaSponsors :    Hospital Universitari Vall d'Hebron Research Institute;   Strategic Plan for Research and Innovation in Health (ref. BDNS 542793)Not yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04988880?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-08-04 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
713,135,2021-08-04 13:22:57.000000,A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Drug: Lu AG06466;   Drug: PlaceboSponsor :    H. Lundbeck A/SNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04990219?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-08-04 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
714,134,2021-07-30 17:01:11.000000,Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis,Condition:    Spasticity With Multiple SclerosisInterventions:    Drug: Nabiximols;   Drug: PlaceboSponsor :    GW Pharmaceuticals Ltd.Not yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04984278?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-30 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
715,133,2021-07-29 14:28:11.000000,Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants,Condition:    Multiple Sclerosis Healthy SubjectsIntervention:    Drug: RIPK1 inhibitorSponsor :    SanofiNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04982991?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-29 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
716,132,2021-07-28 18:48:11.000000,Telerehabilitation in Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Other: Telerehabilitation;   Other: Video exerciseSponsor :    Marmara UniversityRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04979845?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-28 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
717,131,2021-07-28 18:48:11.000000,Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis,"Conditions:    Multiple Sclerosis, Relapsing-Remitting;   Magnetic Resonance Imaging;   MethylprednisoloneIntervention:    Drug: Methylprednisolone succinateSponsor :    Mazandaran University of Medical SciencesEnrolling by invitation ",https://clinicaltrials.gov/ct2/show/NCT04979650?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-28 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
718,130,2021-07-28 18:48:11.000000,Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis,Conditions:    Multiple Sclerosis;   Anxiety;   Depression;   Patient SatisfactionInterventions:    Other: Intensive Use of Patient Reported Outcome Measures and Open PROM Availability to Treating Neurologist;   Other: Conservative Use of Patient Reported Outcome Measures and Blinded PROM Availability to Treating NeurologistSponsors :    University of Alberta;   University Hospital FoundationNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04979546?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-28 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
719,129,2021-07-28 18:48:11.000000,The Validity and Reliability of the Upper Extremity Exercise Testing (UULEX) in Patients With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: Upper extremity endurance test (UULEX)Sponsor :    Marmara UniversityRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04979819?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-28 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
720,128,2021-07-27 15:16:12.000000,Gray Matter Demyelination in Primary Progressive MS at 7T,Condition:    Primary Progressive Multiple SclerosisIntervention:    Sponsors :    Danish Research Centre for Magnetic Resonance;   Scleroseforeningen;   Danish Multiple Sclerosis CenterNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04977622?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-27 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
721,127,2021-07-23 12:56:11.000000,Strengthening Mental Abilities With Relational Training (SMART) in Multiple Sclerosis (MS): A Feasibility Trial,"Condition:    Multiple SclerosisInterventions:    Behavioral: SMART;   Behavioral: Sham brain training (Sudoku)Sponsors :    University of Lincoln;   University of Exeter;   Nottinghamshire Healthcare NHS Trust;   National University of Ireland, Maynooth;   University of NottinghamNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04975685?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-23 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
722,126,2021-07-22 17:03:44.000000,Effects of Chiropractic Care on Cytokine Levels in Multiple Sclerosis,"Condition:    Multiple Sclerosis, Relapsing-RemittingInterventions:    Other: Spinal Manipulation;   Other: Sham Spinal ManipulationSponsor :    University of Alabama at BirminghamNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04972929?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-22 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
723,125,2021-07-22 17:03:44.000000,Functional Disorders of the Musculoskeletal System in People With Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Rehabilitation;   Musculoskeletal ComplicationInterventions:    Behavioral: Manual physiotherapeutic correction (MFK) Method;   Behavioral: Dynamic Neuromuscular Stabilization (DNS) MethodSponsor :    Charles University, Czech RepublicCompleted ",https://clinicaltrials.gov/ct2/show/NCT04973501?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-22 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
724,124,2021-07-21 12:32:44.000000,Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial,Condition:    Relapsing-Remitting Multiple SclerosisInterventions:    Drug: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Ocrelizumab;   Drug: AlemtuzumabSponsors :    Universitätsklinikum Hamburg-Eppendorf;   Neovii Biotech;   Clinical Trial Center North (CTC North GmbH & Co. KG)Not yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04971005?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-21 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
725,123,2021-07-21 12:32:44.000000,Quantifying Gait Alteration in Multiple Sclerosis Using a Wearable Device,Condition:    Multiple SclerosisIntervention:    Other: Wearable sensorSponsor :    Nantes University HospitalNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04969848?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-21 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
726,122,2021-07-20 13:49:06.000000,"The Effect of Emotional Freedom Technique on Depression, Anxiety and Distress of Individuals With Multiple Sclerosis",Conditions:    Multiple Sclerosis;   Anxiety;   Depressive Symptoms;   Distress;   Psychiatric NursingIntervention:    Behavioral: Emotional Freedom TechniqueSponsor :    Dokuz Eylul UniversityRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04969562?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-20 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
727,121,2021-07-19 12:15:08.000000,Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Relapsing-RemittingInterventions:    Biological: Ocrelizumab (CinnaGen, Iran);   Biological: Ocrelizumab (Roche, Switzerland)Sponsor :    CinnagenActive, not recruiting ",https://clinicaltrials.gov/ct2/show/NCT04966338?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-19 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
728,120,2021-07-16 13:27:06.000000,An Observational Study to Investigate the Role of B Cells in Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: Analysis of B cellsSponsor :    University of OsloRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04964336?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-16 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
729,119,2021-07-16 13:27:06.000000,Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab,"Condition:    Multiple SclerosisIntervention:    Drug: NatalizumabSponsor :    Multiple Sclerosis Center of Northeastern New YorkActive, not recruiting ",https://clinicaltrials.gov/ct2/show/NCT04964700?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-16 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
730,118,2021-07-16 13:27:06.000000,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton&#39;s Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),Condition:    Relapsing Multiple SclerosisIntervention:    Drug: SAR442168Sponsor :    Peking University Third HospitalRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04964791?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-16 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
731,117,2021-07-15 12:52:04.000000,Effects of a User-centered Exergame Training on Motor and Cognitive Functions in PwMS,Condition:    Multiple SclerosisIntervention:    Behavioral: Exergame TrainingSponsor :    Eling DeBruinRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04963335?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-15 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
732,116,2021-07-09 11:20:04.000000,"A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis","Condition:    Multiple SclerosisIntervention:    Biological: IMS001Sponsors :    ImStem Biotechnology;   Rho, Inc.Not yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04956744?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-09 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
733,115,2021-07-08 14:32:36.000000,Technology-assisted Conscientiousness Therapy for People With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Behavioral: Conscientiousness CoachSponsor :    State University of New York at BuffaloRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04953689?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-08 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
734,114,2021-07-07 11:59:36.000000,Clinical Isolation Syndrome of Spinal Cord and Multiple Sclerosis,Conditions:    Clinical Isolation Syndrome of Spinal Cord;   Multiple SclerosisIntervention:    Sponsor :    Peking University Third HospitalRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04952246?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-07 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
735,113,2021-07-07 11:59:36.000000,Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults,Conditions:    Kidney Transplant;   Extracorporeal Dialysis;   Myeloma;   Cancer;   Hematologic Malignancy;   Multiple Sclerosis;   Hypergammaglobulinemia;   Malignant Tumor;   Hiv;   Diabetes Type 2Intervention:    Biological: Biological samplesSponsor :    Centre Hospitalier Régional d'OrléansRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04952766?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-07-07 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
736,112,2021-06-29 16:46:42.000000,CONNECT Trial of eSupport Online Health-coach Moderated Support Groups for Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Behavioral: eSupport Health Weekly Group Sessions for PwMSSponsor :    eSupport HealthNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04943887?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-29 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
737,111,2021-06-29 16:46:42.000000,Impact of Direct Current Electrical Stimulation on Spasticity Levels and Functional Muscle Use in MS,Condition:    Multiple SclerosisIntervention:    Device: NeuBieSponsors :    Centura Health;   NeuFit - Neurological Fitness and EducationNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04942938?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-29 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
738,110,2021-06-29 16:46:42.000000,Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis,"Condition:    Primary Progressive Multiple SclerosisIntervention:    Biological: DUOC-01Sponsor :    Joanne Kurtzberg, MDNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04943289?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-29 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
739,109,2021-06-29 16:46:42.000000,Regular Exercise Improves Physical Capacity and Promotes Neurotrophins in Patients With Multiple Sclerosis,Conditions:    Multiple Sclerosis;   Exercise Intervention;   Neuro-Degenerative DiseaseIntervention:    Behavioral: Regular ExerciseSponsor :    Ege UniversityCompleted ,https://clinicaltrials.gov/ct2/show/NCT04944251?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-29 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
740,108,2021-06-28 16:23:24.000000,PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers,"Condition:    Multiple SclerosisIntervention:    Drug: PIPE-307Sponsor :    Pipeline Therapeutics, Inc.Not yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04941781?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-28 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
741,107,2021-06-25 20:40:29.000000,Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen,Conditions:    Relapsing-remitting Multiple Sclerosis;   Active Secondary Progressive Multiple SclerosisIntervention:    Other: KesimptaSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04940065?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-25 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
742,106,2021-06-24 16:09:29.000000,Reading Problems Associated With Central Nervous System (CNS) Pathologies.,"Conditions:    Injury Brain;   Eye Abnormalities;   Multiple Sclerosis;   Parkinson Disease;   Ataxia, CerebellarIntervention:    Diagnostic Test: eye trackingSponsors :    Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA;   Hospital Clínico Universitario de Valladolid;   Hospital del Río HortegaEnrolling by invitation ",https://clinicaltrials.gov/ct2/show/NCT04937725?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-24 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
743,105,2021-06-23 16:33:29.000000,The Effect of Self-Acupressure Application on Functional Composite and Quality of Life in Multiple Sclerosis Patients,Condition:    Multiple SclerosisIntervention:    Other: Self-AcupressureSponsor :    Istanbul Sabahattin Zaim UniversityNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04936555?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-23 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
744,104,2021-06-22 14:45:49.000000,Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS),"Condition:    Multiple SclerosisIntervention:    Drug: CladribineSponsors :    Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   Merck Hellas sa., GreeceRecruiting ",https://clinicaltrials.gov/ct2/show/NCT04934800?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-22 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
745,103,2021-06-21 20:04:49.000000,Investigation of Hand Functions and Related Parameters in People With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Sponsors :    Uğur OVACIK;   Istanbul University-CerrahpasaNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04933110?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-21 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
746,102,2021-06-21 20:04:49.000000,Tele-Assessment and Face-to-Face Evaluation of Functional Gait Assessment in Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Sponsor :    Istanbul University-CerrahpasaRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04932616?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-21 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
747,101,2021-06-21 20:04:49.000000,Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent,Condition:    Multiple SclerosisIntervention:    Other: SiponimodSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04933552?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-21 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
748,100,2021-06-18 22:15:49.000000,Feasibility of Neuromodulation With Connectivity-Guided iTBS for Cognitive Impairment in MS,Conditions:    Multiple Sclerosis;   Cognitive ImpairmentInterventions:    Other: Intermittent theta burst stimulation (iTBS);   Other: Sham Intermittent theta burst stimulation (iTBS)Sponsor :    University of NottinghamNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04931953?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-18 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
749,99,2021-06-18 22:15:49.000000,Description of Adherence to the Main Preventive Health Campaigns of Persons With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: phone interviewSponsor :    University of SienaRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04930380?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-18 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
750,98,2021-06-18 22:15:49.000000,The Gut Microbiome in Adult Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Sponsor :    National MS Center MelsbroekCompleted ,https://clinicaltrials.gov/ct2/show/NCT04929145?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-17 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
751,97,2021-06-16 18:08:49.000000,Multiple Sclerosis and Voiding Symptoms: How to Assess?,Conditions:    Multiple Sclerosis;   Lower Urinary Tract Symptoms;   Voiding DisordersIntervention:    Other: voiding phase evaluationSponsor :    Pierre and Marie Curie UniversityCompleted ,https://clinicaltrials.gov/ct2/show/NCT04928716?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-16 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
752,96,2021-06-16 18:08:49.000000,Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran,Condition:    Relapsing Multiple SclerosisIntervention:    Drug: Glatiramer AcetateSponsor :    CinnagenCompleted ,https://clinicaltrials.gov/ct2/show/NCT04928313?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-16 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
753,95,2021-06-15 16:34:48.000000,Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis,Condition:    Multiple Sclerosis (MS)Interventions:    Drug: Fingolimod;   Drug: Ofatumumab;   Drug: Siponimod;   Other: Fingolimod placebo;   Other: Siponimod placebo;   Other: Ofatumumab placeboSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04926818?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-15 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
754,94,2021-06-14 17:57:48.000000,Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis,"Condition:    Secondary-progressive Multiple SclerosisInterventions:    Drug: Mayzent;   Drug: OcrevusSponsor :    Robert Zivadinov, MD, PhDNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04925557?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-14 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
755,93,2021-06-14 17:57:48.000000,Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate,Condition:    Relapsing Remitting Multiple SclerosisIntervention:    Drug: monomethyl fumarateSponsor :    Banner Life Sciences LLCNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04925778?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-14 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
756,92,2021-06-08 15:45:00.000000,"EEG and TMS-based Biomarkers of ALS, MS and FTD","Conditions:    Amyotrophic Lateral Sclerosis;   Frontotemporal Dementia;   Multiple SclerosisInterventions:    Procedure: 128 electrode electroencephalography (EEG);   Procedure: Transcranial magnetic stimulation (TMS)Sponsors :    University of Dublin, Trinity College;   Motor Neurone Disease Association, UK;   Irish Research Council, IE;   Health Research Board, IE;   Research Motor Neurone, IE;   Thierry Latran Foundation, FR;   ALS Association, USARecruiting ",https://clinicaltrials.gov/ct2/show/NCT04918251?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-08 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
757,91,2021-06-08 15:45:00.000000,Motor Asymmetry in Progressive Multiple Sclerosis Patients,"Conditions:    Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary ProgressiveInterventions:    Radiation: Magnetic Resonance Imaging;   Diagnostic Test: Neurological examination;   Diagnostic Test: Multiple Sclerosis Functional Composite;   Diagnostic Test: Physiotherapist examinationSponsor :    Rennes University HospitalNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04918225?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-08 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
758,90,2021-06-03 15:01:28.000000,Exercise Booster Sessions in People With Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Combination Product: Systematic aerobic training;   Combination Product: Systematic resistance training;   Combination Product: Aerobic training booster sessions;   Combination Product: Resistance training booster sessionsSponsors :    University of Aarhus;   Oxford Brookes UniversityNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04913012?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-06-03 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
759,89,2021-06-01 17:47:28.000000,"A Comprehensive Assessment of Trunk, Scapula and Upper Limb in Neurological Patients. Reliability, Validity and Interrelatedness","Conditions:    Multiple Sclerosis;   StrokeInterventions:    Other: Clinical Scapular protocol (ClinScaP);   Other: the prevalence of trunk, scapula and upper limb impairments.;   Other: the interaction between trunk, scapula and upper limb impairments.Sponsors :    Hasselt University;   Revalidatie & MS Centrum Overpelt;   Ziekenhuis Oost-Limburg;   National MS Center Melsbroek;   Jessa HospitalRecruiting ",https://clinicaltrials.gov/ct2/show/NCT04908891?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-31 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
760,88,2021-06-01 17:47:28.000000,"Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis",Condition:    Relapsing Forms of Multiple SclerosisInterventions:    Drug: EHP-101 25 mg OD;   Drug: EHP-101 25 mg BID;   Drug: EHP-101 50 mg OD;   Drug: EHP-101 50 mg BIDSponsor :    Emerald Health PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04909502?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-31 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
761,87,2021-06-01 17:47:28.000000,Creating Satisfying Engagement in Daily Life Through Coaching for People With Multiple Sclerosis,Conditions:    Multiple Sclerosis;   Quality of LifeIntervention:    Behavioral: Occupational Performance CoachingSponsor :    Queen's UniversityNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04908085?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-31 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
762,86,2021-05-28 12:44:08.000000,Evaluation of New MRI Sequences Including 3D-FGAPSIR for the Optimization of Inflammatory Spinal Cord Lesions Research,Condition:    Estimate the Number of Spinal Cord Lesions Detected With the 3D FGAPSIR Sequence That Were Not Detected With the 3D PSIR SequenceIntervention:    Device: MRISponsor :    Fondation Ophtalmologique Adolphe de RothschildEnrolling by invitation ,https://clinicaltrials.gov/ct2/show/NCT04906928?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-28 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
763,85,2021-05-28 12:44:08.000000,Next-Gen MS: Feed-forward PRO Data for MS Research,"Condition:    Multiple SclerosisIntervention:    Sponsor :    EMD Serono Research & Development Institute, Inc.Not yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04907305?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-28 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
764,84,2021-05-28 12:44:08.000000,The Therapeutic Effects of Forced Aerobic Exercise in Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Behavioral: Forced Aerobic Exercise (FE);   Behavioral: Voluntary Aerobic Exercise (VE)Sponsor :    The Cleveland ClinicNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04906057?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-28 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
765,83,2021-05-27 12:09:08.000000,Pilot Investigation to Evaluate FlowOx2.0™ for Experimental Treatment of Spasticity,"Conditions:    Multiple Sclerosis;   Spasticity, Muscle;   PainIntervention:    Device: FlowOx™Sponsors :    Otivio AS;   Haukeland University HospitalRecruiting ",https://clinicaltrials.gov/ct2/show/NCT04904016?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-27 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
766,82,2021-05-26 15:30:08.000000,The Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients,"Condition:    Multiple Sclerosis RelapseIntervention:    Sponsor :    IRCCS National Neurological Institute ""C. Mondino"" FoundationNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04902690?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-26 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
767,81,2021-05-20 11:40:26.000000,Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study,Condition:    Secondary Progressive Multiple Sclerosis With Inflammatory Disease ActivityIntervention:    Other: SiponimodSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04895202?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-20 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
768,80,2021-05-19 11:05:28.000000,Adapting mHealth Technology to Improve Patient Activation,Conditions:    Spinal Cord Injuries;   Stroke;   Multiple SclerosisIntervention:    Behavioral: Fatigue self-management SMS interventionSponsors :    Washington University School of Medicine;   The Foundation for Barnes-Jewish HospitalRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04893590?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-19 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
769,79,2021-05-19 11:05:27.000000,"Evaluation of Clinical, Morphologic and Biochemical Markers in Multiple Sclerosis",Condition:    Multiple SclerosisIntervention:    Other: blood sampleSponsor :    Medical University of GrazRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04892134?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-19 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
770,78,2021-05-18 10:30:26.000000,Investigation of the Effects of Technology Supported Different Physiotherapy Approaches on Patients With Multiple Sclerosis,"Condition:    Multiple SclerosisInterventions:    Other: Technology Supported Task-Oriented Circuit Training;   Other: Home-based TelerehabilitationSponsor :    Hacettepe UniversityActive, not recruiting ",https://clinicaltrials.gov/ct2/show/NCT04891341?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-18 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
771,77,2021-05-17 17:47:26.000000,Holter of Movement in Patients With Multiple Sclerosis in Controlled Environment.,"Condition:    Multiple SclerosisInterventions:    Device: Actimyo°;   Device: IMUSponsors :    Dr. Stéphanie Delstanche;   SYSNAV;   Centre Hospitalier Universitaire de LiègeActive, not recruiting ",https://clinicaltrials.gov/ct2/show/NCT04888689?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-17 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
772,76,2021-05-14 12:06:26.000000,The Effects of Respiratory-based Telerehabilitaion in Patients With MS,"Conditions:    Multiple Sclerosis;   Telerehabilitation;   Compliance, PatientIntervention:    Other: pulmonory based home exercisesSponsors :    Dr. Anıl Tosun;   Trakya UniversityEnrolling by invitation ",https://clinicaltrials.gov/ct2/show/NCT04887051?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-14 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
773,75,2021-05-13 16:26:30.000000,Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab (KYRIOS),Condition:    Multiple SclerosisIntervention:    Drug: OfatumumabSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04869358?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-03 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
774,74,2021-05-13 10:18:31.000000,An Examination of Cognitive Fatigue Using Functional Neuroimaging,"Condition:    Multiple Sclerosis, Relapsing-RemittingIntervention:    Drug: ZeposiaSponsors :    Kessler Foundation;   Celgene;   Hackensack Meridian Health;   St. Barnabas Medical CenterNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04885894?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-13 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
775,73,2021-05-12 10:42:31.000000,Holter of Movement in Patients With Multiple Sclerosis in Uncontrolled Environment.,Condition:    Multiple SclerosisIntervention:    Device: ActimyoSponsors :    Dr. Stéphanie Delstanche;   SYSNAV;   Centre Hospitalier Universitaire de LiègeRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04882891?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-12 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
776,72,2021-05-11 11:06:31.000000,"Sport, Rehabilitation and Nutrition in Multiple Sclerosis: The LINUS Project",Condition:    Multiple SclerosisIntervention:    Behavioral: B-HIPE (Brief High Impact Preparatory Experience)Sponsor :    Fondazione Don Carlo Gnocchi OnlusRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04881422?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-11 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
777,71,2021-05-10 12:29:31.000000,Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis,"Conditions:    Multiple Sclerosis, Relapsing-Remitting;   FatigueInterventions:    Drug: TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY];   Drug: PlaceboSponsors :    Harvard Medical School;   Gilead SciencesNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04880577?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-10 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
778,70,2021-05-10 12:29:31.000000,Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Drug: SAR441344 IV;   Drug: placebo IV;   Drug: SAR441344 SC;   Drug: placebo SC;   Drug: MRI contrast-enhancing preparationsSponsor :    SanofiRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04879628?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-10 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
779,69,2021-05-07 11:43:30.000000,Ocrelizuamb for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.,"Conditions:    Radiologically Isolated Syndrome;   Multiple SclerosisInterventions:    Drug: Ocrelizumab;   Other: PlaceboSponsors :    Yale University;   Genentech, Inc.Not yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04877457?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-07 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
780,68,2021-05-07 11:43:30.000000,A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,Condition:    Relapsing Multiple Sclerosis (RMS)Interventions:    Drug: Ofatumumab;   Biological: mRNA COVID-19 vaccine;   Drug: interferon or glatiramer acetateSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04878211?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-07 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
781,67,2021-05-06 11:08:31.000000,Sonification Techniques for Gait Training,"Conditions:    Parkinson Disease;   Stroke;   Multiple SclerosisInterventions:    Device: Gait rehabilitation with ""sonification"";   Other: Standard gait rehabilitation (without sonification)Sponsor :    Istituti Clinici Scientifici Maugeri SpARecruiting ",https://clinicaltrials.gov/ct2/show/NCT04876339?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-06 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
782,66,2021-05-06 11:08:31.000000,EMDR for Depressed People With Multiple Sclerosis,Conditions:    Multiple Sclerosis;   DepressionIntervention:    Behavioral: Eye Movement Desensitization and Reprocessing - EMDRSponsors :    Fondazione Don Carlo Gnocchi Onlus;   EMDR Europe;   Catholic University of the Sacred HeartNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04875832?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-06 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
783,65,2021-05-05 10:42:09.000000,Sensor-based Assessment and Rehabilitation of Balance in Neurological Diseases,"Conditions:    Stroke;   Multiple Sclerosis;   Parkinson DiseaseInterventions:    Device: Experimental Group;   Other: Control GroupSponsors :    IRCCS San Camillo, Venezia, Italy;   IRCCS San Raffaele;   Istituti Clinici Scientifici Maugeri SpA;   IRCCS National Neurological Institute ""C. Mondino"" Foundation;   I.R.C.C.S. Fondazione Santa LuciaRecruiting ",https://clinicaltrials.gov/ct2/show/NCT04874051?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-05 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
784,64,2021-05-05 10:42:09.000000,Investigation of the Effect of Ocrelizumab on Peripheral Lymphocyte Immunophenotypes With Suppressive Capacity in MS,Condition:    Multiple SclerosisIntervention:    Drug: OcrelizumabSponsors :    Dr Recai Turkoglu;   Health Sciences University Istanbul Haydarpaşa Numune Training and Research HospitalNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04874597?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-05 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
785,63,2021-05-05 10:42:09.000000,From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: Biological sample collectionSponsor :    Nantes University HospitalRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04873492?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-05 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
786,62,2021-05-03 11:30:09.000000,Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab,Condition:    Multiple SclerosisIntervention:    Drug: OfatumumabSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04869358?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-05-03 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
787,61,2021-04-30 10:48:20.000000,Validation of a Novel Instrument Task for Assessing Upper Limb,Condition:    Assessment of Arm and Hand Sensorimotor Functions in Multiple Sclerosis SubjectsIntervention:    Other: Assessment of the upper limb (VPIT + PPIT)Sponsors :    Swiss Federal Institute of Technology;   Kliniken ValensNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04868370?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-30 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
788,59,2021-04-28 12:01:02.000000,COVID-19 and Multiple Sclerosis Disease Modifying Therapies,Conditions:    Covid19;   Multiple SclerosisIntervention:    Sponsor :    Nottingham University Hospitals NHS TrustEnrolling by invitation ,https://clinicaltrials.gov/ct2/show/NCT04863586?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-28 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
789,58,2021-04-27 12:25:02.000000,Validation of the French Adaptation of the MSWDQ-23 Questionnaire,Condition:    Multiple SclerosisIntervention:    Other: questionnairesSponsor :    Centre Hospitalier Universitaire de NiceNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04860791?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-27 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
790,57,2021-04-27 12:25:02.000000,"Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients",Condition:    Multiple SclerosisInterventions:    Diagnostic Test: Brain MRI;   Diagnostic Test: Spinal Cord MRI;   Diagnostic Test: Retinal imagingSponsors :    Centre Hospitalier Universitaire de Nīmes;   Institut de Recherches en BiothérapieRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04860947?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-27 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
791,56,2021-04-26 12:49:02.000000,MS Relapses During COVID-19 Pandemic,Conditions:    Multiple Sclerosis;   Covid19;   Relapsing Remitting Multiple SclerosisIntervention:    Other: No InterventionSponsor :    Nottingham University Hospitals NHS TrustNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04858763?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-26 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
792,55,2021-04-23 20:54:01.000000,Effect of Variance on Error Correction During Coupling,Conditions:    Multiple Sclerosis;   Progressive Multiple SclerosisIntervention:    Other: synchronisation abilitiesSponsors :    Hasselt University;   National MS Center Melsbroek;   Noorderhart Revalidatie & MSRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04856384?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-23 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
793,54,2021-04-23 20:54:01.000000,Running Title: Walking to Music and in Silence on a Treadmill,Condition:    Multiple SclerosisInterventions:    Other: Walking with music with synchronisation;   Other: Walking with music without synchronisation;   Other: walking without musicSponsors :    Hasselt University;   Noorderhart Revalidatie & MSRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04856345?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-23 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
794,53,2021-04-23 20:54:01.000000,Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis,Condition:    Relapse Remitting Multiple SclerosisIntervention:    Sponsor :    Thomas Jefferson UniversityRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04857489?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-23 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
795,52,2021-04-22 20:19:01.000000,Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS,"Conditions:    Multiple Sclerosis;   Gait Disorders, Neurologic;   Motility Disorder;   Cognitive ImpairmentInterventions:    Device: Robotic Exoskeleton Rehabilitation;   Other: Conventional Gait TherapySponsors :    Kessler Foundation;   Kessler Institute for RehabilitationRecruiting ",https://clinicaltrials.gov/ct2/show/NCT04855825?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-22 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
796,51,2021-04-22 20:19:01.000000,Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis,"Condition:    Multiple SclerosisIntervention:    Drug: OcrelizumabSponsors :    NYU Langone Health;   Genentech, Inc.Recruiting ",https://clinicaltrials.gov/ct2/show/NCT04855617?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-22 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
797,50,2021-04-21 10:57:40.000000,Investigation of the Effects of Selective Exercise Training in Multiple Sclerosis,Conditions:    Multiple Sclerosis;   ExerciseIntervention:    Other: exerciseSponsor :    Sanko UniversityCompleted ,https://clinicaltrials.gov/ct2/show/NCT04853654?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-21 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
798,49,2021-04-19 11:50:37.000000,GentleCath Air (Urinary Self-catheterization) - Pain in Female Patients With Neurological Vesico-sphincter Disorders,Conditions:    Spinal Cord Injuries;   Multiple Sclerosis;   Parkinsonian Disorders;   AllodyniaIntervention:    Device: GentleCath™ Air catheterSponsors :    ConvaTec Inc.;   ClinSearchNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04847609?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-19 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
799,48,2021-04-19 11:50:37.000000,A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,Condition:    Relapsing Multiple SclerosisInterventions:    Other: Ofatumumab;   Other: Covid-19 vaccineSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04847596?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-19 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
800,47,2021-04-14 10:53:38.000000,Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People,Conditions:    Autoimmune or Autoinflammatory Diseases;   HIV;   Multiple Sclerosis;   Solid Tumors or Cancers;   Solid Organ TransplantIntervention:    Other: Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19Sponsor :    Assistance Publique - Hôpitaux de ParisNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04844489?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-14 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
801,46,2021-04-14 10:53:38.000000,Effects of Lutein Supplementation on Cognition and MPOD in Multiple Sclerosis Patients-,"Condition:    Multiple SclerosisInterventions:    Dietary Supplement: Lutein;   Dietary Supplement: PlaceboSponsors :    University of Illinois at Urbana-Champaign;   Division of Nutritional Sciences, University of Illinois at Urbana-ChampaignRecruiting ",https://clinicaltrials.gov/ct2/show/NCT04843813?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-14 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
802,45,2021-04-14 10:53:38.000000,Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA),Condition:    Multiple SclerosisIntervention:    Drug: SARS-COV-2 mRNA VaccineSponsor :    NYU Langone HealthNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04843774?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-14 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
803,44,2021-04-09 13:11:11.000000,The Effect of Telerehabilitation Based Pilates Training in Multiple Sclerosis Patients,Condition:    Multiple SclerosisIntervention:    Other: Telerehabilitation-based Pilates ExerciseSponsor :    Gazi UniversityRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04838886?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-09 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
804,43,2021-04-09 13:11:11.000000,TELEMS: Feasibility of Remote Patient Visits in MS,Condition:    Multiple SclerosisInterventions:    Other: EDSS;   Other: Discussion of symptomsSponsor :    Medical University of ViennaRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04838990?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-09 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
805,42,2021-04-08 11:57:29.000000,Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab,"Conditions:    Multiple Sclerosis;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune Diseases of the Nervous System;   Nervous System Diseases;   Demyelinating Diseases;   Autoimmune Diseases;   Immune System Diseases;   Pathologic ProcessesIntervention:    Device: Elecsys semi-quantitative Anti-SARS-CoV-2 antibody testSponsor :    Dragonfly Research, LLCRecruiting ",https://clinicaltrials.gov/ct2/show/NCT04837651?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-08 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
806,41,2021-04-08 11:57:29.000000,Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS,"Condition:    Multiple SclerosisIntervention:    Sponsor :    University Hospital, Strasbourg, FranceRecruiting ",https://clinicaltrials.gov/ct2/show/NCT04838015?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-08 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
807,40,2021-04-08 11:57:29.000000,Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis,Conditions:    Multiple Sclerosis;   Covid19Intervention:    Sponsor :    St. Barnabas Medical CenterRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04834401?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-07 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
808,39,2021-04-08 11:57:29.000000,Impact of Neuropsychological Disorders in Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: Three dimensional gait analysis with eyetrackingSponsor :    Lille Catholic UniversityNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04837365?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-08 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
809,38,2021-04-08 11:57:29.000000,Therapeutic Adherence of Multiple Sclerosis Patients,Condition:    Multiple SclerosisIntervention:    Other: Study of the role of sociocognitive factorsSponsor :    Lille Catholic UniversityNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04837352?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-08 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
810,37,2021-04-06 11:14:24.000000,"The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia in Multiple Sclerosis Patients: A Three Arms Randomized Trial","Conditions:    Multiple Sclerosis, Relapsing-Remitting;   Pain, Chronic;   Fatigue Syndrome, Chronic;   KinesiophobiaInterventions:    Behavioral: PMR: Progressive Muscle Relaxation;   Behavioral: BRT:Benson Relaxation TechniqueSponsor :    Hacettepe UniversityCompleted ",https://clinicaltrials.gov/ct2/show/NCT04833673?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-06 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
811,36,2021-04-05 11:38:24.000000,Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants,Condition:    Relapsing Remitting Multiple SclerosisIntervention:    Drug: NatalizumabSponsor :    BiogenRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04832399?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-05 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
812,35,2021-04-05 11:38:24.000000,Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour,"Condition:    Multiple SclerosisIntervention:    Other: Exposure to methylprednisolone during pregnancySponsors :    Jena University Hospital;   Ruhr University of Bochum;   Interdisciplinary Center of Clinical Research of the Medical Faculty Jena;   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyRecruiting ",https://clinicaltrials.gov/ct2/show/NCT04832269?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-04-05 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
813,34,2021-03-30 11:05:24.000000,Imaging Evaluation of Central Nervous Autoimmune Diseases,Conditions:    MS (Multiple Sclerosis);   NMO Spectrum DisorderIntervention:    Diagnostic Test: MRISponsor :    Qilu Hospital of Shandong UniversityNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04822623?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-30 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
814,33,2021-03-30 11:05:24.000000,Effects of Repeated Mesenchymal Stem Cells (MSC) in Patients With Progressive Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Biological: Mesenchymal Stem Cells (MSC)Sponsor :    Hadassah Medical OrganizationCompleted ,https://clinicaltrials.gov/ct2/show/NCT04823000?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-30 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
815,32,2021-03-29 11:19:37.000000,Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences,"Condition:    Multiple Sclerosis (MS)Interventions:    Procedure: SC MRI;   Other: patient questionnaireSponsors :    University Hospital, Basel, Switzerland;   Freie Akademische Gesellschaft BaselNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04819737?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-29 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
816,31,2021-03-29 11:19:36.000000,Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis,"Condition:    Multiple SclerosisIntervention:    Other: biological collectionSponsor :    University Hospital, RouenRecruiting ",https://clinicaltrials.gov/ct2/show/NCT04821596?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-29 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
817,30,2021-03-26 13:30:35.000000,Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Sclerosis,"Conditions:    Urinary Bladder, Neurogenic;   Multiple SclerosisInterventions:    Drug: VESIcare 10Mg Tablet;   Drug: Botox 100 UNT InjectionSponsors :    Brigitte Schürch;   Centre Hospitalier Universitaire VaudoisNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04819360?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-26 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
818,29,2021-03-26 13:30:35.000000,The Use of Arabic Otago Exercise Program in People With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: Otago Exercise ProgramSponsor :    University of JordanNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04818008?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-26 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
819,28,2021-03-25 11:16:53.000000,Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity,"Conditions:    Spasticity;   Cerebrovascular Accident;   Multiple Sclerosis;   Traumatic Brain Injury;   Cervical Spinal Cord Injury;   Cerebral PalsyInterventions:    Drug: rimabotulinumtoxinB;   Drug: PlaceboSponsor :    Supernus Pharmaceuticals, Inc.Not yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04815967?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-25 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
820,27,2021-03-19 11:55:20.000000,Neuroplasticity of Cortical Areas Induced by Cognitive Training in Patients With Multiple Sclerosis MS-NEUROPLAST,"Conditions:    Multiple Sclerosis;   Cognitive DeclineIntervention:    Other: Cognitive TrainingSponsors :    Aristotle University Of Thessaloniki;   King Fahad Medical CityActive, not recruiting ",https://clinicaltrials.gov/ct2/show/NCT04806568?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-19 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
821,26,2021-03-19 11:55:20.000000,Virtual Reality in Physical Therapy in Multiple Sclerosis,"Condition:    Multiple SclerosisInterventions:    Device: Neuroproprioceptive ""facilitation and inhibition"" in virtual reality;   Other: Neuroproprioceptive ""facilitation and inhibition""Sponsor :    Charles University, Czech RepublicNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04807738?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-19 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
822,25,2021-03-19 11:55:20.000000,Nature of the Link Between Executive Functions and Theory of Mind in Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: Theory of MindSponsor :    Lille Catholic UniversityNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04806217?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-19 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
823,24,2021-03-18 11:23:53.000000,Emotions in Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Diagnostic Test: Carrying out a tests and questionnaires batterySponsor :    Lille Catholic UniversityNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04804787?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-18 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
824,23,2021-03-15 14:45:21.000000,Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Clinically Isolated SyndromeInterventions:    Biological: blood sample;   Biological: cerebro-spinal fluidSponsors :    University Hospital, Bordeaux;   University of BordeauxNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04798651?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-15 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
825,22,2021-03-15 14:45:21.000000,Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication,Condition:    Multiple SclerosisIntervention:    Other: Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virusSponsor :    Providence Health & ServicesNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04796584?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-15 16:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
826,21,2021-03-12 14:58:20.000000,Role of Individualized Versus Traditional Exercise in Combating Fatigue,Condition:    Multiple SclerosisInterventions:    Other: Adapted and individualized physical training program;   Other: traditional training programSponsor :    Centre Hospitalier Universitaire de Saint EtienneNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04796272?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-12 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
827,20,2021-03-11 12:25:31.000000,Post-COntrast 3D SE T1 Versus Coronal SE T1-WI MRI in Detecting Optic Neuritis (COCON),Conditions:    Optic Neuritis;   Multiple SclerosisIntervention:    Diagnostic Test: Magnetic Resonance ImagingSponsor :    Fondation Ophtalmologique Adolphe de RothschildCompleted ,https://clinicaltrials.gov/ct2/show/NCT04793087?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-11 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
828,19,2021-03-11 12:25:31.000000,3D FLAIR Versus Coronal T2-WI MRI in Detecting Optic Neuritis (FLACON),Conditions:    Optic Neuritis;   Multiple Sclerosis;   EncephalopathyIntervention:    Diagnostic Test: Magnetic Resonance ImagingSponsor :    Fondation Ophtalmologique Adolphe de RothschildCompleted ,https://clinicaltrials.gov/ct2/show/NCT04792866?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-11 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
829,18,2021-03-11 12:25:30.000000,Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC),Condition:    Secondary Progressive Multiple SclerosisInterventions:    Drug: BAF312;   Drug: Baseline disease modifying therapies (DMTs)Sponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04792567?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-11 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
830,17,2021-03-09 14:59:53.000000,Open Label Randomized Multicenter to Assess Efficacy &amp; Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS,Condition:    Multiple SclerosisInterventions:    Drug: Ofatumumab;   Drug: First line DMTSponsor :    Novartis PharmaceuticalsNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04788615?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-09 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
831,16,2021-03-09 14:59:53.000000,T Cell Profiling in Patients With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Other: Blood SampleSponsor :    Boston Children's HospitalNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04789551?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-09 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
832,15,2021-03-08 13:43:03.000000,Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis,"Conditions:    Multiple Sclerosis, Relapsing-Remitting;   Sexual DysfunctionIntervention:    Behavioral: Behavioural intervention for physical activity for multiple sclerosis (BIPAMS)Sponsors :    University of Alabama at Birmingham;   National Multiple Sclerosis SocietyNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04768777?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-02-24 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
833,14,2021-03-08 13:43:03.000000,miRNA Biomarkers in Multiple Sclerosis,Conditions:    Multiple Sclerosis;   miRNA;   Epigenetic;   BiomarkerIntervention:    Genetic: miRNASponsor :    University of GaziantepCompleted ,https://clinicaltrials.gov/ct2/show/NCT04772495?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-02-26 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
834,13,2021-03-08 13:43:03.000000,Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis,Condition:    Multiple Sclerosis (MS)Intervention:    Other: At-home natalizumab treated MS patientSponsors :    Nantes University Hospital;   Rennes University HospitalNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04777539?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-02 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
835,12,2021-03-08 13:43:03.000000,ATOMIC (Active Teens Multiple Sclerosis) Physical Activity Research Program,Condition:    Pediatric Multiple SclerosisInterventions:    Behavioral: Physical Activity (PA) Intervention;   Behavioral: Waitlist attention-controlSponsors :    The Hospital for Sick Children;   Children's Hospital of Philadelphia;   University of Alabama at Birmingham;   Queen's University;   National Multiple Sclerosis SocietyRecruiting ,https://clinicaltrials.gov/ct2/show/NCT04782466?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-04 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
836,11,2021-03-08 13:43:03.000000,Digital Gait Analysis in the Home Environment of Patients With Multiple Sclerosis,Condition:    Multiple SclerosisIntervention:    Sponsors :    Medical Valley Digital Health Application Center GmbH;   Celgene Corporation;   NeuroSys GmbH;   Fraunhofer Institute for Integrated Circuits IIS;   Portabiles HealthCare Technologies GmbH;   University of RegensburgNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04771858?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-02-25 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
837,10,2021-03-08 13:43:03.000000,Acceptability of Exoskeleton Assisted Walking for Persons With Mobility Issues Due to Multiple Sclerosis,"Conditions:    Multiple Sclerosis;   Pathologic Processes;   Sclerosis;   Autoimmune Diseases of the Nervous System;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune DiseasesInterventions:    Behavioral: Standard Exercise Training;   Device: Phoenix Exoskeleton suitSponsor :    Sheffield Teaching Hospitals NHS Foundation TrustNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04786821?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-08 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
838,9,2021-03-08 13:43:03.000000,Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis,Condition:    Multiple SclerosisInterventions:    Drug: Belimumab;   Drug: Short-course Ocrelizumab;   Drug: Continued OcrelizumabSponsors :    Johns Hopkins University;   GlaxoSmithKlineNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04767698?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-02-23 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
839,8,2021-03-08 13:43:03.000000,The Effect of Extra Virgin Olive Oil in People With Multiple Sclerosis,"Condition:    Multiple SclerosisIntervention:    Dietary Supplement: High Phenolic Extra Virgin Olive OilSponsors :    University of Cyprus;   World Olive Center for Health;   Ellis-Farm, Eliama Daily ValueNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04787497?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-08 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
840,7,2021-03-08 12:17:02.000000,Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension),"Condition:    Multiple SclerosisIntervention:    Drug: Mavenclad®Sponsor :    Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNot yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04783935?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-05 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
841,6,2021-03-08 12:17:02.000000,Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension),"Condition:    Multiple SclerosisIntervention:    Drug: Mavenclad®Sponsor :    Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyRecruiting ",https://clinicaltrials.gov/ct2/show/NCT04776213?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-01 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
842,5,2021-03-02 14:12:09.000000,COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations (SARS),"Conditions:    SARS-CoV Infection;   COVID-19;   Allergic Reaction;   Mast Cell Disorder;   Non-atopicInterventions:    Biological: Moderna COVID-19 Vaccine;   Biological: Pfizer-BioNTech COVID-19 Vaccine;   Biological: PlaceboSponsors :    National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN);   Rho Federal Systems Division, Inc.Not yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04761822?term=biontech&amp;sfpd_d=14&amp;sel_rss=new14,2021-02-21 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
843,4,2021-01-03 01:00:00.000000,Antibody Response to COVID-19 Vaccines in Liver Disease Patients,Condition:    Chronic Liver DiseaseInterventions:    Biological: BNT162b2;   Biological: CoronaVac;   Biological: AZD1222Sponsor :    Humanity & Health Medical Group LimitedNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04775069?term=biontech&amp;sfpd_d=14&amp;sel_rss=new14,2021-03-01 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
844,3,2021-02-27 01:00:00.000000,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older",Conditions:    SARS-CoV-2 Infection;   COVID-19;   Maternal ImmunizationInterventions:    Biological: BNT162b2;   Other: PlaceboSponsors :    BioNTech SE;   PfizerNot yet recruiting ,https://clinicaltrials.gov/ct2/show/NCT04754594?term=biontech&amp;sfpd_d=14&amp;sel_rss=new14,2021-02-15 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
845,2,2021-02-27 01:00:00.000000,National Cohort Study of Effectiveness and Safety of SARS-CoV-2&#x2F;COVID-19 Vaccines (ENFORCE),"Condition:    SARS-CoV InfectionInterventions:    Biological: COMIRNATY - BioNTech Manufacturing GmbH;   Biological: COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH;   Biological: COVID-19 Vaccine AstraZeneca suspension for injectionSponsors :    Jens D Lundgren, MD;   Ministry of the Interior and Health, DenmarkRecruiting ",https://clinicaltrials.gov/ct2/show/NCT04760132?term=biontech&amp;sfpd_d=14&amp;sel_rss=new14,2021-02-18 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
846,1,2021-02-27 01:00:00.000000,COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations,"Conditions:    SARS-CoV Infection;   COVID-19;   Allergic Reaction;   Mast Cell Disorder;   Non-atopicInterventions:    Biological: Moderna COVID-19 Vaccine;   Biological: Pfizer-BioNTech COVID-19 Vaccine;   Biological: PlaceboSponsors :    National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN);   Rho Federal Systems Division, Inc.Not yet recruiting ",https://clinicaltrials.gov/ct2/show/NCT04761822?term=biontech&amp;sfpd_d=14&amp;sel_rss=new14,2021-02-21 17:00:00.000000,12.0,,12.0,Clinical Trials.gov,https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000
